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SUMMARY
BACKGROUND
Owing to the long-term health risks associated w ith  increased adiposity and the lim ited 
efficacy o f existing anti-obesity agents, there is an urgent need for further development of 
alternative therapeutic options to serve as an adjunct to lifestyle measures to address global 
cardiometabolic risk and thus reduce the risk of developing obesity-related illnesses such as 
type II diabetes and cardiovascular disease.
AIMS & METHODS
The studies presented in this thesis aimed to investigate the effects of novel (CBi antagonist) 
and existing (metform in) pharmacological agents on components of the metabolic syndrome 
using in vitro and in vivo models. This was undertaken w ith in vitro studies of the effect o f CBi 
receptor modulation on white, brown and prim ary (subcutaneous and omental) pre­
adipocyte proliferation, adipogenesis and adipokine production; as well as a randomised, 
double-blind cross-over tria l of the effects o f metformin on vascular function and metabolic 
profile in young women w ith polycystic ovary syndrome (in vivo).
RESULTS
CBi receptor antagonism inhibited white and prim ary pre-adipocyte proliferation and 
increased expression of term inal markers o f adipogenesis while promoting adiponectin 
production. In young women w ith PCOS, short term metformin therapy improved arterial 
stiffness and endothelial function, resulted in modest weight loss and an elevation in serum 
adiponectin. There is increasing evidence for the key role the latter plays in metabolic 
processes and vascular health, and these increases in adiponectin levels may underlie some of 
the mechanisms mediating the changes observed. Therefore treatments targeting a switch 
inthe adipokine profile as the therapeutic goal represent a new approach to addressing global 
cardiometabolic risk.
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CHAPTER 1: GENERAL INTRODUCTION - MODELS OF THE
METABOLIC SYNDROME
1.1 Historical Perspective
The concept of the metabolic syndrome, or a clustering of metabolic abnormalities arising 
from the increasing prevalence of obesity, has existed since the 1920s, when the Swedish 
physician Kylin first described an association between hypertension, hyperglycaemia and 
hyperuricaemia [1]. A correlation with upper body adiposity (android or male-type obesity) 
was acknowledged by Vague in the 1940s [2] while the association with insulin resistance 
was made towards the end of the 1980s [3]. Since then numerous labels have been applied 
including the "deadly quartet," "syndrome X" and the "insulin resistance syndrome" 
eventually leading to today's terminology of the metabolic syndrome referring to the 
coexistence of glucose intolerance and insulin resistance, central obesity, dyslipidaemia and 
hypertension [4]. These are all well recognised risk factors predisposing individuals to the 
development of type II diabetes and cardiovascular disease, both associated with increased 
morbidity and mortality. With a growing worldwide prevalence, addressing the metabolic 
syndrome has therefore become a global public health challenge.
1.2 Definition Of The Metabolic Syndrome
Over recent years numerous expert groups have attempted to develop an internationally 
accepted and unified definition of the metabolic syndrome (Table 1.1), including the World 
Health Organisation (WHO), the European Group for the Study of Insulin Resistance (EGIR), 
and the National Cholesterol Education Program Expert Panel on the Detection, Evaluation 
and Treatment of High Blood Cholesterol in Adults - Third Adult Treatment Panel (NCEP-ATP
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Ill), as well as position statements from the American Association of Clinical Endocrinology 
(AACE) and the International Diabetes Federation (IDF) [4, 5].
Table 1.1: Definitions Of The Metabolic Syndrome■
Central obesity Waist hip ratio 
>0.9 S 
> 0.85 $ 
or BMI > 30 kg/m2
Waist
circumference
> 94 cm S
> 80 cm 9
Waist
circumference
> 102 cm S
> 88 cm 9
BMI > 25 kg/m2
Dysglycaemia
(mmol/1)
Fasting glucose £ 
6.1 or 2 hours 
post glucose 
challenge £ 7.8
Fasting glucose > 
6.1
Fasting glucose £ 
6.1
(modified to > 5.6 
in 2004)
Fasting glucose £ 
6.1 or 2 hours 
post glucose 
challenge £ 7.8
Insulin
resistance
Glucose uptake 
below lowest 
quartile measured 
under
hyperinsulinaemic
euglycaemic
conditions
Top 25% of 
fasting insulin 
values among the 
non-diabetic 
population
Not applicable Not applicable
Blood Pressure 
(mmHg)
>140/90 £ 140/90 or
treated
hypertension
>130/85 or
treated
hypertension
>130/85
Triglycerides
(mmol/1)
> 1.7 >2.0 > 1.7 > 1.7
HDL cholesterol 
(mmol/1)
S < 0.9 
9 < 1.0
< 1.0 or on 
treatment
c? < 1.03 
9 <1.29
$ < 1.03 
9 <1.29
Other factors Microalbuminuria 
(urinary albumin 
excretion rate > 
20 pg/min or 
albumin: 
creatinine ratio > 
30 mg/g)
Not applicable Not applicable Family history of 
type II DM 
Polycystic Ovary 
Syndrome 
Sedentary lifestyle 
Increasing age 
Ethnicity
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While all groups are in agreement over the core components of obesity, hyperglycaemia, 
hypertension and dyslipidaemia, considerable confusion and controversy exists regarding the 
specific criteria and cut-off points for each individual component, and the applicability of 
these criteria to differing populations. The assessment of obesity has been most difficult, with 
older definitions failing to account for ethnic variations in body mass index (BMI) and waist 
circumference, though this has been addressed in the 2005 IDF consensus statement 
recommending an updated global definition for the metabolic syndrome (Table 1.2). By 
accounting for ethnic variations in the measurement, and implications, of central obesity, the 
IDF definition should enable physicians internationally to identify and treat at risk 
individuals, whilst also allowing comparison of the prevalence and health outcomes of this 
syndrome in differing populations [5]. This definition also requires the presence of central 
obesity for the diagnosis, thus recognising the strong correlation with other features of the 
metabolic syndrome.
Table 1.2: IDF Worldwide Definition Of The Metabolic Syndrome [5]
Triglycerides (mmol/1) > 1.7 or treated hypertriglyceridaemia
HDL cholesterol (mmol/1) c? <1.03 $<1.29
Blood pressure (mmHg) Systolic > 135 or diastolic > 85
Dysglycaemia (mmol/1) Fasting glucose > 5.6 or previously diagnosed type II DM
Ethnicity specific central obesity 
(waist circumference - cm)
Europeans 
USA (Caucasians)
S £ 94 cm 9 > 80 cm 
S £ 102 cm $ > 88 cm
South Asians S ^ 90 cm 9 > 80 cm
i
Chinese <$ > 90 cm 9 ^ 80 cm
Japanese S ^ 90 cm 9 > 80 cm
South & Central Americans Use South Asian values till 
further data available
Sub-Saharan Africans 
Eastern Mediterraneans 
Middle Easterns
Use European values till further 
data available
40
1.3 Pathogenesis Of The Metabolic Syndrome
The complex pathogenesis of the metabolic syndrome and its key components is still to be 
fully elucidated. Both insulin resistance together with central or visceral adiposity are the 
dominant causative factors recognised to date. The global obesity epidemic is thought to be 
the most important driving force for the increasing prevalence of both insulin resistance and 
the metabolic syndrome [5]. Environmental factors which include cigarette smoking and 
sedentary lifestyles also contribute to the development of many of the major metabolic 
disturbances [4].
1.3.1 Obesity & Abnormal Body Fat Distribution
Epidemiological studies have demonstrated a clear association between increasing body 
weight, measured by the body mass index [BMI), and all-cause mortality [10]. Furthermore, 
amongst individuals with similar BMI values, those w ith greater abdominal adiposity [as 
assessed by measurement of waist circumference or waist-hip ratio), are at greater risk of 
developing type II diabetes mellitus [DM), hypertension and cardiovascular disease (CVD) 
[11,12]. This excess in visceral, as compared to subcutaneous, accumulation of adipose tissue 
has been shown to be associated with adverse and potentially atherogenic metabolic 
disturbances in both men and women, including fasting hypertriglyceridaemia, reduction in 
high-density lipoprotein (HDL), and elevations in both fasting and post-prandial insulin and 
glucose levels [13].
The hypotheses which link central obesity w ith components of the metabolic syndrome have
arisen from the recent understanding of the function of adipose tissue as not only an energy
store, but an endocrine organ capable of secreting adipocytokines, growth factors and other
bio-active substances (Table 1.3) known to impair the action o f insulin. These include free
fatty acids (FFA) and the inflammatory mediators tumour necrosis factor-alpha (TNF-a) and
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interleukin-6 (IL-6) [14]. TNF-a has been shown to promote insulin resistance, stimulate 
lipolysis and thus increase FFA release, and inhibit peripheral glucose uptake while IL-6 
increases hepatic glucose production & triglyceride synthesis. Excess visceral adipose tissue 
is also associated with a reduction in the insulin-sensitising cytokine adiponectin, and thus a 
loss of its anti-diabetic, anti-inflammatory, and anti-atherosclerotic properties [14]. These 
pathogenic processes are illustrated further in Figure 1.1.
Table 1.3: Proteins Secreted By Adipocytes [15]
Adiponectin Insulin sensitisationImproved fatty acid transport and utilisation
Leptin Hypothalamic energy regulation Maturation of reproductive function
Resistin Impairs insulin sensitivity
Tumour necrosis factor alpha
Mediator of the acute phase response 
Increased insulin resistance
(i lipogenesis, t  lipolysis, J, insulin-induced glucose uptake)
Interleukin 6 Increases hepatic glucose production & triglyceride synthesis
Plasminogen activator inhibitor 1 Potent inhibitor of the fibrinolytic system
Angiotensinogen Regulator of blood pressure & electrolyte homeostasis
Transforming growth factor beta Regulator of growth & differentiation
Insulin like growth factor 1 Stimulates cell proliferation and mediates many effects of growth hormone
Adipsin ? link between activation of the complement pathway and 
adipose tissue metabolism
Acylation Stimulating Protein
Activates diacylglycerol acyltransferase 
Inhibits lipase
Stimulates Glucose transporter 4 translocation to cell surface
Tissue factor Initiator of the coagulation cascade
PGI2 PGF2alpha Implicated in blood clotting, ovulation & menstruation
Migration inhibitory factor Involved in proinflammatory processes & immunoregulation
Adipocyte protein 2 Involved in intracellular trafficking and targeting of fatty acids
Agouti protein
? induces insulin resistance through increasing intracellular
free calcium concentrations
Increases appetite & decreases energy expenditure
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1.3.2 Insulin Resistance & Glucose Intolerance
There is clear evidence supporting a major role of insulin resistance in the development of the 
metabolic syndrome, though the exact underlying mechanism is not yet fully understood. It is 
present in the majority of individuals meeting the criteria for the metabolic syndrome with a 
strong association with the other dominant components, as well as the correlation with the 
development of type II DM and CVD [5]. The Bruneck study examined the prevalence of 
insulin resistance in random subjects from the general population aged between 40 and 79 
years by the homeostasis model assessment (HOMA), and demonstrated a clear correlation 
between increasing degrees of insulin resistance and the number of co-existing metabolic 
abnormalities [16]. Meta-analysis of previous data has shown hyperinsulinaemia in non­
diabetic men and women to be an independent risk factor for CVD, especially in non-white 
populations, though this does still require further study [17].
1.3.2.1 The Role Of Obesity In The Pathogenesis Of Insulin Resistance
An overabundance of FFAs, derived predominantly from lipolysis of triglyceride stores within 
adipose tissue, is thought to be a main contributor to the development of insulin resistance 
[4], Insulin itself has important antilipolytic properties, thus further compounding the 
problem in the setting of insulin resistance. The excess FFAs further antagonise the actions of 
insulin by stimulating hepatic gluconeogenesis thus contributing to hyperglycaemia, whilst 
also suppressing peripheral skeletal muscle glucose transport leading to reduced muscle 
glycogen synthesis and glycolysis [18]. The increasing and prolonged exposure to the 
resultant elevated concentrations of insulin eventually leads to the development of frank type 
II DM, deterioration in pancreatic (3-cell function and therefore a fall in insulin secretion with 
worsening hyperglycaemia [19]. These pathogenic processes are illustrated further in Figure 
1.1.
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Figure 1.1: The Role Of Obesity & Insulin Resistance In The Pathogenesis Of The
Metabolic Syndrome [4, 20, 21]
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1.3.2.2 Impaired Insulin Receptor Signalling In Insulin Resistance
Insulin binding induces tyrosine phosphorylation of the insulin receptor, resulting in the 
binding of a number of intracellular proteins such as the insulin receptor substrates (IRS-1
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and IRS-2) [22]. Phosphorylated tyrosine residues on these proteins serve as docking sites for 
the recruitment and binding of downstream signalling proteins such as phosphoinositide 3 
kinase (PI3K) and Akt, a family of genes encoding serine/threonine-specific protein kinases, 
eventually regulating responses including glucose transport, protein and glycogen synthesis 
[22].
In obese states, lipid accumulation can occur in ectopic sites outside of adipose tissue due to 
excess fat intake, fatty acid synthesis and reduced fatty acid disposal. Moreover lipid 
accumulation w ithin myocytes and hepatocytes is strongly associated with increased insulin 
resistance [18]. Accumulation of excess lipid within skeletal muscle and the liver inhibits 
tyrosine phosphorylation of IRS-1, which in turn follows serine phophorylation therefore 
inhibiting PI3K binding and activation and thus reducing insulin-stimulated glucose transport 
[23]. Candidate proteins implicated in this serine phosphorylation include the protein kinase 
C family which may be activated by accumulation of lipid, as well as inflammatory 
intermediaries such as TNFa and IL-6 which may be activated within adipose tissue in obese 
states [23].
1.3.3 Dyslipidaemia
The dyslipidaemic profile seen in the metabolic syndrome tends to be characterised by the 
pro-atherogenic pattern of raised triglycerides (TG) and low HDL, as well as other lipoprotein 
changes including elevated small dense low-density lipoprotein (LDL) and apolipoprotein B 
(Apo B) [24]. As discussed previously, obesity gives rise to excess FFAs which in turn 
exacerbate insulin resistance. As well as stimulating hepatic gluconeogenesis, FFAs also 
increase hepatic TG synthesis and the production of Apo B-containing, triglyceride-rich very 
low-density lipoprotein (VLDL) [25]. TGs are also primarily responsible for an associated 
remodelling of HDL by a process of reverse cholesterol transport and cholesterol 
esterification leading to a reduction in the cholesterol content of HDL [26].
45
1.3.4 Elevated Blood Pressure
Hypertension is closely associated with obesity and insulin resistance and is associated with a 
two-fold increase in CVD risk for every 20/10 mmHg increment in blood pressure 
commencing at 115/75 mmHg [27, 28]. Several mechanisms have been postulated linking 
insulin resistance with the development of elevated blood pressure. For instance, there is 
evidence indicating increased renal sodium reabsorption in the metabolic syndrome, 
especially in Caucasian populations [29], as well a loss of vasodilatory effects of insulin 
observed in a normal physiological setting [30]. Furthermore insulin also stimulates 
sympathetic nervous activity [31] while FFAs themselves mediate a relative vasoconstrictive 
effect [32].
1.3.5 Promflammatory Cytokines & Adiponectin
Numerous other parameters have also been demonstrated to feature in individuals w ith the 
metabolic syndrome including a pro-inflammatory state, as indicated by elevated plasma 
TNF-a, IL-6 and C-reactive protein (CRP), markers of a pro-thrombotic state, the most 
common being plasminogen activator inhibitor-1 [PAI-1], and adverse adipocytokine profiles, 
especially low circulating adiponectin [5]. The latter is a cytokine produced almost 
exclusively by adipocytes and enhances insulin sensitivity and inhibits numerous steps in the 
inflammatory process [33]. In the liver it suppresses endogenous glucose production while 
improving glucose transport and fatty acid oxidation in skeletal muscle [34, 35]. Furthermore, 
TNFa is also over expressed in adipose tissue and induces insulin resistance through acute 
and chronic effects on insulin-sensitive tissues [36]. As discussed previously, the increase in 
proinflammatory cytokines probably reflects over-production by the expanded adipose tissue 
mass seen in these individuals. However, these features have not been incorporated into 
current definitions of the metabolic syndrome to date.
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1.4 Prevalence Of The Metabolic Syndrome
Due to differences in the existing definitions of the metabolic syndrome, there are varying 
reports of its prevalence depending on the definition used and the ethnic group studied. Most 
studies suggest a prevalence of 10-30% in the general adult population in developed 
countries and urban areas of developing countries (Figure 1.2) [37].
Figure 1.2: Prevalence Of The Metabolic Syndrome From NCEP ATP 111 Definition
Adapted from Cameron etal [4, 37]
□  Women 
■  Men
Countiy/age (years)
The prevalence of the metabolic syndrome, as defined by the NCEP ATP III criteria, was
evaluated in 8814 adults in the United States in the third National Health and Nutrition
Examination Survey (NHANES III). The overall prevalence was shown to be 22 percent, with
an age-dependent increase and higher prevalence rates seen in Mexican and African
subgroups [38]. Data from NHANES 1999-2000 confirms that the prevalence has continued
to increase, particularly in women [39]. The prevalence of the metabolic syndrome by NCEP
ATP III criteria was also assessed in a middle-aged cohort of 3323 Framingham Heart Study
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participants who did not have diabetes or cardiovascular disease at an initial examination in 
the early 1990s. At baseline, the prevalence of the metabolic syndrome was 26.8 percent in 
men and 16.6 percent in women. Following an eight year period there was an age-adjusted 56 
percent increase in prevalence among men and a 47 percent increase among women [40].
1.5 Consequences Of The Metabolic Syndrome
There is considerable controversy and dispute about the concept of the metabolic syndrome -  
some believe that this label adds little practical clinical value to individual patient 
management whilst others value the metabolic syndrome as a screening tool to detect and 
target those at high risk of diabetes and CVD [41,42]. Components of the metabolic syndrome 
are associated with an increased risk of type II DM and CVD, and there are now numerous 
studies indicating the presence of the metabolic syndrome itself as a predictor of future 
diabetes, though this is not surprising given the presence of insulin resistance and glucose 
intolerance in the defining criteria [43]. Furthermore, an increased mortality has been 
demonstrated by meta-analysis in non-diabetic individuals meeting the WHO criteria for the 
metabolic syndrome [44]. The overall hazard ratios for all-cause and cardiovascular mortality 
in persons with the metabolic syndrome compared w ith persons without it  were respectively 
1.44 and 2.26 in men and 1.38 and 2.78 in women after adjustment for age, blood cholesterol 
levels, and smoking. Application of the NCEP ATP III criteria to 10537 participants from the 
NHANES III study also indicated a significant relationship between the syndrome and both 
myocardial infarction and stroke in men and women [45].
Apart from type II DM and CVD, the metabolic syndrome is also associated w ith several other 
disorders all of which demonstrate a clear link w ith obesity, including non-alcoholic 
steatohepatitis [46], chronic kidney disease [47], polycystic ovary syndrome [48], obstructive 
sleep apnoea [49] and cognitive decline, though this is by no means an exhaustive list.
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Other studies have disputed whether application of the metabolic syndrome provides any 
additional information over and above the individual well-established CVD risk factors which 
may in part reflect the inadequacies and inconsistencies in the definitions used [50]. It is not 
clear whether the metabolic syndrome simply reflects the increasingly sedentary lifestyle and 
dietary habits of today's society or if  accumulating excess central fat deposits was associated 
w ith survival benefits in the past There is however clear evidence that the metabolic 
syndrome, considered either as a separate disease entity or a constellation of risk factors, 
predisposes to cardiovascular risk [51-53]. These individuals represent an at-risk population 
and require further attention.
1.6 Management Of The Metabolic Syndrome
The metabolic syndrome represents a common cluster of metabolic disturbances associated 
with increased risk of type II DM and CVD, predominantly arising from the increasing 
prevalence of obesity. In 2003 a report from the American Heart Association and the National 
Institutes of Health recommended two main therapeutic goals for the management of the 
metabolic syndrome [54], Firstly this involves lifestyle modification to treat the underlying 
causes of obesity and physical inactivity by intensifying weight management and increasing 
physical activity. This should be followed by treatment of cardiovascular risk factors i f  they 
persist despite lifestyle modification, and includes treatment with insulin sensitising agents, 
anti-hypertensive and lipid-lowering drugs. However, at present there is no direct evidence 
supporting the attempts to prevent type II DM and CVD by treating the metabolic syndrome 
and no trials comparing the lifestyle modifying vs. pharmacological approaches in improving 
outcome.
Weight loss, regardless of how this is accomplished, improves metabolic parameters, reduces
cardiovascular risk and improves disease outcome [Table 1.4). However, sustained weight
loss is challenging to achieve, and most individuals find lifestyle modifications difficult to
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adhere to long-term. The few existing drugs that have been used for the treatment of obesity 
do help achieve modest weight loss in the short-term but many patients return to their pre­
treatment body weights within a few years of treatment discontinuation. Although the core 
approach to the treatment of obesity, and thus the metabolic syndrome, encompasses weight 
reduction and increased physical activity, there may also be a role for pharmacotherapy in 
reducing the burden of diabetes and cardiovascular disease; hence the adipocyte represents a 
major molecular target for novel therapeutic agents.
Table 1.4: Benefits Of 10kg Weight Loss [55]
Mortality
20-25% i  total mortality 
30-40% i  diabetes-related deaths 
40-50% I  obesity-related cancer deaths
Blood pressure 10 mmHg i  systolic pressure 20 mmHg I  diastolic pressure
Lipid Profile
10% i  total cholesterol 
15% |  LDL cholesterol 
30% i  triglycerides 
8% | HDL cholesterol
Glycaemia
>50% I  risk of developing diabetes 
30-50% I  fasting blood glucose 
15% i  HbAlc
Angina 91% I  symptoms 33% t  exercise tolerance
1.7 Models Of The Metabolic Syndrome
We have chosen to study the effect of pharmacomodulation in two models representing 
features of the metabolic syndrome: firstly, the endocannabinoid system, as an in vitro model 
of obesity, and secondly, polycystic ovary syndrome (PCOS], as an in vivo model for the 
syndrome itself. We hypothesise that novel (CBi antagonist] and existing (metformin]
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pharmacolotherapy targets may generate new benefits through changes in obesity, and in 
particular, central adiposity.
1.8 The Endocannabinoid System (ECS)
1.8.1 Role Of The ECS In Contributing To Obesity
The discovery of the ECS can be traced back almost 4000 years when the ancient Indians first 
described the pleasure-inducing medicinal properties of the plant Cannabis sativa [56], 
though the identification of A9-tetrahydrocannabinol (A9-THC) as the principal active 
compound of marijuana was not made until the late 20th century leading to further 
characterisation of the cannabinoid receptors and their endogenous ligands [57]. More recent 
research into the physiology of the ECS has aroused considerable interest, with the 
recognition of significant effects in the regulation of food intake as well as energy metabolism 
via central and peripheral mechanisms in both animals and humans [58, 59]. The ECS is 
therefore emerging as a novel therapeutic target for management of components of the 
metabolic syndrome.
The elements of the ECS comprise the cannabinoid receptors, the endogenous lipid ligands, 
the proteins required for their biosynthesis and inactivation, and the affected intracellular 
signalling pathways. In addition to its role in energy metabolism, the ECS also contributes to 
numerous other physiological functions including behaviour regulation, neuroprotection, 
nociception, and immunomodulation [60].
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1.8.2 Cannabinoid Receptors
Two cannabinoid receptors, namely cannabinoid receptor type 1 (CBi) and cannabinoid 
receptor type 2 (CB2), have been identified to date, and form part of the seven 
transmembrane G protein-coupled family of receptors [60] (Figure 1.3).
Figure 1.3 : Schematic Representation of Human CB1 and CB2 Receptors
Adapted from Shire et al [61]
(where •  represents amino acids common to both CB1 & CB2)
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CBi receptors are located extensively throughout the central nervous system particularly
specific mesolimbic regions, the pituitary and the hypothalamus, especially in regions known
to be involved in the control of calorie intake and satiety, as well as in other organs involved
in energy homeostasis including adipose tissue, liver, gastrointestinal tract, pancreas and
skeletal muscle. They are also found in the myocardium and vascular endothelium, while CB2
receptors are predominantly expressed on immune and blood cells [62]. Therefore CBi
receptor modulation appears to affect metabolic function whereas CB2 activation has been
52
implicated in pain and immune modulation. Recent studies from CBi and CB2 receptor 
knockout mice have also suggested the existence of non-CBi, non-CB2 endocannabinoid 
receptors but these remain the subject of ongoing study [63]. Given its role in energy 
homeostasis, this thesis w ill focus on the effects of CBi in the ECS.
1.8.3 Endogenous Endocannabinoids
The cannabinoid receptors are activated by a group of naturally occurring, cannabis-like 
lipids known as the endocannabinoids, the earliest of which to be identified were the 
arachidonic acid derivatives arachidonylethanolamide (anandamide or AEA) in 1992, 
followed by 2-arachidonylglycerol (2-AG) [60, 64] (Figure 1.4).
Figure 1.4 : Schematic Representation Of The Endocannabinoids
Adapted from Di Marzo et al [65]
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More recently other bioactive mediators have also been described including noladin ether, 
virodhamine and oleamide, though their physiological functions have not yet been fully
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established [60]. AEA synthesis occurs via the phosphodiesterase-mediated cleavage of the 
membrane phospholipid, N-arachidonoyl-phophatidylethanolamine [66]. Being lipophilic 
compounds the endocannabinoids cannot be stored in vesicles like other neurotransmitters 
and are therefore synthesised upon demand from membrane phospholipids by cells at the 
site of action [64]. Following release and local receptor activation, the products are then 
rapidly degraded by hydrolysis via fatty acid amide hydrolase (FAAH), thus acting primarily 
near their site of synthesis by binding to cannabinoid receptors on the neighbouring cell 
surfaces [64]. Both AEA and 2-AG are capable of binding to CBi and CB2 but w ith differing 
affinities and activation efficiencies [60].
1.8.4 Exogenous CBi Receptor Ligands
The exogenous CBi receptor ligands can be further classified according to their ability to 
either activate (agonists] or inactivate (antagonists] CBi receptors.
1.8.4.1 Exogenous CBi Agonists
The first exogenous CB ligand to be identified was the Cannabis sativa plant-derived A9-THC, 
with the ability to activate both CBi and CB2 [57]. The desire for therapeutic potential has led 
to the development of synthetic CB agonists with selective affinity for either CBi or CB2 
receptors depending on the treatment target. HU210, a synthetic derivative of A9-THC, is one 
of the most potent CBi agonists as is the AEA derivative arachidonyl-2'-chloroethylamide, 
both w ith very limited activity on CB2 (Figure 1.5) [60].
1.8.4.2 Exogenous CBi Antagonists
These compounds represent novel therapeutic agents with the potential for treating
components of the metabolic syndrome. These ligands act either as competitive antagonists
54
of CBi receptor activation by endocannabinoids, or as inverse agonists that modulate CBi 
receptor activity by shifting it from an active "on" to an inactive "off' state [60]. The first and 
most extensively used CBi receptor antagonist is SR141716, which has also been developed 
into the pharmacological agent rimonabant for human use, but other compounds that have 
been characterised include AM251, AM281, and SR14778 (Figure 1.5) [60].
Figure 1.5: Exogenous CBI Receptor Ligands
Adapted from Di Marzo et al [67]
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1.8.5 Endocannabinoid-Mediated Intra-Cellular Signalling
Several mechanisms involved in endocannabinoid-mediated signalling have been described
over the recent years and some of these signalling cascades have been schematically
represented in Figure 1.6. CBi receptors are coupled via G-proteins, negatively to adenylate
cyclase and positively to mitogen-activated protein kinase, as well as to potassium and
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calcium ion channels [68]. G-protein stimulation by CBi activation inhibits ATP to cAMP 
conversion mediated by adenylate cyclase [60]. cAMP is in turn thought to bind to regulatory 
subunits of protein kinase A (PKA) resulting in the activation of A-type potassium (K+A) 
channel while G-protein mediated effects on protein kinase C (PKC) can result in activation of 
inwardly-rectifying potassium (Kir) channels and the inhibition of calcium channels [60]. CBi 
activation also stimulates numerous intracellular kinases eventually resulting in gene 
expression and transcription. It is important to note that these events have been reported in 
different cell systems and thus may not all occur in the same cell type [60].
Figure 1.6: Effects Of CBI Activation On Intracellular Signalling Cascades
Adapted from Pagotto et al [60]
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1.8.6 Endocannabinoid-Mediated Neuronal Signalling
Neurotransmitters released from vesicles within pre-synaptic neurons activate post-synaptic 
neuronal synthesis and release of endocannabinoids [69]. The endogenous CBi ligands diffuse 
back and bind to CBi receptors located on the pre-synaptic nerve terminals resulting in G- 
protein activation, calcium channel inhibition and eventual inhibition of neurotransmitter 
release (Figure 1.7) [69].
Figure 1.7: Endocannabinoid-Mediated Neurotransmitter Signalling
Adapted from Piomelli et al [69]
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1.8.7 Role Of The ECS In The Modulation Of Energy Regulation
1.8.7.1 Animal Studies
The vital function of the ECS in normal physiology is proposed by its evolutionary 
preservation and presence even in lower-level organisms [70]. Its role in the regulation of 
energy balance has been demonstrated in animal studies where chronic activation of the ECS 
increases food intake and promotes weight gain [71]. Conversely, CBi blockade in the diet-
induced obese mouse reduces fat mass while CBi receptor knock-out mice maintain a lean
phenotype and are resistant to diet-induced obesity [72]. These feeding experiments suggest 
that endocannabinoids affect the homeostatic control of body weight, not only through 
central orexigenic mechanisms at known sites in the hypothalamus and limbic forebrain but 
also through factors independent of food intake by peripheral effects in the regulation of 
energy metabolism [58]. These peripheral actions of the ECS include mediation of lipogenesis 
and modulation of adipocytokine profiles in adipose tissue and the liver, and gluconeogenesis 
in skeletal muscle [60].
1.8.7.2 Human Studies
A potential link between the ECS and obesity has also been suggested by clinical data in 
human studies. Higher concentrations of circulating endocannabinoids and CBi receptor 
expression have been noted in obese as compared to lean women [73]. Similarly, both AEA 
and 2-AG levels are significantly enhanced in individuals with binge eating disorders [74]. 
Genetic studies have also shown an association between a polymorphism in the gene 
encoding the main endocannabinoid-degrading enzyme, fatty acid amide hydrolase (FAAH), 
and elevated BMI in white and black patient groups, though not in subjects of Asian origin 
[75].
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Patients with obesity, or hyperglycaemia associated w ith type II diabetes, also display greater 
concentrations of endocannabinoids in visceral fat, or serum, respectively, than 
corresponding normal-weight, euglycaemic controls [76]. The metabolic effects of the ECS are 
also borne out in phase III clinical trials of the first selective CBi receptor antagonist 
SR141716, or rimonabant, where treatment promoted significant weight loss and reduction 
in waist circumference [77]. These have been accompanied by parallel improvements in the 
metabolic profile, namely reductions in fasting insulin and triglyceride levels, a rise in HDL 
cholesterol and adiponectin [77-81].
1.8.8 Therapeutic Potential Of CBi Receptor Ligands In The Management Of
Obesity
Stimulation of the ECS favours several adverse metabolic processes resulting in weight gain, 
lipogenesis and impaired glucose metabolism, thus making it a novel therapeutic target for 
managing features of the metabolic syndrome, principally obesity and its associated 
cardiovascular sequelae. Furthermore, the observations outlined in the above studies raise 
the possibility that by reducing central adiposity, CBi receptors may exert differential effects 
in visceral as opposed to subcutaneous fat depots, making both important areas for study. 
The potential sites of action and proposed therapeutic clinical benefits of CBi receptor 
antagonist treatment have been summarised in Table 1.5.
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Table 1.5 : Potential Sites And Therapeutic Effects Of CBi Antagonists
Adapted from Pagotto et al [82]
Hypothalamus Anorexigenic effect Body weight
c .  * Nucleus Accumbens I Food intake Abdominal obesity
OS Adipose tissue t Adiponectin I Lipogenesis Dyslipidaemia Insulin resistance
Muscle |  Glucose uptake Insulin resistance
O0 Liver jLipogenesis Dyslipidaemia 
Insulin resistance
-0 Gastrointestinaltract t  Satiety signals Body weight Abdominal obesity
1.9 Polycystic Ovary Syndrome (PCOS)
PCOS is the commonest endocrinopathy in women of reproductive age, affecting up to 10% of
the premenopausal population [83]. It has become increasingly apparent that in addition to
its well-established effects on female reproductive health, PCOS also comprises multiple
metabolic abnormalities associated with long-term health risks, including glucose intolerance
and insulin resistance, type II diabetes, hypertension, dyslipidaemia, visceral adiposity and
endothelial dysfunction [84-91]. Although there is a lack of sufficient epidemiological data in
regard to absolute cardiovascular event rates, the increased prevalence of the above
cardiovascular risk factors has been clearly documented. Developing therapeutic strategies to
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minimise this vascular burden is therefore important. The recognition of insulin resistance as 
a factor in the pathogenesis of PCOS had resulted in the widespread and accepted use of 
insulin-sensitising agents in the treatment of this condition. Despite evidence for increased 
presence of surrogate markers of cardiovascular disease, it is still unclear whether this is 
associated with accelerated atherosclerosis and endpoint data are lacking, an issue we aim to 
address in this study.
1.9.1 Diagnosis of PCOS
Patients with PCOS present with a multitude of complaints ranging from hirsutism, acne, 
menstrual irregularities and infertility, and are therefore seen by a variety of healthcare 
professionals including primary care physicians, endocrinologists, dermatologists, and 
gynaecologists, making a clear consensus for diagnosis vital. The first international 
conference on PCOS was held at the National Institutes of Health in 1990, when three key 
features were identified by majority opinion as necessary for the diagnosis of PCOS [92]:
1. Clinical and/or biochemical hyperandrogenism
2. Chronic anovulation
3. Exclusion of other endocrine disorders including congenital adrenal hyperplasia, 
hyperprolactinaemia, Cushing's syndrome, thyroid dysfunction, and androgen- 
secreting tumours.
The most recent consensus statement from the European Society of Human Reproduction and 
Embryology/American Society for Reproductive Medicine (ESHRE/ASRM)-sponsored PCOS 
workshop group in Rotterdam in 2003 revised the criteria for diagnosis to include two from 
the following three features in addition to the exclusion of other endocrine diseases [93]:
1. Clinical and/or biochemical hyperandrogenism
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2. Oligomenorrhoea or chronic anovulation
3. Radiological evidence of polycystic ovaries
Despite the increasing awareness of insulin resistance and other metabolic abnormalities 
associated with PCOS, no aspects of these features are included in the current definition.
1.9.2 Pathogenesis Of PCOS
The exact aetiology of PCOS remains unknown though multiple genetic and extrinsic factors 
contribute towards the phenotypic expression. PCOS was originally thought to arise as a 
result of abnormal pituitary function and androgen excess; however there is now increasing 
evidence for insulin resistance as an additional pathogenetic factor.
1.9.2.1 Abnormal Pituitary Function
One of the first laboratory abnormalities identified in PCOS is excessive pituitary secretion of 
luteinising hormone (LH) relative to follicle stimulating hormone [FSH], associated with 
increased pulses of hypothalamic gonadotrophin releasing hormone (GnRH); this implicated 
in the pathogenesis of PCOS by increasing ovarian theca cell androgen synthesis [94]. 
However, abnormal pituitary function alone does not account for all cases as not all women 
with PCOS exhibit elevated LH concentrations [95].
1.9.2.2 Abnormal Steroidogenesis
Elevated androgen levels in PCOS are thought to result from the dysregulation of
steroidogenesis arising from either functional ovarian hyperandrogenism (FOH) or functional
adrenal hyperandrogenism (FAH). FOH is found in about 70% of subjects with PCOS
characterised by excessive secretion of 17-hydroxyprogesterone (17-OHP) in response to
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GnRH agonist stimulation and failure of dexamethasone to suppress free plasma testosterone 
[95]. FAH is found in approximately 50% of patients with PCOS and can be demonstrated by 
increased secretion of dehydroepiandrosterone (DHEA) in response to adrenocorticotropic 
hormone (ACTH) [95]. The most likely cause of the excessive androgen secretion in both 
glands may be dysregulation of the 17-hydroxylase and 17,20-lyase activities of P-450cl7, the 
rate-limiting steps in androgen biosynthesis (Figure 1.8) [95]. The cause of this abnormal 
regulation remains unknown, though hyperinsulinaemia may play a role in many cases.
Figure 1.8: Ovarian Steroid Biosynthesis Pathways [95]
(Adapted from Rosenfield et al)
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1.9.2.3 Insulin Resistance
A link between abnormal insulin action and reproductive abnormalities was first described in
1921 by Achard and Thiers in their case of "diabete des femmes a barbe" (diabetes in a
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bearded woman) [96], and later described as an association between amennorhoea, cystic 
ovaries and masculinisation by Stein and Leventhal in the 1930s leading to the term Stein- 
Leventhal syndrome [97]. This association with hyperandrogenism and PCOS was eventually 
confirmed in the early 1980s [98, 99]. There is evidence for insulin resistance prevalent from 
an early age in PCOS and at a level disproportionate to that expected from BMI [100]. Up to 
10% of women with PCOS w ill have type II diabetes by the age of 40, and approximately one- 
third w ill have an abnormal glucose tolerance test -  both rates significantly higher than in 
matched controls [84]. Also, PCOS is often accompanied by acanthosis nigricans, a 
dermatological marker of insulin resistance [101]. Although excess androgen levels can cause 
modest reductions in glucose tolerance as seen in anabolic steroid users, in PCOS the 
predominant abnormality is thought to be stimulation of ovarian and adrenal steroidogenesis 
as a result of insulin excess [95,102].
1.9.3 Insulin Resistance And Its Role In Reproductive Abnormalities In PCOS
Despite resistance to insulin action in adipose tissue and skeletal muscle, the ovary and 
adrenal glands appear to remain relatively sensitive, i f  not hypersensitive to the effects of 
insulin. Both insulin and insulin-like growth factor (IGF) have stimulating effects on androgen 
production resulting in abnormal ovarian follicular development (Figure 1.8) [95]. This 
phenomenon is not just restricted to obese women with PCOS, as even lean subjects have 
been shown to display ovarian insulin hypersensitivity and hypersecretion in the setting of 
otherwise normal insulin sensitivity [103]. Also, states of hyperinsulinaemia and 
hyperandrogenism are associated with reduced circulating levels of sex-hormone binding 
globulin (SHBG), resulting in further elevations in free androgen concentrations [104]. These 
processes contribute to the clinical manifestations of increased androgen activity in the form 
of hirsutism, acne, alopecia, as well as ovarian dysfunction and menstrual irregularity [105].
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1.9.4 Insulin Resistance And Its Role In Metabolic Abnormalities In PCOS
Insulin resistance in PCOS is not only linked w ith the reproductive abnormalities discussed 
above, but also w ith a wide spectrum of metabolic abnormalities that are known to predate 
type II diabetes and cardiovascular disease (Figure 1.9).
Figure 1.9: Consequences Of Insulin Resistance In PCOS
Adapted from Sattar et al [105]
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1.9.4.1 Obesity And Central Body Fat Redistribution
Obesity is an extremely common clinical feature in PCOS with 50-60% women having a BMI > 
25 kg/m2 [105]. Numerous studies have also illustrated body fat redistribution with a greater 
tendency towards accumulation of central adiposity. This is evidenced by greater waist 
circumference measurements and waist:hip ratios in PCOS independent of BMI [106], and 
two-fold higher visceral and pre-peritoneal fat thickness in women with PCOS compared to 
BMI-matched controls [107]. This increased central obesity has also been shown to correlate 
with higher insulin resistance rates as well as elevated fasting insulin and triglyceride levels 
in this population, further supporting the growing evidence for a pivotal role of visceral fat 
tissue in the development of adverse metabolic profiles [107,108].
1.9.4.2 Glucose Intolerance And Type II Diabetes
Obesity is one of the strongest predictors for type II diabetes as demonstrated by the Bruneck 
study which identified a rising incidence of impaired fasting glucose [IFG], impaired glucose 
tolerance [IGT] and frank diabetes proportional to rising BMI [109]. The higher incidence of 
obesity in PCOS therefore contributes to the excess risk seen in this population. However, 
studies have also demonstrated that women with PCOS have a greater risk for altered glucose 
metabolism even after accounting for total adiposity [Figure 1.10] [105].
One American study identified overall prevalence rates of IGT at 31.1% and of type II diabetes 
at 7.5% in PCOS women aged 14-44 years, and in the non-obese PCOS population (BMI < 27 
kg/m2] the prevalence of IGT was 10.3% and diabetes 1.5% [85]. These rates were 
significantly higher than in controls matched for age, weight and ethnicity even at this young 
age. Overall, current clinical evidence suggests an overall increased risk of IGT/type II 
diabetes of two to four-fold in women with PCOS compared to age and weight matched 
controls [105].
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Figure 1.10: Increased Insulin Resistance In PCOS
Adapted from Sattar et al [105]
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1.9.4.3 Lipids And Lipoprotein Profiles
Dyslipidaemia is the most common metabolic abnormality observed in women with PCOS 
affecting up to 70% of this population [110]. The atherogenic lipid profile associated with 
PCOS mirrors that seen in type II diabetes and is generally characterised by elevated serum 
triglycerides and VLDL, a reduction in HDL concentration and a modest rise in LDL [89, 111]. 
These findings are present in both obese and lean PCOS subjects and remain significant when 
compared to matched controls. These studies have also demonstrated an association of the 
adverse lipid profile with both elevated insulin levels in non-diabetic women as well as an 
unsurprising correlation with the presence of diabetes.
Insulin is a major positive regulator of lipoprotein lipase, suppresses lipolysis and increases
free fatty acid mobilisation from adipose tissue stores, therefore the elevations in
triglycerides and reduction in HDL may be more closely related to insulin resistance [112].
24-40% of women with PCOS also display qualitative changes in LDL which may contribute to
an increase in cardiovascular risk in PCOS [113, 114]. The LDL lipoprotein phenotype
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reported is an increase in LDL density with a common finding being type III or type IV LDL 
subclasses (LDL III, density range = 1-033-1*038 g/ml; LDL IV and LDL V in the density range 
= 1-038-1-050 g/ml) [115]. Theses variations in LDL are less dependent on changes in body 
weight and insulin resistance, and may partly be related to hyperandrogenism [112,116].
1.9 A  A  Blood Pressure
There is currently no convincing data confirming excess risk of hypertension in PCOS 
compared to a control population, though the current evidence is limited by the availability of 
only a restricted number of small studies addressing this issue [111]. Zimmerman et al found 
no differences in 24-hour ambulatory blood pressure or left ventricular mass between 
subjects w ith PCOS and normal controls, despite significant differences in insulin resistance 
[117]. However, Fridstrom and colleagues further evaluated the effect of pregnancy on blood 
pressure in PCOS by means of a case-control trial and demonstrated an increased risk of 
hypertension in the third trimester and during labour [118]. Whether PCOS therefore 
represents a high risk state for hypertension still requires further clarification. A large long­
term follow-up study by Wild and colleagues, suggested an increased prevalence of 
hypertension in patients with PCOS, but with no absolute evidence of increased risk of 
mortality and morbidity from coronary heart disease [119].
1.9.4.5 Haemostatic Factors
There is now increasing evidence linking raised plasma levels of haemostatic factors 
(including PAI-1, tissue plasminogen activator inhibitor (t-PA) and fibrinogen) w ith risk for 
coronary heart disease (CHD). Furthermore PAI-1 is positively associated with insulin 
resistance and predictive of T2DM in the general population [120, 121]. PAI-1 has been 
shown to be elevated in PCOS correlating directly with obesity and inversely with insulin 
sensitivity [87].
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1.9.4.6 Inflammation
Chronic, low grade inflammation, as reflected by an increase in surrogate markers such as 
CRP, independently predicts those at risk for CHD and type 2 diabetes [122]. Women with 
PCOS have higher circulating CRP concentrations in comparison to controls [91,123]. These 
elevations are independent of BMI and are also associated with greater insulin resistance. 
Preliminary genetic studies have also suggested a potential link between polymorphisms in 
the genes encoding TNF-a and IL-6 with hyperandrogenism and PCOS [124,125].
1.9.4.7 Adipocytokine Profiles
Studies evaluating serum concentrations of adiponectin, an insulin sensitising cytokine, have 
shown a clear correlation with BMI and central obesity. Obese women with PCOS 
demonstrate reduced levels of adiponectin though no difference has been seen in comparison 
to weight-matched controls [126].
1.9.4.8 Prevalence Of The Metabolic Syndrome In PCOS
As discussed previously, the metabolic syndrome represents a potential means of identifying 
individuals at elevated risk of future CVD. Women with PCOS have a greater prevalence of the 
metabolic syndrome of 15-50% depending on the criteria used to define the syndrome [127- 
129]. Dokras et al found a 47.3% prevalence rate of the metabolic syndrome, according to the 
WHO criteria, in PCOS in contrast to 4.3% in an age-adjusted control population and 23.4% in 
the NHANES study group (Figure 1.11) [127]. These studies also highlight an increased 
prevalence of the individual components of the syndrome compared to control populations 
and this has also been demonstrated in the preceding sections.
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Figure 1.11: Prevalence Of The Metabolic Syndrome In PCOS
Adapted from Dokras et al [127]
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1.9.5 Vascular Abnormalities In PCOS
1.9.5.1 Endothelial Dysfunction
Endothelial dysfunction, a marker of vascular damage, has recently been linked to the 
development of atherosclerosis and is now considered to be an independent predictor of 
future CVD events [130]. Numerous studies have shown early impairment of endothelial 
structure and function in PCOS, affecting even the young, normal-weight, non-dyslipidaemic, 
non-hypertensive women [91, 131]. Whether therapeutic interventions to improve 
endothelial function translate into any clinical benefit w ith reduced CVD events however, 
remains unknown.
1.9.5.2 Subclinical Atherosclerosis
There are a growing number of studies highlighting an increased vascular risk in PCOS based
on surrogate end-points of CVD, including carotid intima media thickness (CIMT), and
coronary artery calcification. In women undergoing coronary angiography, those w ith more
extensive coronary artery disease (CAD} were more likely to have polycystic ovaries on
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ultrasound associated with androgenic and metabolic abnormalities [132]. Also, coronary 
artery and aortic calcification is more prevalent in PCOS than in obese and non-obese women 
of a similar age and is comparable to the rates seen in men at the same age [128, 133]. 
Women over the age of 45 years with PCOS have significantly greater CIMT compared to age 
and BMI-matched controls suggesting premature carotid atherosclerosis [134]. Moreover, 
women with PCOS also display altered vascular function, as measured by surrogate markers 
of arterial stiffness including brachial pulse wave velocity, which may be associated with a 
functional defect in the vascular action of insulin [135].
1.9.5.3 Coronary Heart Disease Risk In PCOS
Despite a clear association between PCOS and an increased prevalence of adverse metabolic 
features and elevated markers of vascular risk, there is limited evidence confirming an 
absolute
increase in CVD events in this group and larger studies are still required to elucidate the 
actual risk. A long-term retrospective cohort study comparing women with PCOS to age- 
matched controls demonstrated that a history of nonfatal cerebrovascular disease and 
cardiovascular risk factors including diabetes are more prevalent among women with PCOS
[136]. However, this study has been criticised for identifying cases of PCOS based only upon 
histopathology records from women who had undergone ovarian surgery and thus not truly 
representing the PCOS population. The Nurses' Health Study is one of the largest studies 
assessing the risk for CHD and stroke associated with a history of irregular menstrual cycles
[137]. 82 439 female nurses were followed prospectively for 14 years and women reporting 
usually irregular or very irregular cycles had an increased risk for both nonfatal and fatal CVD 
as well as a non-significant increase in overall stroke risk [137]. Since 80-90% of women 
reporting menstrual irregularity have PCOS, these data suggested a 50% excess CHD risk in 
PCOS compared to age and BMI matched controls, in keeping with the greater prevalence of 
the metabolic syndrome in this group [105].
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1.9.6 The Role Of Metformin In The Treatment of PCOS
The mainstay of treatment for PCOS is lifestyle modification. However, i f  cardiovascular risk 
remains a concern despite measures to address diet, exercise and smoking cessation, then the 
insulin sensitiser, metformin, is increasingly being used in the therapeutic adjunct in the 
management of PCOS. While metformin exerts its predominant metabolic and 
glucoregulatory action in the liver, considerable interest in its use has arisen by the 
recognition of its pleiotropic actions on several tissues affected by insulin resistance, 
including adipose tissue and the endothelium [138]. In subjects with PCOS, metformin not 
only improves insulin sensitivity [139], but also reduces circulating concentrations of 
endothelin-1, a marker of endothelial dysfunction [140]. This potential action on the vascular 
endothelium w ill be evaluated further in this thesis.
1.10 Thesis Aims And Objectives
The metabolic syndrome comprises a cluster of disturbances, including central obesity, 
dyslipidaemia and hypertension, centred around insulin resistance. Affected individuals are 
at increased risk of type II diabetes and CVD, therefore developing novel therapeutic 
strategies to minimise this is a priority public health challenge.
The adipocyte represents a major molecular target for novel therapeutic agents. CBi 
receptors are expressed in adipocytes, and early trials of a CBi antagonist (SR141716) 
confirm the potential value of this compound in the metabolic syndrome. Some of its effects 
may be mediated via inhibition of preadipocyte proliferation and differentiation as well as a 
change in adipocytokine production.
PCOS is the commonest endocrinopathy in young women with well-established effects on
reproductive and metabolic health. It is also apparent that PCOS is a vascular disorder
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associated w ith insulin resistance. Metformin therapy improves insulin sensitivity in PCOS 
but there is limited evidence to support whether these benefits improve vascular risk or 
indeed whether they represent a direct effect of the drug on the vasculature, or an indirect 
action mediated through adipokine production or other factors relating to adipose mass.
When the present study was originally designed, the aim had been to investigate the 
pharmacological effects of a single agent, a CBi receptor antagonist, on aspects of the 
metabolic syndrome using in vitro and in vivo models. This was however not feasible due to 
number of factors. Being a novel therapeutic drug, it was not possible to obtain this for 
independent study in a clinical trial setting at the time this project was commenced. 
Furthermore the agent was subsequently withdrawn from clinical use shortly afterwards for 
reasons that w ill be detailed in the final chapter. Therefore, whilst CBi receptor modulators 
were utilised in the in vitro experiments, metformin was chosen as an alternative 
investigational medicinal product for the in vivo studies.
The overall hypothesis for this thesis is that existing (metformin) and novel (CBi antagonist) 
pharmacological agents that target components of the metabolic syndrome may exert their 
benefits not only by improving insulin sensitivity and obesity, but also through indirect 
mechanisms involving a switch in the adipokine profile. This hypothesis w ill be tested using 
appropriate models of the metabolic syndrome in vitro (adipogenesis) and in vivo (PCOS) as 
follows:
1. To evaluate the actions of cannabinoid receptors on proliferation, differentiation and 
adipokine production in models of in vitro adipogenesis.
2. To determine the in vivo effects of metformin therapy on arterial stiffness, endothelial 
function, adipokine profile and insulin sensitivity in young women with PCOS.
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CHAPTER 2 : ESTABLISHMENT OF PLASMID STANDARD CURVES
FOR MEASUREMENT OF TRANSCRIPT EXPRESSION
2.1 INTRODUCTION
Analysis of the activation or inactivation of gene expression has long been used to provide 
insight into the understanding of the regulation of cellular function and thus the 
pathophysiology of disease processes. As DNA is transcribed to mRNA and the latter 
translated to produce functional proteins, quantification of mRNA levels can be used to study 
gene expression [141]. Numerous techniques have been developed to allow such study 
including Northern blot analysis, ribonuclease protection assay, microarrays, serial analysis 
of gene expression as well as conventional and quantitative real time polymerase chain 
reaction. An overview of some of these methods, including their advantages and limitations, is 
discussed below.
2.1.1 Northern Blot Analysis
The technique of Northern blotting was developed by James Alwine et al at Stanford 
University in 1977, and refers to a process by which electrophoretically separated bands of 
RNA are transferred to a nylon or nitrocellulose membrane, and specific transcripts 
subsequently detected by hybridisation to radio-labelled DNA probes followed by 
autoradiography. 32P-labelled probes have been conventionally used but non-radioactive 
systems have now also become available [142,143].
Northern blotting allows mRNA size determination and can thus be useful to demonstrate 
alternatively spliced transcripts or mutations that result in modified mRNA sizes [144]. While 
this method allows detection of highly specific RNA bands, it  supplies information about
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tissue distribution, but not cellular location of target RNA, and is further limited by the 
requirement for large quantities of total RNA from whole tissue. This technique has been 
superseded, in recent years, by the development of more modern techniques that have 
increased sensitivity, are less time-consuming and provide more quantitative results.
2.1.2 Ribonuclease Protection Assay
The ribonuclease protection assay (RPA) is a highly sensitive and specific method for 
detecting RNA and its subsequent quantification. RNA extracted from cells is hybridised with 
RNA probes, synthesised with the aid of bacteriophage-derived RNA polymerases, containing 
sequences complementary to those of the gene of interest allowing the formation of double­
stranded RNA. Single stranded RNA is then cleaved by RNAse resulting in residual fragments 
specific to the gene of interest [144,145]. Based on the quantity of target RNA present in the 
study sample, information can be derived concerning levels of gene expression. The 
simultaneous use of multi-probe RNA systems has the advantage of allowing the absolute 
quantification of multiple species of RNA in a single specimen enabling their comparison, but 
the method is limited by the large volume of source material required.
2.1.3 cDNA microarrays
In a cDNA array, multiple gene-specific oligonucleotides derived from RNA transcripts are
individually arranged on a single matrix which is then probed with fluorescently tagged cDNA
representations from total RNA pools [144, 146]. The relative amount of transcript present
can therefore be determined by the type of fluorescent signal generated. A single array can
contain tens of thousands of probes, therefore this high-throughput method enables the
simultaneous study of multiple genes and also allows comparison of gene expression profiles
in different settings, for example, in experiments studying the effects of the presence or
absence of a specific drug [144]. The main disadvantages include cost, as well as the
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challenge of accurate statistical analysis and interpretation of the vast quantities of data 
generated.
2.1.4 Polymerase Chain Reaction
2.1.4.1 Conventional Polymerase Chain Reaction [147]
Polymerase Chain Reaction [PCR) allows highly sensitive detection and amplification of short 
[approximately 100-500 base pairs), target sequences of a larger DNA molecule in a relatively 
short period of time in an in vitro setting. A typical PCR reaction w ill require a sample of 
target [genomic or plasmid) DNA, a thermostable DNA polymerase, forward and reverse 
oligonucleotide primers to recognise the target DNA sequence, deoxynucleotide 
triphosphates [dNTPs), reaction buffer and magnesium. The reaction mix is then placed in an 
automated thermal cycler that proceeds through stages at different temperature settings for 
different periods of time, each series of which is referred to as a single cycle of amplification. 
Each individual PCR cycle w ill theoretically double the quantity of the target DNA sequence. 
Therefore ten cycles w ill multiply the sequence by a factor of about one thousand, and twenty 
cycles by a factor of more than a million in just a few hours.
The PCR process occurs in three main stages. The first stage is the initial DNA denaturation 
step which separates the two intertwined strands of DNA from each other producing single­
stranded DNA templates necessary for the DNA polymerase. The complete denaturation of 
the DNA template at the start of the PCR reaction is of key importance as incomplete 
denaturation of DNA results in inefficient utilisation of the DNA template in the first 
amplification cycle and thus poor yield of PCR product [amplicon). This initial denaturation 
should be performed over an interval of 1 to 5 minutes at 95°C.
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The next stage includes the actual amplification cycles and occurs in three steps. The first step 
denatures the DNA at the start of each cycle. This also occurs at 95°C but lasts for 30 seconds 
to 2 minutes. Since the PCR product synthesized in the first amplification cycle is significantly 
shorter than the template DNA, it is completely denatured under these conditions. This is 
followed by the primer annealing step for which the temperature is reduced to 40-60°C for 
30-60 seconds. At this temperature, the oligonucleotide primers can form stable associations 
(annealing) w ith the separated target DNA strands and enable the third step of the cycle, i.e. 
DNA synthesis by a thermostable DNA polymerase performed at 70-75°C lasting 1-2 minutes. 
The number of times this cycle of denaturation, annealing and DNA synthesis is repeated 
depends upon the amount of template DNA and expected yield of the PCR product. Usually
25-40 cycles are performed.
After the last cycle, the samples are incubated at 72°C for 5-15min for the final extension 
stage to fill-in the protruding ends of newly synthesized amplicons. The reactions are then 
held at 4°C until required for further analysis of e.g. size, quantity and sequence, or for use in 
further experimental procedures such as cloning in plasmid vectors. A schematic 
representation of the PCR cycle is given in Figure 2.1.
Figure 2.1: Schematic Diagram Of The PCR Cycle
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PCR can be used for semi-quantitative measurement of transcript expression i f  the number of 
cycles is kept within the logarithmic phase of amplification. The PCR product amount is then 
determined by densitometric analysis of ethidium bromide fluorescence upon gel 
electrophoresis and co-amplification of the transcript of interest with internal controls can 
allow comparison between different samples.
2.1.4.2 Quantitative Polymerase Chain Reaction (QPCR)
QPCR is a highly sensitive technique for studying gene expression by amplification of defined 
sequences of target RNA. Extracted RNA is initially reverse transcribed to complementary 
DNA (cDNA), followed by PCR amplification. Quantification of the PCR product occurs during 
the exponential phase allowing both absolute and relative measurement of the gene of 
interest. QPCR has the advantage of allowing the simultaneous analysis of multiple samples 
by standardising data to a known calibrator (housekeeper gene), thus enabling the direct 
comparison of samples collected from separate populations and different points in time 
[144]. The most sensitive QPCR machines use glass capillaries and are able to detect 
transcript copy numbers as low as multiples of ten, whereas the higher throughput machines 
utilise 96 well plates with sensitivity for transcript numbers in the hundreds. It is, therefore, 
also a useful technique in circumstances where source material is limited. However, the 
validity of this procedure is dependent upon careful optimisation of all reaction components 
as well as accurate quantification of the amplification product.
QPCR is identical to conventional PCR but also allows real time monitoring of the reaction
process by including a fluorescent reporter molecule either in the form of a double-stranded
DNA-binding dye e.g. SYBR® Green (Figure 2.2), or dye-labelled probes e.g. Taqman®. The
SYBR® based assays are relatively easier to design and optimise compared to the probe
based techniques and have been used to study gene expression for the purposes of the
present study. SYBR® Green has a strong affinity for dsDNA and upon binding there is a
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1000-fold increase in its fluorescence (Figure 2.2). As the PCR proceeds the quantity of 
dsDNA synthesised rises which further augments SYBR® binding and thus fluorescence. The 
first cycle at which the ambient background fluorescence can be distinguished from that 
generated by PCR amplification is termed the threshold cycle (Ct). This Ct value is directly 
proportional to the quantity of DNA present in the initial template.
Figure 2.2: Schematic Representation Of SYBR® Green QPCR
* * * y  'w  * m n r
*
— -  DNA
Primer
#  SYBR Green Denaturation Primer annealing DNA synthesis
2.1.4.3 Methods Of Quantification
QPCR enables both absolute and relative measurement of mRNA.
Absolute quantification measures the total quantity of the target sequence and is usually 
expressed as the number of copies of mRNA present in a given sample. The gene of interest 
can be cloned in a plasmid vector allowing measurement of plasmid DNA concentration. A 
QPCR standard curve can then be generated by amplification of serial dilutions of the plasmid 
DNA and plotting the log of the initial known template copy number against the Ct value 
obtained for each corresponding dilution. Therefore copy numbers in experimental samples 
can be determined by comparison of their Ct values to this standard curve.
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Relative quantification allows gene expression to be reported relative to that of an 
endogenous control or housekeeper gene whose expression is constant in all samples [144]. 
This process helps control for differences between samples that may have arisen during RNA 
extraction and reverse transcription. Gene expression can also be expressed as fold-changes 
relative to a calibrator, such as Day 0 in time-course experiments or by comparison to an 
untreated, negative control.
A combination of both the above QPCR methods was utilised in this study. Absolute mRNA 
copy numbers were determined for each sample following which the results were normalised 
to housekeeper gene expression.
2.1.5 Chapter Aims
This chapter aims to describe the methods used to produce a series of plasmid cDNA 
standards and optimise QPCR conditions to allow measurement of transcript expression for 
human and murine CBi and CB2 receptors, and markers of adipogenesis. The transcriptional 
control of adipogenesis and details of these individual genes is discussed in further depth in 
Chapter 3.
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2.2 MATERIALS AND METHODS
All centrifugation steps were performed in a Rotina 46R Hettich Zentrifiigen (Patterson 
Scientific, Luton, UK), unless otherwise stated.
2.2.1 Genomic DNA Extraction
Ethical approval was obtained to extract genomic DNA from human and mouse whole blood 
samples which was undertaken with the use of the QIAamp DNA Blood Mini Kit (QIAGEN Ltd, 
Crawley, UK) as per the manufacturer's instructions. 200 pi of whole blood was combined 
with 20 pi 20 mg/ml RNAse A (Promega UK Ltd, Hampshire, UK), 25 pi Proteinase K and 200 
pi Buffer AL (lysis buffer), incubated at 70°C for 10 minutes then mixed with 210 pi of 
absolute ethanol by vortexing. The sample was transferred to a QIAamp spin column placed 
within a 2 ml collection tube, and centrifuged at 8000 rpm for 1 minute. The column was then 
transferred to a clean 2 ml collection tube and the previous sample discarded. 500 pi of Buffer 
AW (wash buffer) was added and the column centrifuged at 8000 rpm for 1 minute. The 
column was again placed in a fresh 2 ml collection tube, combined with another 500 pi of 
Buffer AW and centrifuged at 13000 rpm for a further 3 minutes. The column was then 
transferred to a clean 1.5ml Eppendorf tube and DNA eluted with 200 pi of ultra pure water 
preheated to 70°C, by centrifugation at 8000 rpm for 1 minute.
2.2.2 DNA Quantification
DNA concentration was quantified by measuring absorbance at 260nm (A260) and 280nm 
(A 2so) using a Gene Quant Pro spectrophotometer (Gene Quant, GE Healthcare), and purity of 
the sample assessed by the A260/A 280 ratio.
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2.2.3 Primer Design
Primers are short nucleic acid chains usually 15-30bp in length, specific to the gene of 
interest, and serve as a starting point for DNA replication. Longer primers provide higher 
specificity. The primer should not be complementary to itself or to any other primer in the 
reaction mixture in order to avoid the formation of primer-dimers and hairpins. All possible 
sites of binding between primers and the template DNA should be noted to ensure correct 
identification of the target DNA sequence.
Nucleotide mRNA sequences were obtained for the genes encoding human and murine CBi 
and CB2 receptors, murine markers of adipogenesis - preadipocyte factor 1 (Pref-1), CCAAT- 
enhancer-binding protein (3 (C/EBPp), peroxisome proliferator-activated receptor-y (PPARy), 
and glycerol-3-phosphate dehydrogenase (GPDH); and house keeper gene acidic ribosomal 
phosphoprotein (ARP), from the online database GenBank available at the National Centre for 
Biotechnology Information website (http://www.ncbi.nlm.nih.gov/). Based on these 
published sequences, primers were designed using the online PRIMER3 software available at 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi. Ideally primers should be 
designed to hybridise to different exons to avoid amplification from contaminating genomic 
DNA, however this was not always possible as the genes encoding CB receptors were all noted 
to contain a single exon.
Once designed, specificity of the primer sequences was analysed with a BLAST (Basic Local 
Alignment Search Tool) search (http://www.ncbi.nlm.nih.gov/blast) to ensure no cross­
reactivity with other genes. Primer sequences were manufactured by Invitrogen (Invitrogen 
Ltd, Paisley, UK). Plasmid cDNA standards for the human markers of adipogenesis - C/EBPp, 
PPARy, lipoprotein lipase (LPL) and uncoupling protein-1 (UCP-1); and the housekeeper 
gene adenosine phosphoribosyltransferase (APRT), were kindly provided by Dr Lei Zhang 
(Centre for Endocrine & Diabetes Sciences, Cardiff University).
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2.2.4 PCR Amplification
PCR was performed in compatible 500 pi polypropylene tubes using a Techne Genius DNA 
Thermal Cycler (Techne Cambridge Ltd, Cambridge, UK). A reagent master mix was prepared 
to increase reaction consistency and minimise pipetting error. Each reaction contained 
approximately 100 ng of genomic DNA (human or mouse), 1 pi forward primer (10 pmol/1), 1 
pi reverse primer (10 pmol/1), 1 pi dNTPs, 2.5 pi lOx reaction buffer, 0.4 pi (5 units/pl) Taq 
DNA polymerase (Promega, Southampton, UK), and ultra pure water to complete a total of 25 
pi per reaction. Higher magnesium concentrations were required in the reactions containing 
mouse DNA and primers. This was achieved by using a magnesium-free buffer supplemented 
with 5 pi of 25 mM MgCh. A single reaction containing all reagents except genomic DNA was 
also performed as the negative control to confirm the absence of contamination. The PCR 
reagents and thermal cycling settings are shown in Tables 2.1 and 2.2.
Table 2.1: PCR Reagents For Amplification From Genomic DNA
Sterile H2O to complete final volume of 25 pi
lOx Taq DNA polymerase buffer
(100 mM Tris-HCl, 500 nM KC1,15 mM MgCl2) 2.5 pi
dNTP mix
(lOmM each dATP, dCTP, dGTP, dTTP) lp l
Forward primer (10 pmol/1) l p l
Reverse primer (10 pmol/1) l p l
Taq DNA polymerase (5 units/pl) 0.4 pi
Genomic DNA 1 0 0  ng
Total volume 25 pi
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Table2.2: PCR Thermal Cycling Protocol
Temperature Time Ne o f cycles
In itial Denaturation 95°C 5 minutes 1
Denaturation 95°C 1  minute
Annealing 60°C 30 seconds 40
DNA synthesis 72°C 1  minute
Final extension 72°C 5 minutes 1
2.2.5 Agarose Gel Electrophoresis Of PCR Products
Following PCR the product size was verified using agarose gel electrophoresis. A 2% gel was 
prepared with 40 ml TAE lx  buffer (Tris-Acetate-EDTA), 0.8 g agarose and 2 pi of lOmg/ml 
ethidium bromide (Sigma). (To make 5Ox TAE buffer add 121g Tris base in 250ml H2O. stir to 
dissolve, add 28.6mL acetic acid, add 50ml 0.5M EDTA pH 8.0) The same concentration of 
ethidium bromide i.e. 0.5 pg/ml, was maintained in the TAE running buffer. The solution was 
heated in a conventional microwave to enable the agarose to dissolve completely and then 
allowed to set by cooling at room temperature for 2 0  minutes in the minigel apparatus. 1 0  pi 
of each amplicon and 2 pi of 6 x loading dye (Promega, UK) were placed in individual wells 
with 5 pi of 100 bp DNA ladder (Promega) and 1 pi 6 x loading dye in the final lane for 
comparison. The gel apparatus was run at 150 volts for 30 minutes and then visualised under 
an ultraviolet light source connected to a computer using an Alpha Imager™ gel 
documentation system (Alpha Innotech, San Leandro, California, USA).
2.2.6 PCR Product Purification
This protocol and reagents provided by QIAGEN (QIAGEN Ltd, Crawley, UK), was followed to 
purify each PCR product from primers, dNTPs, DNA polymerase and salts present in the PCR 
reaction, resulting in pure DNA for use in the subsequent experimental procedures.
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3 volumes of Buffer QG (solubilisation and binding buffer) was added to 1 volume of the PCR 
reaction product and mixed thoroughly by vortexing. Before proceeding it was necessary to 
ensure yellow colouration of the mixture indicating a pH < 7.5, i.e. optimal for DNA adsorption 
to the QIAquick membrane. The solution was transferred to a QIAquick spin column placed 
within a 2 ml collection tube and centrifuged at 13000 rpm for 1 minute. 0.75mls of Buffer PE 
(wash buffer) was applied to the column and centrifuged again for 1 minute. The flow­
through was discarded, column centrifuged for an additional minute and then placed in a 
clean collection tube. DNA was eluted by the addition of 50 pi of Buffer EB (Elution buffer - 
lOmM Tris-Cl, pH 8.5) to the column and a final centrifugation step at 13000 rpm for 1 
minute.
2.2.7 DNA Concentration Calculation By Agarose Gel Analysis
The purified PCR product size was verified by agarose gel electrophoresis as described in 
section 2.2.5. The quantity of the PCR product was estimated by comparison of the signal 
intensity against standard quantitative molecular weight markers on a 1 kb and 100 bp DNA 
ladder (Promega) allowing calculation of DNA concentration within the purified product 
using the following formula:
Estimated weight (ng)
------------------------------------------------------------------------ = DNA concentration (ng/pl)
Volume of PCR product loaded in gel apparatus (pi)
2.2.8 Plasmid Vector Ligation
A plasmid is a DNA molecule capable of autonomous replication. Insertion of the gene to be
replicated and then transfection into competent cells allows large scale DNA amplification by
bacterial culture. The commercially available pGEM®-T Easy plasmid vector (Promega,
Southampton, UK) contains genes encoding ampicillin resistance (Ampr) as well as the a-
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subunit of Lad ((3-galactosidase) allowing later selection of suitably transformed cell 
colonies. The bacterial host DNA encodes the remaining D-subunit thus forming functional (3- 
galactosidase upon successful transformation of competent cells. Key features of the vector 
are illustrated in Figure 2.3 including the multiple cloning region contained within the Lad 
coding region which is flanked by recognition sites for restriction enzymes e.g. EcoRl, which 
can be used to verify the presence of an insert, providing the insert itself has no EcoRl site, in 
which case 1 or more of the other restriction enzymes would be used for digestion.
Figure 2.3: pGEM®-T Easy Plasmid Vector Map & Sequence Reference Points
(adapted from Promega technical manual available at www.promega.com/tbs)
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Purified PCR amplicons were ligated with the pGEM®-T Easy plasmid in vector-insert ratios 
of 1:1, 1:3, and 3:1 based on molarity. The amount of PCR product (insert) to be included in 
ach reaction was calculated using the following formula obtained from the Promega website 
at www.promega.com/tbs:
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ng of vector x kb size of insert x vector: insert molar ratio = ng of insert 
kb size of vector
Each reaction contained 50 ng vector, 5 |xl of 2x ligase buffer, 1 pi [0.1 units) T4 
bacteriophage-derived DNA ligase (Promega), either 1, 3 or 9 ng insert DNA, and ultrapure 
water to complete a total of 1 0  pi per reaction, and then incubated at room temperature for 6  
hours prior to transfection into competent cells. This protocol has been summarised in table 
2.3.
Table 2.3: Protocol For pGEM®-T Easy Vector Ligation With PCR Amplicons
Ultrapure water 2  pi l p l Opl
2 x ligase buffer 5 pi 5 pi 5 pi
pGEM®-T Easy Vector DNA 50 ng 50 ng 50 ng
Insert DNA 
(PCR product) 3 ng 9ng 1 ng
T4 DNA Ligase 
(0.1 units per pi) l p l lp l l p l
Total volume 10 pi 10 pi 10 pi
2.2.9 Transformation Of Competent Cells
2.2.9.1 Preparation Of Culture Media
Luria Bertani (LB) medium (USB, Cleveland, Ohio) was prepared for use as bacterial growth
medium by adding 5 g LB to 200 mis distilled water and autoclaving for 1 hour. The medium
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was then cooled to 55°C before being supplemented with 200 pi of 100 mg/ml ampicillin for a 
final concentration of 1 0 0  pg /  ml.
10 mis of sterile modified SOC solution (super-optimal broth with catabolic repressor) was 
prepared by combining lOmls LB with 100 pi of 2M glucose solution (3.6 g glucose dissolved 
in 10 mis distilled water and filter sterilised) for a final concentration of 20mM glucose.
100 mg X-gal (5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside) was dissolved in 2mls 
dimethylformamide for a stock solution concentration of 50 mg/ml and stored sheltered from 
light at -20°C.
2.2.9.2 Preparation Of Agar Plates
14.8g LB-agar was added to 400mls distilled water and autoclaved for 1 hour. The solution 
was then incubated at 55°C for 2 hours and supplemented with 400 pi of 100 mg/ml 
ampicillin (final concentration 100 pg/ml) and 640 pi of 50 mg/ml X-gal (final concentration 
80 pg/ml). 25mls of the final solution was added to each 10 cm petri dish and allowed to set 
at room temperature. The agar plates were then stored inverted at 4°C until use.
2.2.9.3 Transfection
There are two main methods for preparing competent bacterial cells for transformation -
incubation in cold calcium containing buffers (chemical) or by electroporation. Both these
techniques render the cell membranes transiently permeable to extracellular DNA in the
environment thus allowing transfection with plasmid DNA. The commercially available
chemically competent Escherichia coli (£. Coif) DH5a (Invitrogen) were used in these
experiments. 4 pi of plasmid ligation products were combined with 20 pi aliquots of E. Coli
DH5a and incubated on ice for 30 minutes. The samples were then heat-shocked at 42°C for
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90 seconds and returned to ice for 5 minutes. 1 ml of sterile SOC medium (LB containing 
20mM glucose) was added to each sample and incubated at 37°C for 1 hour w ith gentle 
shaking at 150 rpm following which the samples were centrifuged at 3000 rpm for 5 minutes. 
600 pi of the medium supernatant was discarded and following gentle resuspension, 200 pi of 
the remaining transformation mix was spread onto LB-agar plates containing 100 pg/ml 
ampicillin and 80 pg/ml X-gal and incubated, inverted, overnight at 37°C.
2.2.10 Culture Of Selected Colonies
X-gal supplemented in the agar plates is a colourless galactose sugar that is metabolised by p- 
galactosidase to 5-bromo-4 chloroindole, an insoluble bright blue product. Successful cloning 
of an insert into the pGEM®-T Easy Vector interrupts the coding sequence of (3-galactosidase 
allowing recombinant clones to be identified by colour screening on indicator plates.
Using this method of blue-white screening, E.coli colonies were selected (Figure 2.4) using a 
micro-inoculator loop and used to inoculate 5 ml of LB medium containing 100 mg/ml 
ampicillin (Sigma-Aldrich Company Ltd, Dorset, UK). Cultures were grown overnight in an 
orbital shaking incubator at 200 rpm at 37°C.
Figure 2.4: Selection Of Bacterial Colonies Containing Plasmid Vector
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2.2.11 Small-Scale Isolation Of Plasmid cDNA By Alkali Lysis (Mini-prep)
1.5 ml of overnight culture fluid containing transformed cells was transferred to a 1.5 ml 
Eppendorf tube and centrifuged at 13000 rpm for 1 minute. The cell pellet was then 
resuspended in 1 ml of SET (20% sucrose, 50mM Tris.HCl, 50mM EDTA, pH 7.5) and 
centrifuged again at 13000 rpm for 1 minute. The supernatant was removed and pellet 
resuspended in 150 pi SET. This was then combined with 5 pi of 4mg/ml DNAse-free RNAse 
A (Promega UK Ltd, Hampshire, UK) and 350 pi of freshly prepared lysis solution (0.2M 
NaOH, 1% SDS [8.8 ml H20, 0.2 ml 10M NaOH and 1 ml 10% SDS]). Samples were kept on ice 
for 10 minutes, combined w ith 250 pi 3M sodium acetate (pH 5.2) and mixed by inverting the 
tube several times and kept on ice for a further 30 minutes. This was followed by 
centrifugation at 15000 rpm for 5 minutes at 4°C. The supernatant was transferred to a clean 
tube to which an equal volume of isopropanol was added and then centrifuged at 13000 rpm 
for 10 minutes at room temperature. The supernatant was discarded and DNA pellet washed 
with 1 ml 70% v /v  ethanol 30 % TioEi (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and centrifuged 
for 5 minutes. The supernatant was again discarded and DNA pellets air-dried prior to 
resuspension in 20 pi TioEi buffer.
DNA concentration was quantified by measuring absorbance at 260nm (A26o) and 280nm 
(A28o) using a Gene Quant Pro spectrophotometer, and purity of the sample assessed by the 
A26o/A2so ratio.
2.2.12 Restriction Digest Analysis Of Purified Plasmid cDNA
Following isolation of plasmid cDNA, a single-enzyme digestion was undertaken w ith the 
restriction enzyme EcoRl to allow release of the insert. Each reaction contained lp l (10 
units/ pi) EcoRl (Promega), 1 pi lOx reaction buffer, approximately 1 pg cDNA and made up 
to 10 pi w ith H20. The samples were then incubated in a 37°C water bath for 2 hours.
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2.2.13 Agarose Gel Electrophoresis
Following digestion the product size was verified using agarose gel electrophoresis. A 1.2% 
gel was prepared with 50 ml Tris-acetate-EDTA (TAE) lx  buffer, 0.6 g agarose and 2.5 pi of 
lOmg/ml ethidium bromide. The same concentration of ethidium bromide i.e. 0.5 pg/ml, was 
maintained in the TAE running buffer. The undigested and digested plasmids were compared 
to lOObp and lkb  DNA ladders. Bands corresponding to the 3 kb plasmid vector were seen in 
all lanes. Samples which also confirmed the presence of an insert of the expected size, 
released by restriction digest, were selected for DNA sequencing prior to proceeding to large- 
scale plasmid DNA preparation.
2.2.14 Automated DNA Sequencing
The plasmid cDNA products resulting from the alkali lysis procedure containing inserts of the 
expected size were analysed to ensure correct DNA sequence incorporation into the plasmid 
vectors and successful amplification in bacteria.
The sequencing reactions were performed on a Techne Genius DNA Thermal Cycler (Techne 
Cambridge Ltd, Cambridge, UK). Two reactions were undertaken for each individual cDNA 
specimen, one containing the corresponding forward primer, and one with the reverse 
primer. Each reaction contained 2 pi Big Dye Terminator Cycle Sequencing Ready Reaction 
(v3.1, ABI Prism, PE Biosystems), 2 pi 5x Big Dye reaction buffer, 1 pi 10 pmol/L primer 
(Invitrogen), approximately 200 ng cDNA, and made up to 10 pi with H2O. The PCR settings 
used are shown in Table 2.4.
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Table 2.4: PCR Protocol For DNA Sequencing
Tem perature Time of cycles
96°C 3 minutes 1
96°C 30 seconds
30
60°C 4 minutes
2.2.14.1 Sodium Acetate Precipitation
Following PCR, 1.5 pi of 3M Sodium Acetate, 31.5 pi ice-cold 95% v/v  ethanol and 10 pi sterile 
water was added to each sample. These were incubated at room temperature for 15 minutes 
and then centrifuged at 15,000 rpm for 20 minutes at 4°C. The supernatant was discarded and 
the DNA pellet washed with 250 pi ice-cold 70% v /v  ethanol and centrifuged further at 
15,000 rpm for 5 minutes at 4°C. The supernatant was removed and samples incubated for 1 
minute at 95°C prior to being resuspended in 10 pi 70% v /v  ethanol and analysed on an ABI 
310 Genetic Analyser. The resulting DNA sequences were analysed with a BLAST search to 
ensure correspondence with the genes of interest and alignment with the initial primer 
sequences.
2.2.15 Maxiprep
100 mis of LB medium containing 100 pg/ml ampicillin was inoculated with 1 ml of bacterial 
culture preserved prior to mini-prep. Cultures were grown in a 200 ml conical flask overnight 
in an orbital shaking incubator at 250 rpm at 37°C. Plasmid DNA was then extracted using the 
Qiafilter Plasmid Maxi Kit (Qiagen) according to the following protocol. The bacterial cells 
were harvested by centrifuging the overnight culture fluid at 3600 rpm for 30 minutes at 4°C 
and supernatant discarded. The cell pellet was resuspended in 10 mis Buffer PI
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(resuspension buffer with RNase A) by vortexing, combined with 10 mis Buffer P2 (alkaline 
lysis buffer), incubated at room temperature for 5 minutes and then neutralised with 10 mis 
chilled Buffer P3 (neutralisation buffer). The lysate was poured into the barrel of a QIAfilter 
cartridge, and incubated at room temperature for a further 10 minutes prior to filtration 
through a QIAGEN-tip, allowing binding of plasmid DNA to an anion-exchange resin. Protein 
and RNA impurities were removed by washing with 30mls Buffer QC (medium salt wash) and 
DNA eluted with 15 mis Buffer QF. DNA was further concentrated and purified by 
precipitation w ith 10.5 mis room-temperature isopropanol added to the eluted DNA and 
centrifugation at 11000 rpm for 30 minutes at 4°C. The supernatant was discarded, DNA 
pellet washed w ith 5 mis room temperature 70% v /v  ethanol and centrifuged at 11000 rpm 
for another 10 minutes at 4°C. The DNA pellet was then air-dried for 10 minutes, resuspended 
in 100 pi sterile water and final DNA yield calculated by measuring absorbance at 260 nm 
using a Gene Quant Pro spectrophotometer, and purity of the sample examined by the 
A260/A 280 ratio.
The purified plasmid DNA was again analysed by restriction enzyme digest and agarose gel 
electrophoresis as described in sections 2.2.12 and 2.2.13.
2.2.16 Calculation Of Transcript Copy Numbers From DNA Concentration
Determination of transcript copy numbers from DNA concentration required use of the 
following formulae obtained from http://www.promega.com/biomath:
1. Conversion of DNA concentration from pg/ml to pmol/ml based on the following formula:
pgDNA x pmol x 106pg x 1 = pmolDNA/ml
ml 660pg lpg N
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where: N = # of nucleotides in plasmid DNA (vector + inserted PCR product)
660pg = average molecular weight of a nucleotide pair.
2. Calculation of transcript copy numbers.
Based on the Avogadro constant there are 6  x 1023 copies of a molecule in 1 mole, and 1 
pmol = 10 12 moles. Therefore:
6  x 1023 copies x pmol DNA/ml x 10 3 = copies/pl
1012
2.2.17 Storage Of Plasmid DNA Stock Solutions
Following calculation of transcript copy numbers, the maxi-prep plasmid DNA samples were 
diluted in sterile water to create stock solutions of 109 copies per pi and stored at -80°C.
2.2.18 QPCR
2.2.18.1 QPCR optimisation
Efficiency of QPCR is dependent upon a number of factors. Primers should be carefully 
designed and checked for specificity to the gene of interest and where possible primers 
should span intron-exon boundaries to avoid amplification from contaminating genomic DNA. 
Amplification efficiency is also affected by differences in the melting temperature (Tm) of the 
forward and reverse primers which in turn is dependent upon the primer's own
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concentration within the reaction. Therefore the optimal Tm for each primer can be achieved 
by altering the primer concentrations.
The most favourable primer concentrations were determined by performing the primer 
matrix test (Table 2.5), where QPCR was performed using differing forward and reverse 
primer concentrations for known copy numbers of plasmid DNA. The optimum primer 
combination was that which resulted in the lowest Ct values at both high and low copy 
numbers of the target gene.
Table 2.5: Primer Concentrations Used In The Primer Matrix Test
lOOnM Forward 300nM Forward 500nM Forward
lOOnM Reverse lOOnM Reverse lOOnM Reverse
lOOnM Forward 300nM Forward 500nM Forward
300nM Reverse 300nM Reverse 300nM Reverse
lOOnM Forward 300nM Forward 500nM Forward
500nM Reverse 500nM Reverse 500nM Reverse
2.2.18.2 QPCR Amplification Efficiency & Quality Checks
As well as optimising the primer concentrations further quality checks were performed to 
ensure maximum QPCR efficiency. The Ct value should occur during the exponential phase of 
cDNA amplification, therefore the standard curve generated by plotting the Ct values against 
the log of the transcript copy numbers should generate a linear graph with a correlation 
coefficient close to 1 .0 .
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A second quality check is analysis of the melting point (Tm), the temperature at which 50% of 
dsDNA dissociates into single strands. This is identified during QPCR by a significant 
reduction in fluorescence. The correct DNA product for a specific pair of primers w ill have the 
same Tm dependent on the nucleotide base composition, with GC-rich DNA requiring a higher 
Tm than AT-rich DNA. At the end of QPCR amplification, the temperature is therefore 
increased to the Tm to identify a single peak representing a single amplified product - the 
presence of other smaller peaks indicates contaminating DNA, primer-dimers, or alternatively 
spliced transcripts.
QPCR experiments should also include negative controls where mRNA is used as the nucleic 
acid template without having undergone reverse transcription (should not yield an 
amplification product). Another precaution to avoid genomic DNA contamination is to treat 
mRNA samples w ith DNAse prior to reverse transcription.
2.2.18.3 QPCR Protocol
QPCR was performed using Stratagene's Brilliant® SYBR® Green Master Mix. Each 25 pi 
reaction contained 12.5 pi Master Mix, forward and reverse primer (as per optimised 
concentrations) and ultrapure water. Reactions were set up in Stratagene 96-well PCR plates 
and centrifuged for 1 minute at 3000 rpm prior to being transferred to the Stratagene 
MX3000P® thermocycler. The thermal cycling protocol is listed in Table 2.6.
2.2.19 QPCR Product Verification
The QPCR products were analysed by agarose gel electrophoresis, to confirm the presence of 
products of the expected base-pair size, and by DNA sequencing as described previously to 
ensure correct sequence amplification.
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Table 2.6: QPCR Thermal Cycling Protocol
Temperature Time of cycles
Enzyme activation 95°C 1 0  minutes 1
Denaturation 94°C 30 seconds
Annealing 60°C 60 seconds 40
Extension 72°C 30 seconds
95°C 60 seconds
Dissociation 55°C 30 seconds 1
95°C 30 seconds
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2.3 RESULTS
2.3.1 Genomic DNA concentrations
The human and genomic DNA concentrations are shown in table 2.7. A260 and A280 are the 
optical spectrometer measurements of absorbance at the wavelengths of 260 nm and 280 nm 
respectively. A260 is used to measure nucleic acid concentration and A280 is used to measure 
protein concentration. A ratio of A260/A 280 > 1.8 suggests little protein contamination in a 
nucleic acid sample.
Table 2.7: Quantification Of Genomic DNA Concentration
Human 0.129 0.065 129 1.985
Murine 0.049 0.028 49 1.75
2.3.2 Primer Sequences
Tables 2.8A and 2.8B list details of all the human and murine primers used during these 
experiments, including the primer nucleotide sequence, exon location, expected PCR product 
size and Tm. There were difficulties encountered while designing primers and it was not 
always possible to obtain forward and reverse primers derived from differing exons due to 
lack of product specificity or failure of PCR amplification.
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Table 2.8A: Primer Sequences for Human CB Receptors and Markers Of Adipogenesis
CBl
Forward AAG ACC CTG GTC CTG ATC CT 1 lOOnM
1 QQ
60
Reverse CGC AGG TCC TTA CTC CTC AG 1 300nM
loo
60
CB2
Forward TAG ACA CGG ACC CCT TTT TG 1 lOOnM
241
60
Reverse TTC TCC CAA GTC CCT CAT TG 1 lOOnM 60
APRT
Forward GCT GCG TGC TCA TCC GAA AG 3 lOOnM
247
60
Reverse CTT TAA GCG AGG TCA GCT GC 5 lOOnM 60
C/EBPp
Forward AAC TTT GGC ACT GGG G 1 lOOnM
304
60
Reverse GGC CCG GCT GAC AGT T 1 lOOnM 60
PPARy
Forward CAG TGG GGA TGT CTC ATA 3 300nM
390
60
Reverse CTT TTG GCA TAC TCT GTG AT 5 500nM 60
LPL
Forward GAG ATT TCT CTG TAT GGA CC 7 300nM
275
60
Reverse CTG CAA ATG AGA CAC TTT CTC 9 300nM 60
UCP-1
Forward GGG GCT TCA GCG GCA AAT CAG 2 500 nM
236
60
Reverse TAT AAG TCC CCG TGT AGC GAG TT 3 300 nM 60
Table 2.8B: Primer Sequences for Murine CB Receptors and Markers Of Adipogenesis
CBl
Forward ACA GGG CAG TAC CCC TTC TT 1 lOOnM
175
60
Reverse AGC CCC TGG TGG TAT TCT CT 1 lOOnM 60
CB2
Forward TCA TTG CCA TCC TCT TTT CC 1 500nM
188
60
Reverse GAA CCA GCA TAT GAG CAG CA 1 lOOnM 60
i 1
ARP
Forward GAG GAA TCA GAT GAG GAT ATG GGA 7 lOOnM
172
60
Reverse AAG CAG GCT GAC TTG GTT GC 7 lOOnM 60
Pref-1
Forward CGT GAT CAA TGG TTC TCC CT 5 300nM
1 A O
60
Reverse AGG GGT ACA GCT GTT GGT TG 5 500nM
14o
60
C/EBPp
Forward CAA GCT GAG CGA CGA GTA CA 1 500nM
157
60
Reverse CAG CTG CTC CAC CTT CTT CT 1 500nM
. . . . . .  . i
60
PPARy
Forward TTT TCA AGG GTG CCA GTT TC 6 300nM
220
60
Reverse AAT CCT TGG CCC TCT GAG AT 6 300nM 60
GPDH
Forward ATG CTC GCC ACA GAA TCC ACA C 8 500nM
124
60
Reverse AAC CGG CAG CCC TTG ACT TG 8 500nM 60
2.3.3 PCR Amplification
Figure 2.5 illustrates the human and murine CBi and CB2 PCR products visualised on a 2% 
agarose gel stained w ith 0.5 pg/ml ethidium bromide. Comparison was made to a 100 bp DNA 
ladder to ensure the amplified product bands were of the expected size.
Figure 2.5: Human and Murine CB PCR Products
500 bp
Lane
1
100 bp DNA 
ladder
-
2 Human CBI 188 bp
3 Murine CBI 175 bp
4 Human CB2 241 bp
5 Murine CB2 188 bp
2.3.4 Restriction Digest Analysis Of Mini-Preps
Figure 2.6 provides an example of two Human CBi mini-prep products following EcoRl 
restriction enzyme digest, visualised on a 1.2% agarose gel stained with 0.5 pg/ml ethidium 
bromide. Comparison was made to a 1 kb and 100 bp DNA ladder. Bands corresponding to 
the 3 kb plasmid vector size were seen in both samples but only 1 contained an insert of the 
expected size, released by restriction digest. This sample was selected for DNA sequencing 
followed by large-scale plasmid DNA preparation.
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Figure 2.6: Human CBi Mini-Prep Restriction Digest Products
Lane Contents
100 bp DNA ladder
Plasmid vector only
Plasmid vector and CBi insert
1 kb DNA ladder
Lane
2.3.5 Measurement of Maxi-Prep DNA Concentration
Table 2.9 lists the plasmid DNA concentrations determined by spectrophotometer analysis of 
each maxi-prep. This information was then used to calculate the transcript copy numbers 
(Table 2.10).
Table 2.9: Maxi-Prep DNA Concentrations
CBI 0.106 0.055 106 1.927
CB2 0.331 0.185 331 1.789
CBI 0.882 0.435 882 2.028
CB2 1.727 0.879 1727 1.965
ARP 0.398 0.208 398 1.913
Pref-1 1.639 0.845 1639 1.94
C/EBPP 0.760 0.412 760 1.845
PPARy 2.371 1.277 2371 1.857
GPDH 1.256 0.623 1256 2.016
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Table 2.10: Transcript Copy Numbers Determined From Maxi-Prep DNA Concentration
Gene DNA pg/m l DNA pm ol/m l Copies/pl
CBI 106 50 3 x 1010
CB2 331 156 lx lO 11
CBI 882 419 2.5 x 10^
CB2 1727 817 5 x 1011
ARP 398 189 1 x 10n
Pref-1 1639 785 5 x 1011
C/EBP0 760 363 2 x 1011
PPARy 2371 1110 6.5 x 1011
GPDH 1256 606 4 x  1011
Plasmid DNA standards for the human markers of adipogenesis (C/EBPp, PPARy, LPL) and 
housekeeper (APRT) were kindly provided by Dr Lei Zhang (Centre for Endocrine & Diabetes 
Sciences, Cardiff University}.
2.3.6 Optimisation Of QPCR Primer Concentrations
Table 2.11 lists the Ct values obtained for the primer matrix test when applied to human CBi 
and the optimum primer combination which resulted in the lowest Ct values at both high 
(106) and low (102) copy numbers. Table 2.12 lists the optimised primer concentrations for 
all the genes of interest for this study.
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Table 2.11: Human CBi Primer Matrix Test
(The Ct values presented are the mean of a single QPCR reaction performed in triplicate. The 
lowest values have been highlighted indicating the optimum primer combination)
Ct Values for 10(> copies Ct Values fo r 10- copies
^ \F o r
R e v \^
lOOnM 300nM 500nM
lOOnM 14.37 15.01 15.62
300nM 14.03 16.44 15.33
50OnM 14.78 14.85 16.81
^ \ F o r
R e v \
lOOnM 300nM 500nM
lOOnM 27.02 28.63 29.03
300nM 26.94 28.93 30.18
500nM 27.56 27.83 30.25
Table 2.12: Optimised Concentrations For All QPCR Primers
CBI 100 300
CB2 100 100
APRT 100 100
C/EBPp 100 100
PPARy 300 500
LPL 300
...
300
CBI 100 100
CB2 500 100
ARP 100 100
Pref-1 300 500
C/EBPP 500 500
PPARy 300 300
GPDH 500 500
2.3.7 QPCR Standard Curves
In order to allow estimation of copy numbers of the genes of interest in unknown samples,
standard curves for reference were generated for each gene by QPCR analysis of samples with
known copy numbers determined by serial dilutions of plasmid DNA stock solutions. The
standard curves were obtained by plotting the Ct values against the log of the transcript copy
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numbers to produce a linear graph w ith a correlation coefficient (RSq) close to 1.0 and 
amplification efficiency approaching 100%. Representative examples of the QPCR standard 
curves and amplification plots for human and murine CBi and CB2 are given in Figures 2.7A-D.
Figure 2.7A: SYBR Green® QPCR Standard Curve & Amplification Plots for Human CBi
Standard Curve
Amplification Plots
Log At values 
■ SYBR Standards. RSqO 999 
  SYBR. Y = -3-248*LOG(X)* 33.82. Elf. = 103.2%
Figure 2.7B: SYBR Green® QPCR Standard Curve & Amplification Plots for Murine CBi
Log At values 
■ SYBR Standards. RSqO 999 
  SYBR, Y = -3.182*LOG(X) *  39.05, 0 f = 106.2%
Standard Curve
Amplification Plots
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Figure 2.7C: SYBR Green® QPCR Standard Curve & Amplification Plots for Human CB2
Log fit values
■ SYBR Standards, RSq:0.996 
  SYBR Y = -3.227*LOG(X) + 33.10, Elf = 1M.114
Amplification Plots
Standard Curve
cs * S C * -0 3  > « * * *
Irfc* Cj it t v  : « a
Figure 2.7D: SYBR Green® QPCR Standard Curve & Amplification Plots for Murine CB2
Standard Curve
Log fit values
SYBR Standards. RSq 0.999
SYBR Y = -2.894*LOG(X) + 35,25. Ef. = 121.6%
Amplification Plots
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Figures 2.8A-D illustrate the dissociation curves produced during melting point analysis 
performed after QPCR for human and murine CBi and CB2 w ith a single peak denoting a single 
gene product and the absence of primer dimers.
Figure 2.8A: Dissociation Curve For Human CBi
Figure 2.8B: Dissociation Curve For Murine CBi
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Figure 2.8C: Dissociation Curve For Human CB2
Figure 2.8D: Dissociation Curve For Murine CB2
2.3.8 DNA Sequencing
Direct DNA sequencing was performed after mini-prep and repeated with the QPCR products 
after primer optimisation. The resulting sequences were analysed with a BLAST search to 
ensure correspondence with the genes of interest and alignment with the initial primer 
sequences.
107
2.4 DISCUSSION
Numerous factors need to be considered when studying gene expression in order to choose 
the most sensitive and specific approach for monitoring these transcriptional events. This 
largely depends upon the quantity of tissue available as well as the level of gene expression. 
With PCR-based techniques, it is also essential that a number of quality control measures are 
employed in order to obtain meaningful data. These include designing primers specific to the 
target genes of interest, confirming the absence of genomic DNA by the use of primers that 
span intron/exon junctions and DNAse treatment following reverse transcription, utilisation 
of either exogenous or endogenous standards or positive controls to assess reproducibility, 
and the use of negative controls to verify the absence of contamination.
A number of challenges were encountered during the course of the experiments outlined in 
this chapter. Ideally when designing primers it is preferable to obtain sequences spanning 
intron/extron junctions to help differentiate PCR amplicons from genomic products in 
subsequent experiments. This was however not always possible as a number of the genes of 
interest only contained a single exon. In other instances, such as with PPARy, primers were 
originally designed to contain sequences from different exons but resulted in amplification of 
non-specific sequences as well. Nevertheless, with careful optimisation of QPCR conditions 
there are benefits of using absolute quantification. The results obtained for the gene of 
interest can be compared to transcript expression of housekeeper genes and can thus take 
into account efficiency of the reverse transcription step, DNAse treatment and QPCR 
amplification itself. This does require the use of housekeeper genes whose expression is 
constant in the samples to be studied, and this can be quite a challenge when inducing 
differentiation.
QPCR with SYBR Green® is a sensitive and reproducible method for quantification of
transcript expression during adipogenesis. There are, however, limitations with this
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technique as well. Even higher sensitivity for detection of transcript numbers can be achieved 
with the use of capillary tubes within a Light Cycler heated with hot air instead of QPCR using 
96-well plates heated on thermal blocks but the number of samples which can be run 
simultaneously is reduced. Another shortcoming with QPCR is that detection of transcripts 
does not necessarily correlate with the translated functional protein being present in the cell. 
Therefore alternative ways of verifying these results should also be employed. For example, 
in the pre-adipocyte differentiation experiments undertaken in the following chapters 
adipogenesis is confirmed not only by measurement of mature adipocyte-specific transcript 
expression, but also by morphological appearance on Oil red 0 staining and ELISA 
measurement of adiponectin. Alternative methods, such as the use of hydrolysis probes or 
cDNA arrays can provide simultaneous information about multiple genes in a large number of 
samples but can be more complex to design and are accompanied by increased expense.
This chapter has described the techniques used to clone purified PCR products from human 
and murine genomic DNA and optimise QPCR conditions, eventually resulting in a series of 
standard curves for measurement of CBi and CB2 receptor expression as well as markers of 
differentiation in both species. This method was subsequently applied to quantify transcript 
expression in response to CB receptor modulation during in vitro adipogenesis using cell lines 
and human primary cultures as detailed in the following chapters.
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CHAPTER 3: EFFECT OF CANNABINOID RECEPTOR MODULATION
ON PROLIFERATION AND DIFFERENTIATION IN PRE­
ADIPOCYTE CELL LINES.
3.1 INTRODUCTION
As previously discussed in Chapter 1, excess adipose tissue is associated with clinical features 
of insulin resistance and the metabolic syndrome, therefore the adipocyte represents a major 
molecular target for novel pharmacotherapies aiming to reduce this burden associated with 
long-term risk of diabetes and CVD. Whereas adipose tissue was initially considered to be a 
passive connective tissue store of excess energy in the form of triglycerides, it is now also 
recognised as an endocrine organ capable of metabolic signalling [148]. This was first 
highlighted in the mid-1980s when research published by the Spiegelman and Flier 
laboratories demonstrated that adipocytes are an abundant source of a circulating serine 
protease-adipsin [149]. Since this time numerous other adipocyte secretory proteins, known 
as the adipocytokines, have been described including Acrp30 or adiponectin [150,151], TNFa 
[152], leptin [153], resistin [154], and visfatin [155]. These have been shown to play key roles 
in energy homeostasis, regulation of appetite and satiety, reproduction, and insulin sensitivity 
as well as influencing vascular and immunological functions and have been discussed further 
in Chapter 1 [148].
3.1.1 Cellular Composition Of Adipose Tissue
The predominant cell-type found in adipose tissue is the adipocyte though numerous 
additional cells are also present, collectively known as the 'stromal vascular cells' which 
include pluripotent stem cells and pre-adipocytes both of which possess the ability for
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adipogenesis, as well as endothelial cells, pericytes and macrophages all of which help 
support normal adipose tissue function [156].
3.1.2 Development Of Adipose Tissue
The embryonic development of adipose tissue begins in the second trimester when 
mesenchymal cells with adipogenic potential form clusters at various sites in close proximity 
to vascular structures, predominantly at the neck, shoulder and pelvis as well as surrounding 
essential organs including the heart and kidneys [157,158]. Adipose tissue has been shown to 
secrete specific growth factors including transforming growth factor-p (TGF-p) which 
modulate angiogenesis, suggesting a developmental link with adipogenesis [157]. Adipose 
tissue is present from birth and retains the potential for growth at all stages of life dependent 
upon the site of the fat depot, the nature of the diet, environmental and genetic factors. 
Adipose tissue growth occurs by both ongoing lipid accumulation in existing mature 
adipocytes resulting in cells varying from 25 to 200 pm in diameter, but also by further 
proliferation and differentiation of pre-adipocytes present within the adipose store [159].
3.1.3 Cellular Development & Transcript Expression During Adipogenesis
The sequence of events occurring during adipogenesis has been studied at length in in vitro
models and appears to follow a well recognised temporal sequence illustrated in Table 3.1
[160]. Adipocytes are derived from multipotent mesenchymal stem cells which have multiple
differentiation capabilities including adipogenesis, osteogenesis, chondrogenesis and
myogenesis. Therefore the early stages in adipogenesis involves determination and
commitment to the adipocyte lineage by conversion of the multipotent stem cell to a
unipotent adipoblast and then a pre-adipocyte [148]. Though morphologically similar to its
precursors this cell acquires the machinery that is necessary for lipid transport and synthesis,
insulin sensitivity and the secretion of adipocyte-specific proteins [161]. The molecular
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regulation of these early events is not yet clearly understood but the latter stages have been 
more extensively characterised.
Table 3.1: Cellular Development And Transcript Expression In Adipogenesis
(adapted from Schaffler et al [148] & Ailhaud et al [157]]
Gene
Stage Cell expression
profile
I Determination Mesenchymal stem cell 
[multipotential)
-
I I
Cell
commitment
Adipoblast
[unipotential)
-
I I I
Mitosis & 
Clonal 
expansion
Pre-adipocyte I 
[no lipid)
EARLY
Pref-1 
Krox 20
IV
•
• • 
• •
Pre-adipocyte II 
[lipid-containing)
INTERMEDIATE
C/EBPs
PPARy
V Growth arrest %$> Immature adipocyte [lipid-containing, 
multilocular)
LATE
Lipolytic & lipogenic 
enzymes e.g. LPL, FAS & 
GPDH
VI
Terminal
differentiation
< 1 Mature adipocyte 
[lipid-filled, 
unilocular)
VERY LATE
Adiponectin
Leptin
Resistin
Visfatin
During in vitro adipogenesis using murine models, pre-adipocytes undergo a proliferative 
phase and clonal expansion eventually followed by growth arrest at the Gi/S phase of the cell 
cycle secondary to cell-to-cell contact inhibition, though this step is not essential in primary 
cultures [162]. This process is associated with the downregulation of early differentiation
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markers including Pref-1, a known repressor of adipogenesis [163]. The subsequent stages of 
adipocyte maturation are associated with a cascade of expression of intermediate adipogenic 
factors including CCAAT-enhancer-binding proteins (C/EBP a, p & 6) and peroxisome 
proliferator-activated receptor-y [PPARy) [161]. C/EBPp & C/EBP6 are amongst the earliest 
seen and are implicated in the induction of adipogenesis by inducing PPARy expression 
through C/EBP binding sites in the PPARy promoter [158,164]. PPARy has been described as 
the 'master regulator' of adipogenesis and is essential for both adipogenesis itself and 
maintenance of the differentiated state [165]. PPARy is the most conserved member of the 
PPAR family and controls gene expression through heterodimerisation with the retinoic X 
receptor (RXR). There are 3 PPARy isoforms derived from the same gene through the use of 
alternate promoters [166, 167]. PPARy-1 and PPARy-3 encode for the same protein and are 
found in numerous cell types including adipose tissue, macrophages and colonic epithelium 
whereas PPARy-2 is adipose tissue-specific though the precise roles of these differing 
isoforms of PPARy are yet to be established [166,167]. Numerous studies have demonstrated 
the critical role for PPARy in pre-adipocyte differentiation. For instance in vitro experiments 
by Tontonoz et al have shown that PPARy overexpression in isolation is sufficient to induce 
adipogenesis [168]. Conversely PPARy knockout mice exhibit reduced adipose tissue mass 
while dominant-negative mutations in the human PPARy gene have been described in 
subjects w ith partial lipodystrophy [169-172]. In vivo studies in murine models have 
demonstrated inducible knockout of PPARy to be associated with adipocyte death [160,173], 
whereas PPARy over-expression alone can induce adipogenesis [168].
The transcriptional cascade regulating adipogenesis is centred around PPARy itself whose
expression is mediated by several pro-adipogenic and anti-adipogenic factors as illustrated in
Figure 3.1 [161]. These include the Krupple-like factors (KLF) which can both promote
adipocyte differentiation [KLF 5 & 15) and enhance glucose transport mediated through
increased expression, and translocation to the cell membrane, of glucose transporter 4
[GLUT4) [174, 175], as well as inhibit the process by inhibiting PPARy expression [KLF2)
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[176]. PPARy expression, and thus adipogenesis, is also enhanced indirectly by Krox20, a 
C/EBPp promoter [177], as well as directly by sterol response element binding protein lc  
(SREBPlc) [178]. Conversely, adipogenesis can be inhibited by reduced C/EBP expression by 
the transcription factor homologous to C/EBP [CHOP] [161], as well as PPARy promoter 
inhibition by the glutamyl amino transferidase subunit A transcription factors [GATA] [179].
The terminal stages of adipocyte maturation are associated with expression of enzymes 
required for adipocyte function including lipoprotein lipase (LPL), fatty acid synthase (FAS) 
and glycerol-3-phosphate dehydrogenase (GPDH) and eventual adipocytokine production 
[148,157].
Figure 3.1: Transcriptional Regulation Of Adipogenesis
[adapted from Rosen et al [161])
KLF5 KLF15
CHO P SREBP1
C /E B P y
PPARy
K R O X 20 Genes of terminal
adipocyte
differentiationC/EBP8
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Anti-adipogenic factor
3.1.4 White & Brown Adipose Tissue
Two types of adipocytes are found in mammals: the white and brown adipocyte. Whereas
white adipose tissue (WAT) serves as an energy reservoir, the function of brown adipose
tissue (BAT) is to dissipate energy in the form of heat by non-shivering thermogenesis [180].
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Brown adipocytes store less lipid and contain more mitochondria than white adipocytes, and 
although brown adipocytes have virtually the same enzymatic machinery as white fat cells, 
the accumulated lipid in BAT is predominantly used as a source of fatty acids for oxidisation 
in these mitochondria, as opposed to acting as a systemic energy storage depot [158]. Brown 
adipocytes have a similar gene expression profile to white adipocytes but also express some 
distinct genes, including the uncoupling protein-1 [UCP-1) which allows energy conversion to 
heat [161]. Whereas WAT is present in humans throughout life, until recently BAT was not 
thought to be found beyond the neonatal period where its location is limited to surrounding 
the great vessels in the thoracic cavity and interscapular regions [158]. Recent studies using 
2-[18F]fluoro-2-deoxy-glucose [taken up by members of the glucose transporter family e.g. 
GLUT4) positron emission tomography (FDG PET), initially to trace tumour metastases, have 
identified BAT deposits in adult humans between the anterior neck and thorax [181, 182]. 
Further studies have also demonstrated that these areas of BAT are metabolically active, 
particularly in response to cold exposure [183, 184]. Other studies have utilised sensitive 
PCR-based techniques to demonstrate UCP-1 mRNA expression in WAT suggesting the 
presence of brown fat cells in small numbers within human WAT depots [185]. WAT is 
distributed throughout the body but preferentially accumulates in the subcutaneous and 
visceral depots. An accumulation of the latter reflects central adiposity and is associated with 
increased metabolic risk [3].
White and brown adipocytes are derived from mesenchymal stem cells [Figure 3.2) via the 
concerted action of extracellular signals and intrinsic transcription factors. Questions 
surround several issues in BAT development, including the identity of specific factors that 
promote brown fat adipogenesis, and whether BAT and WAT share common fat precursor 
cells or derive separately from stem cells via brown- and white-specific pre-adipocytes [158]. 
The mechanism by which these stem cells become committed to either white or brown 
adipocyte differentiation, and the extent to which white and brown adipocytes can be
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transdifferentiated to one another, has not yet been fully elucidated, but represents a 
potential physiological and pharmological target for anti-obesity interventions.
Figure 3.2: White & Brown Fat Development From The Mesenchymal Stem Cell
(adapted from Rosen et al [158])
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3.1.5 Cell Lines
The diffuse nature of adipose tissue differentiation lim its the potential to use in vivo and ex 
vivo analyses to study adipogenesis, therefore a series of adipoblast cell lines have been 
developed that differentiate into adipocytes when treated w ith appropriate hormonal 
inducers, and thus allow in vitro studies to take place [160]. One of the most commonly used 
cell lines that readily differentiates into WAT is 3T3-L1 which has been used in the present
study [186], but others have also been developed including 3T3-F442A and Ob 17 [187]. A 
BAT model was also studied using a cell line derived from simian virus transformation of 
human brown pre-adipocytes known as PAZ6 [188], though the physiological significance of 
BAT in adult humans remains controversial.
3.1.5.1 White Pre-Adipocyte: 3T3-L1
The 3T3 cell line, derived from embryonic fibroblasts harvested from the Swiss mouse, was 
established by George Todaro and Howard Green in the early 1960s, followed by 
development of 3T3-L1 cells, a similar and highly resilient cell line with an exaggerated ability 
to accumulate lipid [186,189]. 3T3-L1, illustrated in Figure 3.3, are grown in standard culture 
conditions until proliferation is inhibited by cell-to-cell contact, at which point the cells 
accumulate lip id droplets and mature into adipocytes, a process which can be influenced by 
the hormonal environment. The 3T3-L1 cell line was obtained from the American Type 
Culture Collection (www.atcc.org].
Figure 3.3: Murine 3T3-L1 White Pre-Adipocytes
(magnification 20Ox)
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3.1.5.2 Brown Pre-Adipocyte: PAZ6
The PAZ6 cell line was kindly provided by Vladimir Zilberfarb (Universite Paris Descartes] 
and is illustrated in Figure 3.4.
Figure 3.4: Human PAZ6 Brown Pre-Adipocytes
(magnification 200x)
The PAZ6 cell line was established by transfection of stromal cells derived from human infant 
BAT w ith simian virus-40 antigen under control of the vimentin promoter and, in the 
appropriate hormonal environment, differentiates into mature BAT as confirmed by 
morphological changes of lipid droplet accumulation and QPCR detection of LPL (mature 
adipocyte marker] and UCP-1 (mature brown adipocyte marker] expression [188].
3.1.6 Hormonal Induction Of Adipogenesis
Over the years a number of agents have been empirically selected to induce in vitro 
adipogenesis and this evidence has been used to establish a differentiation protocol within 
our lab at the Centre for Endocrine and Diabetes Sciences at Cardiff University. One of the
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earliest observations for efficient adipocyte differentiation has been the requirement for 
insulin to increase both the number of cells recruited for differentiation as well as enhance 
lipid accumulation [190]. However pre-adipocytes express few insulin receptors and the 
insulin effect has been shown to be mediated by cross-activation of the insulin-like growth 
factor-1 (IGF-1) receptor [191]. Further supplementation of the differentiation medium with 
fetal calf serum rich in IGF-1 therefore also promotes adipogenesis [192]. The glucocorticoid 
dexamethasone has also been used to inhibit pre-adipocyte proliferation in vitro and induces 
differentiation by inhibiting expression of Pref-1 and inducing C/EBP6 [164,193,194]. Given 
the crucial role of PPARy in the regulation of adipogenesis, it is unsurprising that PPARy 
agonists such as the thiazolidinedione pioglitazone, have also been used to stimulate 
differentiation [195].
Another compound known to induce adipogenesis is 3-isobutyl-1-methylxanthine (IBMX), a 
compound thought to act by increasing intracellular cAMP as well as C/EBP0 expression 
[196]. Numerous other hormones have also been used as components of in vitro 
differentiation protocols, though their roles in vivo may not be as well established. These 
include the addition of growth hormone [197], thyroid hormone [198], retinoic acid [199], 
and prostacyclin [200].
3.1.7 In Vitro Evaluation Of Pre-Adipocyte Proliferation
As previously discussed, adipose tissue accumulates by both pre-adipocyte proliferation and 
differentiation, as well as mature adipocyte hyperplasia. Therefore a study of both these 
processes is required when investigating modulators of adipose tissue. The first of these, cell 
proliferation, represents a change in cell numbers arising from cell division or mitosis. 
Stimulators of cell proliferation w ill increase the rate at which cells divide, whereas inhibitors 
w ill cause either growth arrest or a reduction in the rate of cell division. Therefore the effect
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any compound may exert on cellular proliferation can be investigated by determining 
absolute cell numbers before and after a treatment period.
Several techniques are recognised as validated methods of assessing proliferation. The first 
and simplest method is direct visual counting with the use of instruments such as a 
haemocytometer to estimate the number of cells per volume of culture suspension. However 
such methods are limited by both the laborious nature and potential for observer bias, and 
have thus been superseded by the development of electric particle counters [201]. Other 
techniques include radioactive isotope labelling of DNA in dividing cells such as the 3H- 
thymidine incorporation assay, where radioisotope accumulation in samples undergoing 
increased proliferation can be measured by scintillography [202].
Where a reduction in cell proliferation is observed in response to treatment exposure, it  is 
important to exclude cell toxicity as a cause of the decrease in cell numbers. This was 
performed in the present studies by staining with trypan blue, a dye taken up by cells where 
membrane integrity has been lost due to cell necrosis or apoptosis, and by analysis of the cell 
cycle.
3.1.7.1 Cell Cycle Analysis
The cell-division cycle refers to the series of events leading to cell division and thus 
proliferation. The cell cycle can be divided into four phases as illustrated in Figure 3.5, the 
first three of which are collectively known as the interphase: Gap 1 (Gi) phase for cell growth, 
DNA synthesis phase (S), Gap 2 phase for further cell growth (G2), and mitosis (M) [203]. Cells 
can either permanently or temporarily exit the cycle at G1 and become quiescent in a Gap 0 
[Go] phase, and it is at this point that adipogenesis can occur in pre-adipocytes. Checkpoints 
also exist at Gi/S and G2/M  to block cell division if  adverse environmental factors are present 
or if  cell repair is required [204].
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Figure 3.5: Stages Of The Cell Cycle
Go Go -  Gap 0 quiescent cells 
S -  DNA synthesis 
M -  Mitosis
Gi -  Gap 1 cell growth phase 
G2 -  Gap 2 cell growth phase
The amount of DNA present in a cell varies according to the stage of the cell cycle. Therefore, 
if  cells undergoing investigation are fixed in ethanol and stained with a DNA stain such as 
propidium bromide, the amount of DNA present in any cellular sample can be quantified. 
Plotting this value against the known cell number can provide an indication of the 
distribution of cells throughout the cell cycle in a given sample, and thus enable the effect of 
compounds on cell proliferation and the cell cycle to be studied.
3.1.8 In Vitro Assessment Of Adipogenesis
Numerous techniques have been established for assessment of adipogenesis. This can be 
performed by simple direct inspection under light microscopy to observe for morphological 
features of adipocyte maturation, predominantly a rounding up of cell shape and the 
acquisition of lipid droplets, coupled with a count of the number of foci of differentiation per 
high powered microscopic field. This method is again limited by observer bias thus the more 
robust and objective methods outlined below have been employed in this study.
Oil red 0 staining can be used to quantify the amount of lipid accumulation w ithin a sample 
by firstly applying the stain, then extracting the absorbed stain in 100% isopropanol and 
measurement using colourimetry [205]. Another more specific technique is the measurement
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of the expression of transcript specific to the target cell, e.g. terminal adipocyte markers LPL 
and GPDH, by real-time QPCR as described in Chapter 2. Here, RNA is extracted from 
differentiating cells during the adipogenesis protocol and reverse transcribed to cDNA. QPCR 
can then be performed on these samples to quantify the degree of receptor expression and 
thus the influence, if  any, of a treatment upon fat cell differentiation.
3.1.9 Chapter Aims
The ECS plays an important role in regulating weight and energy balance in humans and this 
system is activated to a greater extent in obese individuals. In animal studies, the 
administration of exogenous and endogenous cannabinoids is associated with robust 
increases in food intake and can promote weight gain, an effect believed to be mediated 
through activation of the CBi receptor. Conversely, animal studies of CBi blockade have 
demonstrated reductions in food intake and weight loss with repeated compound 
administration. These reductions in body weight appear to be greater in obese animals and 
may be the result of a dual effect on both food intake and metabolic processes. Clinical trials 
of SR141716 treatment in humans have also demonstrated significant reductions in body 
weight, waist circumference and improvement of lipid and glucose metabolism. Accordingly, 
the ECS represents an important pharmacological target for modulation of adipose tissue 
biology.
This chapter aims to study an in vitro model of pharmacological modulation of a key 
component of the metabolic syndrome -  adipose tissue. To this end the actions of CBi and CB2 
receptors on proliferation and adipogenesis w ill be studied using in vitro models of both WAT 
and BAT.
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3.2 MATERIALS AND METHODS
3.2.1 Cell Populations
The murine white preadipocyte cell line, 3T3-L1, was readily available in the department and 
the human brown preadipocyte cell line, PAZ6, was kindly provided by Vladimir Zilberfarb 
(Universite Paris Descartes).
3.2.2 Reagents
CB receptor modulators (Table 3.2) were purchased from Tocris Bioscience (Bristol, UK). All 
reagents were initially reconstituted in ethanol, and further dissolved in culture medium to 
produce stock solutions of 10 2 molar. The maximum concentration of ethanol in any 
experiment was 0.1% and this concentration was maintained in all control samples. All other 
culture medium constituents were obtained from BioWhittaker (Belgium) unless otherwise 
stated.
Table 3.2: Summary Of CB Receptor Modulators [206]
Anandamide Endogenous CBi and CB2 agonist CBi -  89 nM CB2-371 nM
ACEA CBi agonist 
(>1400-fold CBi selectivity over CB2) 1.4 nM
AM 251 CBi antagonist 
(306-fold CBi selectivity over CB2) 7.49 nM
JWH133 CB2 agonist 
(200-fold CB2 selectivity over CBi) 3.4 nM
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3.2.3 Culture Media
Both the 3T3-L1 and PAZ6 cell lines were routinely cultured in complete medium (CM), the 
contents of which are listed in Table 3.3.
Table 3.3: Constituents Of Cell Culture Media
Dulbecco's modified eagle medium 
(DMEM)
80 mis 82 mis
Ham's F12 80 mis 82 mis
Fetal calf serum (FCS) 10% 8%
Sodium pyruvate 2 mis 2 mis
1.5% Sodium bicarbonate 3 mis n/a
Hepes buffer n/a 3mls
Penicillin (Cambrex, Berkshire, UK) 100 u/m l 100 u/m l
Streptomycin (Cambrex, Berkshire, UK) 100 pg/ml 100 pg/ml
3.2.4 Routine Maintenance Of Cell Lines
All cell culture experiments were performed in sterile conditions at 37°C in an atmosphere 
containing humidified 5% CO2 in air. Both 3T3-L1 and PAZ6 preadipocytes were grown in 75 
cm2 Nunclon™ delta surface flasks (Nunc, Roskilde, Denmark). Culture medium was changed 
every 48 hours and upon reaching approximately 80% confluence, the cells underwent 
passage. This was done by aspirating the culture medium and washing the cellular monolayer 
with 2 mis of 1% w /v  trypsin (Cambrex, Berkshire, UK) pre-heated to 37°C. The trypsin was 
immediately aspirated and the cells were subsequently incubated with a further 2 mis of 1% 
w /v  trypsin until the cells had detached from the flask and were free in suspension, as
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confirmed by microscopy. A further 8 mis of culture medium was added to the solution to 
inactivate the trypsin and the total 10 mis solution was transferred to a universal container 
and centrifuged at 1000 rpm for 5 minutes. The resultant cell pellet was resuspended in 
culture medium and transferred either to fresh flasks or plated for experiments.
3.2.5 Cryopreservation Of Cells
At every passage a proportion of cells were used to restock the cell bank. Cells were 
trypsinised as described above and the cell pellet obtained after centrifugation was 
resuspended in 0.5 ml of culture medium combined with 0.5 ml of freezing mix (FCS 
containing 20% dimethyl sulfoxide (DMSO), Sigma-Aldrich Company Ltd, Dorset, UK), and 
transferred to a 2 ml sterile cryotube. The cryotubes were placed within an insulated 
polystyrene freezing box containing isopropanol (Fisher Scientific UK Ltd, Leicestershire, UK) 
to enable a slow cooling rate of 1°C /  minute and kept at -80°C for 24 hours prior to long-term 
storage in liquid nitrogen at -190°C.
3.2.6 Proliferation Studies
3.2.6.1 Cell Culture Protocol
Both 3T3-L1 and PAZ6 preadipocytes were grown to confluence and trypsinised as described 
previously. The approximate number of cells per ml solution was calculated with the aid of a 
haemocytometer (Camber counter, Weber Scientific International Ltd, Middlesex, UK). Cells 
were subsequently diluted and seeded at l x l  03 per well in 24 well plates (Nunclon™ delta 
surface, Nunc, Roskilde, Denmark) and incubated at 37°C overnight to enable optimal 
attachment. Cells were then incubated in culture medium alone, or supplemented with 
increasing concentrations of Anandamide (109 to 10 s molar), ACEA (109 to 105 molar),
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AM251 (109 to 10’5 molar), or JWH133 (109 to 10 5 molar). Each experiment was completed 
in quadruplicate and performed at least twice.
3.2.6.2 Direct Cell Counting
The pre-adipocytes were collected for direct cell counting after 24 and 72 hours of treatment. 
Each well was washed with 0.5 mis of 1% w /v  trypsin and then incubated with a further 0.5 
mis of 1% w /v  trypsin until cells were free in suspension. The contents of individual wells 
were transferred to corresponding cell counting cuvettes containing 10 mis each of Coulter 
Isoton II Diluent (Beckman Coulter, Gmbh, Germany). Cell densities were measured using a 
Coulter particle counter (Z2, Beckman Coulter Gmbh, Germany) with particle size set between
3.8 nm and 9.0nm. Each sample was counted twice and the average value used for statistical 
analysis.
3.2.6.3 Trypan Blue Toxicity Assay
3T3-L1 and PAZ6 pre-adipocytes were seeded at lx l0 3 per well in 24 well plates as described 
previously and incubated for 72 hours in culture medium (CM) alone, or supplemented with 
increasing concentrations of AM251 (10 9 to 10 s molar). Cells were then trypsinised and the 
resultant cell suspensions were centrifuged at 1000 rpm for 5 minutes and resuspended in 50 
pi CM combined with 50 pi 0.1% Trypan blue (Sigma-Aldrich Company Ltd, Dorset, UK). The 
cells were examined for positive staining, indicating toxic injury, under a light microscope 
with the aid of a haemocytometer.
3.2.6.4 Cell Cycle Analysis /  Flow Cytometry
3T3-L1 and PAZ6 pre-adipocytes were seeded at lx lO 4 per well in 6 well plates as described
previously and incubated for 24 hours in CM alone, followed by a further 48 hour incubation
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in CM alone or supplemented with increasing concentrations of AM251 (10*8 to 106 molar). 
The cell contents of individual wells were trypsinised as described above, centrifuged at 1000 
rpm for 5 minutes, fixed in 1 ml cold (4°C) 70% v /v  ethanol and stored overnight at -20°C. 
The samples were again centrifuged at 1000 rpm for 10 minutes, ethanol aspirated and the 
cell pellet washed twice with PBS. Following this the samples were incubated for a further 20 
minutes at 37°C with propidium iodide (50pg/mL in PBS) and RNAse A (50pg/mL) and 
subsequently analysed with a FACSCalibur flow cytometer. The FACSCalibur flow cytometer 
operation was kindly undertaken by Dr E. Wang, Department of Immunology, School of 
Medicine, Cardiff University.
3.2.7 Adipogenesis Studies
3.2.7.1 Cell Culture Protocol
3T3-L1 and PAZ6 cells were plated in 6 well plates and adipogenesis induced in confluent 
populations of pre-adipocytes by replacing CM with differentiation medium (DM) containing 
5% FCS, 33 pM biotin (Sigma Aldrich), 17 pM panthothenate (Sigma Aldrich), 1 nM T3 (Sigma 
Aldrich), 100 nM dexamethasone (Sigma Aldrich), 1 pM thiazolidinedione (Takeda) and 500 
nM insulin (Sigma Aldrich). Cells were maintained in DM alone, or supplemented with 100 nM 
ACEA or 100 nM AM251, for 12 days with DM changes occurring on days 3, 5, 7, 9 and 12. 
Morphological changes of differentiation were monitored by microscopic examination.
3.2.7.2 Isolation Of Total RNA From 3T3-L1 & PAZ6
Samples for RNA extraction were collected on days 0, 3, 5, 7, 9 and 12. Culture medium was
removed from individual wells and cells washed 3 times with 1 ml PBS. Total RNA was
isolated using Invitrogen’s TRIzol reagent according to the manufacturer’s instructions. Cells
were lysed by adding 1 ml TRIzol to each well pipetting the lysate several times and complete
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cell lysis confirmed by inspection under a light microscope. The contents of individual wells 
were transferred to 1.5 ml tubes and stored at -80°C until further use.
To continue RNA isolation, 200 pi chloroform (Fisher) was added to each thawed 1.5 ml tube 
to separate RNA from DNA and protein. The samples were mixed vigorously and incubated at 
room temperature for 2 minutes prior to centrifugation at 12000 rpm (Mikro 22R, Heittich 
Zentrifiigen, Germany) for 15 minutes at 4°C. The uppermost RNA-containing aqueous phase 
was carefully transferred to clean 1.5 ml tubes and the RNA precipitated by adding 0.5 ml 
isopropanol. The samples were again incubated at room temperature for 10 minutes and 
centrifuged at 12000 rpm for 10 minutes at 4°C. The supernatant was removed, the 
remaining RNA pellet washed with 1 ml 75% v/v  ethanol (Fisher) and centrifuged for a 
further 5 minutes at 4°C at 7500 rpm. The RNA pellet was air dried and redissolved in 20 pi 
nuclease-free water (Promega) by incubating at 60°C for 10 minutes.
The RNA concentration and quality was assessed by spectrophotometry (GeneQuant, GE 
Healthcare) and analysis on a 1.2% agarose gel. Samples were stored at -80°C until further 
use.
3.2.7.3 DNase Treatment Of RNA
To avoid contamination of subsequent experiments with residual traces of genomic DNA, the 
isolated RNA was treated with Promega's RNase-free DNase according to the manufacturer's 
instructions. 1 pg RNA, 1 pi DNase lOx buffer, 1 pi DNase were combined in a 200 pi 
microtube and made up to 10 pi with nuclease-free water. The mixture was briefly 
centrifuged and incubated for 30 minutes in a 37°C water-bath prior to terminating the 
reaction by adding 1 pi Stop Solution and transferring the microtubes to a heating block for 
10 minutes at 65°C.
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3.2.7.4 Reverse Transcription
RNA was reverse transcribed to complementary DNA (cDNA) for use in subsequent QPCR to 
measure transcript expression using the Moloney murine leukemia virus (MMLV) reverse 
transcriptase (Promega). Each reaction contained 4 pi 5x First-Strand buffer (Promega), 1 pi 
40 U/pl RNase inhibitor (Promega), 4 pi 500 ng/pl oligo (dT)is (Promega), 4 pi 10 mM dNTPs 
mix (Sigma-Aldrich), 1 pg DNase-treated RNA pre-heated at 60°C for 10 minutes, 1 pi 20 U/ pi 
MMLV reverse transcriptase and made up to 20 pi with sterile water. The reaction mixture 
was centrifuged briefly and transferred to a Techne Genius DNA Thermal Cycler (Techne 
Cambridge Ltd, Cambridge, UK). The thermal cycling settings are listed in Table 3.4.
Table 3.4: Reverse Transcription Thermal Cycling Protocol
Reverse transcription 37°C 60 minutes 1
Enzyme inactivation 95°C 5 minutes 1
The resulting cDNA samples were stored at -20°C until further use.
3.2.7.5 Conventional PCR
Standard PCR was performed in a Techne Genius DNA Thermal Cycler (Techne Cambridge 
Ltd, Cambridge, UK) using primers for the housekeeping gene phosphoglycerate-l-kinase 
(PGK1). The forward and reverse primers are located on separate exons and can therefore be 
used to differentiate between PCR products amplified from reverse-transcribed cDNA (250 
bp product) and contaminating genomic (650 bp product) when analysed on a 2% agarose 
gel. The PCR reaction constituents and thermocycling protocol are listed in Tables 3.5 and 3.6.
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Table 3.5: PCR Reagents For Amplification From Genomic DNA
Reagents Volume per reaction
Sterile H20 to complete final volume of 25 pi
lOx Taq DNA polymerase buffer 
(100 mM Tris-HCl, 500 nM KC1,15 mM MgCl2) 2.5 pi
dNTP mix 
(lOmM each dATP, dCTP, dGTP, dTTP) l p l
Forward primer (10 pmol/1) l p l
Reverse primer (10 pmol/1) l p l
Taq DNA polymerase (5 units/pl) 0.4 pi
Genomic DNA 100 ng
Total volume 25 pi
Table 3.6: PCR Thermal Cycling Protocol
Temperature Time No of cycles
In itial Denaturation 95°C 5 minutes 1
Denaturation 95°C 1 minute
Annealing 60°C 30 seconds 40
DNA synthesis 72°C 1 minute
Final extension 72°C 5 minutes 1
3.2.7.6 QPCR Measurement Of Markers Of Adipogenesis
Real-time QPCR was performed to measure expression of CBi and CB2 receptors in all 
samples, murine markers of adipogenesis (Pref-1, C/EBPp, PPARy, GPDH) and house keeper 
genes (ARP] in 3T3-L1, and human markers of adipogenesis (C/EBP0, PPARy, LPL) and
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housekeeper (APRT) in PAZ6 as well as UCP-1 in both cell lines. QPCR was performed using 
Stratagene's Brilliant® SYBR® Green Master Mix. Each 25 pi reaction contained 12.5 pi 
Master Mix, forward and reverse primer (as per optimised concentrations detailed in Chapter 
2) and ultrapure water. Reactions were set up in Stratagene 96-well PCR plates and 
centrifuged for 1 minute at 3000 rpm prior to being transferred to the Stratagene MX3000P® 
thermocycler. The thermal cycling protocol is listed in Table 3.7.
Table 3.7: QPCR Thermal Cycling Protocol
Enzyme activation 95°C 10 minutes 1
Denaturation 94°C 30 seconds
Annealing 60°C 60 seconds 40
Extension 72°C 30 seconds
95°C 60 seconds
Dissociation 55°C 30 seconds 1
95°C 30 seconds
3.2.7.7 Oil Red 0  Staining
Oil red 0 stains were performed to confirm the presence of lipid droplet accumulation and
enable foci of differentiation to be counted. 3T3-L1 pre-adipocytes were seeded in 24 well
plates and the differentiation protocol conducted as described above. On day 12, 0.5 g of oil
red 0 was dissolved in 100 mis of isopropanol. 12 mis of this solution was combined with 8
mis of sterile water and filtered immediately. Each well was washed with 1 ml PBS, cells fixed
with 0.5 ml 60% v /v  isopropanol and washed again with 1 ml PBS. 300 pi filtered oil red 0
was then applied to each well for 15 minutes then aspirated. Each well was washed 3 times
with 1 ml sterile water, examined under the light microscope and photographed for
illustration. 200 pi of isopropanol was then added to each well and each individual well's
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contents were then transferred to corresponding wells in a 96 well plate for analysis in an 
optical density reader (OpsysMR microplate reader, Dynex Technologies, Chantilly, USA) set 
at OD490.
3.2.8 Statistical Analysis
Data were analysed using the SPSS (version 14.0) statistical software package.
The data generated by the proliferation and adipogenesis studies were not normally 
distributed (determined by generating Q-Q and P-P plots of data obtained) and therefore 
analysed according to median and interquartile ranges (IQR) using non-parametric statistical 
tests. The Friedman's test was performed on each experiment and the Wilcoxon Signed Ranks 
test was performed on individual treatments relative to control conditions. The QPCR data 
were analysed as absolute values per input microgram of mRNA and corrected relative to the 
appropriate housekeeper gene expression.
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3.3 RESULTS
3.3.1 Endogenous CB Agonist Anandamide Stimulates Proliferation Of 3T3-L1
But Has No Effect On PAZ6
Exposure to the CB agonist anandamide for 24 hours was associated with a concentration- 
dependent increase in proliferation of 3T3-L1 as illustrated in Table 3.8 and Figure 3.6.
Table 3.8: Mean, Median & IQR For 3T3-L1 Treated With Anandamide For 24 Hours
Anandamide
concentration
Control (0.1% 
ethanol)
4428 4392 4152-4716 n/a
1 nM 4730 4790 4443-4979 0.009
10 nM 4977 4996 4799-5181 <0.001
100 nM 5128 5143 4988-5252 <0.001
lp M 5386 5367 5159-5621 <0.001
10 pM 5404 5433 5241-5592 <0.001
Figure 3.6: The Effect Of Anandamide On 3T3-L1 Proliferation At 24 Hours
Cells were counted 24 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman’s test for overall experiment
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The significant, concentration-dependent increase in proliferation of 3T3-L1 was also 
observed after 72 hours exposure to anandamide as illustrated in Table 3.9 and Figure 3.7.
Table 3.9: Mean, Median & IQR For 3T3-L1 Treated With Anandamide For 72 Hours
Control (0.1% 
ethanol)
35374 35394 35014-35744 n/a
1 nM 36973 36997 36566-37289 <0.001
10 nM 38746 38660 38309-39377 <0.001
100 nM 40867 40978 40048-41616 <0.001
1 |iM 40280 40430 39820-40712 <0.001
10 \iM 39984 40039 39480-40511 <0.001
Figure 3.7: The Effect Of Anandamide On 3T3-L1 Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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Treatment with the CB agonist anandamide had no significant effect on proliferation of PAZ6
at 24 hours (Table 3.10 and Figure 3.8) or at 72 hours (Table 3.11 and Figure 3.9).
Table 3.10: Mean, Median & IQR For PAZ6 Treated With Anandamide For 24 Hours
Control (0.1% 
ethanol)
3875 3883 3539-4246 n/a
1 nM 3891 4028 3527-4245 0.966
10 nM 3777 3857 3353-4135 0.346
100 nM 3765 3835 3343-4150 0.407
lp M 3868 3872 3504-4171 0.886
10 pM 3860 3943 3582-4172 0.797
Figure 3.8: The Effect Of Anandamide On PAZ6 Proliferation At 24 Hours
Cells were counted 24 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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Table 3.11: Mean, Median & IQR For PAZ6 Treated With Anandamide For 72 Hours
Control (0.1% 
ethanol)
21405 21535 20896-21841 n/a
1 nM 21239 21255 20893-21659 0.230
10 nM 21193 21270 20937-21482 0.092
100 nM 21345 21429 20950-21633 0.587
l \ iM 21239 21195 20864-21721 0.153
10 \iM 21157 21010 20709-21720 0.067
Figure 3.9: The Effect Of Anandamide On PAZ6 Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman’s test for overall experiment
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3.3.2 CBi Agonist ACEA Stimulates Proliferation Of 3T3-L1 But Does Not Affect 
PAZ6
Exposure to the CBi agonist ACEA for 24 hours was associated with a significant, 
concentration -dependent increase in proliferation of 3T3-L1 as illustrated in Table 3.12 and 
Figure 3.10.
Table 3.12: Mean, Median & IQR For 3T3-L1 Treated With ACEA For 24 Hours
Control (0.1% 
ethanol)
3736 3736 3560-3900 n/a
1 nM 3867 3811 3752-3961 0.028
10 nM 4021 3991 3906-4155 <0.001
100 nM 4405 4428 4257-4571 <0.001
1 |xM 4344 4309 4236-4459 <0.001
10 \iM 4404 4377 4260-4618 <0.001
Figure 3.10: The Effect Of ACEA On 3T3-L1 Proliferation At 24 Hours
Cells were counted 24 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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The significant, concentration-dependent increase in proliferation of 3T3-L1 was also 
observed after 72 hours exposure to ACEA as illustrated in Table 3.13 and Figure 3.11.
Table 3.13: Mean, Median & IQR For 3T3-L1 Treated With ACEA For 72 Hours
ACEA concentration
Control (0.1% 
ethanol)
39835 39805 39230-40355 n/a
1 nM 40717 40624 40290-41121 <0.001
10 nM 41935 41769 41519-42489 <0.001
100 nM 43154 42953 42632-43909 <0.001
1 pM 43371 43596 42495-44046 <0.001
10 pM 42298 42366 41968-42565 <0.001
Figure 3.11: The Effect Of ACEA On 3T3-L1 Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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Treatment with the CBi agonist ACEA had no significant effect on proliferation of PAZ6 at 24
hours (Table 3.14 and Figure 3.12) or at 72 hours (Table 3.15 and Figure 3.13).
Table 3.14: Mean, Median & IQR For PAZ6 Treated With ACEA For 24 Hours
Control (0.1% 
ethanol)
3832 3804 3671-3994 n/a
1 nM 3882 3920 3626-4128 0.627
10 nM 3910 3972 3696-4051 0.201
100 nM 3841 3881 3638-4033 0.710
1 pM 3868 3851 3727-4025 0.689
10 \xM 3842 3868 3652-4006 0.886
Figure 3.12: The Effect Of ACEA On PAZ6 Proliferation At 24 Hours
Cells were counted 24 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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Table 3.15: Mean, Median & IQR For PAZ6 Treated With ACEA For 72 Hours
Control (0.1% 
ethanol)
21310 21355 21111-21510 n/a
1 nM 21291 21341 21092-21479 0.732
10 nM 21162 21168 20888-21347 0.063
100 nM 21279 21252 21072-21542 0.648
l\xM 21303 21360 21124-21576 0.875
10 nM 21347 21431 21124-21576 0.753
Figure 3.13: The Effect Of ACEA On PAZ6 Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman’s test for overall experiment
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3.3.3 Effect Of CBi Antagonist AM 251 On Proliferation Of 3T3-L1 And PAZ6
Exposure to the CBi antagonist AM 251 for 24 hours did not affect proliferation of 3T3-L1 as 
illustrated in Table 3.16 and Figure 3.14.
Table 3.16: Mean, Median & IQR For 3T3-L1 Treated With AM 251 For 24 Hours
p-value 
(vs control)
Control (0.1% 
ethanol)
5433 5443 5302-5537 n/a
1 nM 5414 5390 5313-5522 0.658
10 nM 5401 5356 5317-5480 0.315
100 nM 5442 5462 5341-5523 0.830
lp M 5411 5410 5348-5503 0.511
10 pM 5421 5386 5327-5525 0.764
Figure 3.14: The Effect Of AM 251 On 3T3-L1 Proliferation At 24 Hours
Cells were counted 24 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.
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Exposure to AM 251 for 72 hours was associated w ith a significant, concentration-dependent 
reduction in proliferation of 3T3-L1 as illustrated in Table 3.17 and Figure 3.15.
Table 3.17: Mean, Median & IQR For 3T3-L1 Treated With AM 251 For 72 Hours
AM 251 concentration
Control (0.1% 
ethanol)
39454 39577 39018-39812 n/a
1 nM 39307 39368 39097-39457 0.137
10 nM 39059 39077 38972-39151 0.001
100 nM 38949 38950 38874-39029 <0.001
1 p.M 38947 38932 38880-39054 <0.001
10 \iM
....
38913 38879 38791-39049 <0.001
Figure 3.15: The Effect Of AM 251 On 3T3-L1 Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.
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Treatment with the CBi antagonist AM 251 had no significant effect on proliferation of PAZ6
at 24 hours (Table 3.18 and Figure 3.16) or at 72 hours (Table 3.19 and Figure 3.17).
Table 3.18: Mean, Median & IQR For PAZ6 Treated With AM 251 For 24 Hours
Control (0.1% 
ethanol)
3678 3704 3539-3830 n/a
1 nM 3663 3717 3517-3764 0.376
10 nM 3607 3582 3495-3725 0.130
100 nM 3610 3620 3556-3682 0.056
1 pM 3594 3605 3450-3662 0.059
10 pM 3579 3619 3479-3673 0.081
Figure 3.16: The Effect Of AM 251 On PAZ6 Proliferation At 24 Hours
Cells were counted 24 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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Table 3.19: Mean, Median & IQR For PAZ6 Treated With AM 251 For 72 Hours
Control (0.1% 
ethanol)
21689 21763 21328-21951 n/a
1 nM 21639 21643 21225-21988 0.587
10 nM 21587 21559 21353-21793 0.136
100 nM 21539 21588 21239-21912 0.368
l \ iM 21470 21381 21187-21720 0.058
10 \iM 21621 21660 21264-21946 0.346
Figure 3.17: The Effect Of AM 251 On PAZ6 Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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3.3.4 CB2 Agonist JWH 133 Does Not Affect Proliferation Of 3T3-L1 Or PAZ6
Treatment w ith the CB2 agonist JWH 133 had no significant effect on proliferation of 3T3-L1 
at 24 hours (Table 3.20 and Figure 3.18} or at 72 hours (Table 3.21 and Figure 3.19).
Table 3.20: Mean, Median & IQR For 3T3-L1 Treated With JWH 133 For 24 Hours
Control (0.1% 
ethanol)
4989 4985 4933-5054 n/a
1 nM 4979 4964 4924-5053 0.511
10 nM 4959 4957 4895-5021 0.260
100 nM 4995 5001 4937-5045 0.954
1HM 4966 4974 4908-5026 0.361
10 [iM 4939 4926 4869-5013 0.054
Figure 3.18: The Effect Of JWH 133 On 3T3-L1 Proliferation At 24 Hours
Cells were counted 24 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman’s test for overall experiment
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Table 3.21: Mean, Median & IQR For 3T3-L1 Treated With JWH 133 For 72 Hours
Control (0.1% 
ethanol)
30167 30120 29572-30778 n/a
1 nM 30049 29866 29273-30869 0.607
10 nM 30249 30385 29451-30860 0.511
100 nM 29995 29840 29198-31045 0.549
1 |aM 29879 29823 29102-30709 0.304
10 nM 29897 29802 29245-30634 0.162
Figure 3.19: The Effect Of JWH 133 On 3T3-L1 Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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Treatment with the CB2 agonist JWH 133 had no significant effect on proliferation of PAZ6 at
24 hours (Table 3.22 and Figure 3.20) or at 72 hours (Table 3.23 and Figure 3.21).
Table 3.22: Mean, Median & IQR For PAZ6 Treated With JWH 133 For 24 Hours
Control (0.1% 
ethanol)
3991 3980 3853-4107 n/a
1 nM 4005 4018 3916-4107 0.568
10 nM 4017 3992 3887-4145 0.637
100 nM 3997 3985 3848-4135 0.909
1 |i.M 4011 4003 3986-4131 0.543
10 *iM 3987 3966 3881-4097 0.886
Figure 3.20: The Effect Of JWH 133 On PAZ6 Proliferation At 24 Hours
Cells were counted 24 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman’s test for overall experiment
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Table 3.23: Mean, Median & 1QR For PAZ6 Treated With JWH 133 For 72 Hours
Control (0.1% 
ethanol)
18324 18373 18073-18534 n/a
1 nM 18318 18243 18108-18575 0.989
10 nM 18246 18199 18007-18544 0.331
100 nM 18299 18252 18017-18642 0.819
1 *iM 18379 18445 18148-18602 0.399
10 nM 18217 18169 17966-18516 0.107
Figure 3.21: The Effect Of JWH 133 On PAZ6 Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SEM 
from 3 independent experiments performed in quadruplicate. Statistical significance determined by Wilcoxon 
Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.
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3.3.5 CBi Antagonist AM 251 Inhibition Of Proliferation Is Not Due To Cell
Toxicity
The previous results indicated that treatment w ith AM 251 had an inhibitory effect on 3T3-L1 
proliferation. Overall cell numbers continued to rise between 24 and 72 hours suggesting cell 
toxicity arising from exposure to AM 251 to be unlikely. Trypan blue staining was undertaken 
on control and treated samples to confirm this (Figure 3.22). Some dye uptake was noted in 
all samples and was likely to be a result of manual cell damage that may have occurred during 
the experimental procedure. Overall toxicity was estimated to be less than 1% in both control 
and treated samples.
Figure 3.22: Trypan Blue Staining Of 3T3-L1 After 72 Hours Exposure To AM 251
(Results are from a single experiment performed in quadruplicate. Magnification 200x)
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3.3.6 The Effect Of CBi Antagonist AM 251 On The Cell Cycle
Cell cycle analysis was undertaken in order to determine whether the inhibition of 
proliferation observed in 3T3-L1 following treatment with AM 251 was due to interruption of 
the cell cycle or an increase in cell apoptosis. Figures 3.23 and 3.24 illustrate a significant 
concentration-related increase in cells in the G0/G1 phase as well as a significant decrease in 
the number of cells in the S and G2+M phases of the cell cycle suggesting a block at Gl/S. Also
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the histograms in Figure 3.23 show no pre-Gl peak, indicating that increased apoptosis was 
unlikely to be the cause of the reduced cell numbers. Statistical significance was determined 
by the Kruskal-Wallis test to include both control samples and all treatment concentrations.
Figure 3.23: Histograms Illustrating Effect Of AM 251 On 3T3-L1 Cell Cycle Progression
1 x 104 cells were plated per well and analysed after 48 hours treatment with control or AM 251 followed by DNA 
staining with propidium iodide. The x-axis represents the cell cycle and y-axis provides the cell counts. Data are a 
representative example of 2 independent experiments performed in replicates of six.
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Figure 3.24: The Effect Of AM 251 On 3T3-L1 Cell Cycle
1 x 104 cells were plated per well and analysed after 48 hours treatment with control or AM 251. Results are 
median values of percentages of gated controls for each cell cycle stage
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3.3.7 Summary Of The Effects Of Cannabinoid Receptor Modulation On Pre-
Adipocyte Cell Line Proliferation
When cultured in ordinary CM, 3T3-L1 were noted to exhibit a population doubling time of 
approximately 22 hours while this was longer at almost 28 hours for PAZ6 . Treatment with 
endogenous and exogenous CBi agonists resulted in a statistically significant concentration- 
dependent stimulation of proliferation in 3T3L1 while the CBi antagonist had the opposite 
effect. Further studies w ith cell cycle analysis and trypan blue staining confirmed that the 
effect seen was not due to increased apoptosis or toxic effects of the treatments used but may 
in part be due to cell cycle blockade. CB2 agonist treatment did not have any effect on 3T3-L1 
proliferation Treatment w ith CBi and CB2 agonists and CBi antagonist had no effect on PAZ6 
proliferation.
3.3.8 RNA Quality
RNA concentration and quality were determined by measuring absorbance at A260 and A2so 
using a Gene Quant Pro spectrophotometer [Gene Quant, GE Healthcare), and purity of the 
sample assessed by confirming a A2 60/A 280 ratio greater than 1.8 suggesting little protein 
contamination in the nucleic acid sample. A sample of RNA was also analysed on a 1.2% 
agarose gel w ith ethidium bromide staining (Figure 3.25). The presence of bands at 28s and 
18s confirmed RNA integrity and suitability for reverse transcription.
Figure 3.25: Agarose Gel Electrophoresis Of 3T3-L1 RNA
28s
18s
151
3.3.9 Transcript Expression During 3T3-L1 Pre-adipocyte Differentiation
Figure 3.26 demonstrates transcript expression during adipogenesis in 3T3-L1 cells. While 
CB2 expression was largely unaltered, CBi receptors were upregulated at the midpoint of the 
differentiation protocol coincident with PPARy expression. The increase in GPDH expression, 
a marker present in mature adipocytes, confirmed successful adipogenesis. Both CBi and CB2 
receptor expression was virtually undetectable in PAZ6 w ith Ct values approaching the lim it 
of detection at the maximum number of programmed PCR cycles and no change was noted 
during adipogenesis. This may explain the lack of effect of CB modulation on PAZ6 
proliferation. Therefore all further differentiation experiments were only performed in 3T3- 
L l.
Figure 3.26: Transcript Expression During 3T3-L1 Adipogenesis
All transcript copy numbers were normalised to the housekeeper gene ARP. Results are presented as fold-changes 
in comparison to expression on Day 0 & represent two independent experiments performed in triplicate
MCB2
Pref-1
C/EBPp
PPARv
GPDH
Day 12
Adipogenesis protocol
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3.3.10 The Effect Of CBi Agonist ACEA & CBi Antagonist AM 251 On Foci Of
Differentiation In 3T3-L1
One method of assessing adipogenesis is by manually counting separate foci of differentiation 
occurring w ith in a single observed microscopic field. However, 3T3-L1 differentiation was 
noted to be so widespread that it  was not possible to accurately count foci in order to draw 
comparisons between control and treatment conditions ((Figure 3.27). These effects were 
therefore studied by means of oil red 0 staining and QPCR for terminal markers of 
adipogenesis.
Figure 3.27: Adipogenesis In 3T3-L1
(magnification 200x)
3.3.11 Oil Red 0 Staining
Lipid droplets are exclusively present in mature adipocytes and stain positive w ith oil red 0 
(Figure 3.28). Oil red 0 taken up by the mature adipocytes was dissolved out and assessed by 
direct colourimetry. Figure 3.29 shows treatment with CBi agonist ACEA was associated with 
an increase in oil red 0 whereas CBi antagonist AM 251 had no significant effect.
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Figure 3.28: Oil Red 0 Staining In Mature 3T3-L1 Adipocytes
(magnification 200x)
Figure 3.29: Box-and-Whisker Representation Of The Effect Of CBi Agonist ACEA & 
Antagonist AM 251 On Oil Red O Staining in Mature 3T3-L1 Adipocytes
Data represent the median & IQRs expressed as OD490 from 2 independent experiments performed in 
quadruplicate. Significance was determined by the Wilcoxon Signed Ranks Test for individual treatments relative
to control.
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3.3.12 The Effect Of CBi Agonist ACEA & CBi Antagonist AM 251 On Terminal
Markers Of Adipogenesis In 3T3-L1
QPCR was performed on cDNA derived from RNA collected on day 0 and day 12 of the 
differentiation protocol and transcript expression for GPDH was normalised to housekeeper 
gene (ARP) expression. While exposure to the CBi agonist ACEA had no effect on adipogenesis 
relative to control conditions, supplementation with AM 251 was associated with a significant 
increase in GPDH expression as illustrated in Figure 3.30 and Table 3.24.
Figure 3.30: The Effect Of AM 251 On GPDH Expression In 3T3-L1 During Adipogenesis
Data represent 2 independent experiments performed in triplicate following 12 days culture in DM, ACEA or 
AM251. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to
control.
3000  "
p = 0.699
2 0 0 0 -
Contrnl 
(0.1% ethanol) 
Day 12
100 nM ACEA 
Day 12
155
Table 3.24: The Effect Of AM 251 On GPDH Expression In 3T3-L1 During Adipogenesis
Data represent 2 independent experiments performed in triplicate following 12 days culture in DM, ACEA or 
AM251. Statistical significance determined by Wilcoxon Signed Ranks test for individual treatments relative to
control
H
Day 0
25.44 5736
T
17.51 2187000 26
n/a
26.14 3392 17.04 3175000 11
24.37 7842 18.05 1481000 53
9 1
25.22 6137 17.55 2158000 28
o l
26.13 3416 18.70 908100 38
26.75 2974 18.56 1012000 29
Day 12 
Control 
0.1% ethanol
21.21 138300 18.51 1053000 1313
1095 n/a
21.41 118900 18.25 1276000 932
20.98 164000 18.35 1000000 1640
20.71 200600 16.62 3989000 503
20.96 166800 18.19 1357900 1228
21.15 144900 18.04 1515000 956
Day 12 
100 nM ACEA
19.80 282700 17.21 2739000 1032
1037 0.699
21.34 120900 17.87 1962000 616
20.75 193800 16.98 3472000 558
20.03 257500 17.03 3179000 810
20.78 192200 18.34 1574000 1221
19.66 350100 18.26 1763000 1986
Day 12 
100 nM 
AM 251
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2734 0.015
20.43 241900 17.88 1976000 1224
18.56 517200 17.96 1605600 3221
17.91 836000 17.61 2089000 4002
18.03 787400 17.43 2184000 3605
19.92 423000 17.90 1973000 2144
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3.3.13 The Effect Of CBi Agonist ACEA & CBi Antagonist AM 251 On UCP-1
Expression In Differentiated 3T3-L1
QPCR was performed on cDNA derived from RNA collected on day 0 and day 12 of the 
differentiation protocol and transcript expression for UCP-1 was normalised to housekeeper 
gene (ARP) expression. Transcript expression was at the lim it of QPCR detection (Ct values > 
35) and did not alter w ith adipogenesis in control conditions or when supplemented with 
ACEA or AM 251.
157
3.4 DISCUSSION
Adipocyte cell proliferation and differentiation represent two closely related cell processes 
that control adipose tissue homeostasis [207]. In obesity, adipose tissue accumulates as a 
result of increased pre-adipocyte proliferation (hyperplasia) and differentiation into mature 
adipocytes, as well as excess lipid droplet accumulation within adipocytes causing cell 
hypertrophy. The data from the experiments described in this chapter have demonstrated 
that CBi agonist treatment appears to have a stimulatory effect on pre-adipocyte proliferation 
in the WAT cell line, 3T3-L1, while CBi antagonism may inhibit cell proliferation, thus 
modifying an important step in adipose tissue accumulation. This inhibitory effect does not 
appear to be due to increased apoptosis and toxicity, but may partly be secondary to cell cycle 
blockade with growth arrest in the G1 phase. However, though statistically significant, these 
effects do appear to be relatively small in absolute terms, therefore further work is required 
to determine their biological significance.
Similar studies published in the literature have also confirmed an anti-proliferative effect, 
using the CBi antagonist SR141716, where the findings have been associated with inhibition 
of p42/44 mitogen-activated protein (MAP) kinase activity which has been shown to be 
involved in the CBi signalling pathway [207, 208]. The inhibition of proliferation with CBi 
blockade adds evidence to the importance of the ECS in adipocyte physiology and studies by 
Matias et al have confirmed the presence of the endogenous endocannabinoids 2-AG and AEA 
in murine white adipocytes in vitro [76]. These findings suggest that adipocytes could 
contribute directly to dysregulation of the ECS affecting obesity.
In the experiments presented here, CBi antagonism induced expression of GPDH, a late
marker of adipocyte maturation without an associated increase in lipid droplet accumulation
measured by oil red 0, thus modifying another process in adipose tissue accumulation. These
findings are consistent with those published in previous studies. Gary-Bobo et al have also
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demonstrated a CBi antagonist-induced increase in expression of terminal markers of 
adipogenesis, GPDH and adiponectin, that was not accompanied by lipid droplet accumulation 
[207]. The authors hypothesise that CBi antagonism may cause an uncoupling of the 
association between the inhibition of pre-adipocyte proliferation and lipid accumulation 
through adipogenesis [207]. Though atypical, this property may also account for some of the 
anti-obesity effects seen with CBi blockade but further work is required to clarify this.
CB2 agonists and antagonists had no effect on 3T3-L1 proliferation. The results from these 
experiments suggest that CB2 does not play a significant role in adipocyte biology as 
modulation of CB2 in the present studies had no effect on proliferation, and CB2 transcript 
expression remained unchanged throughout adipogenesis.
There do not seem to be any previous studies examining the effects of CB modulation in BAT. 
Neither CBi nor CB2 modulation had any effect on the BAT human pre-adipocyte cell line 
PAZ6 proliferation, and transcript expression was virtually undetectable for both receptors 
throughout adipogenesis. These findings, though negative, are novel as there are no published 
data of similar studies, though further work would be required to confirm this. It is, however, 
also important to recognise the limitations of the PAZ-6 cell line, which is not always easy to 
use and does not differentiate as readily in reponse to environmental stimuli as the 3T3-L1 
cell line. These characteristics may also have contributed to the negative findings in the 
present studies of CB modulation in BAT.
Our experiments did not confirm the presence of the BAT-specific marker, UCP-1, in
terminally differentiated 3T3-L1. This is in contrast to a recent study by Perwitz et al who
demonstrate that CBi blockade with the antagonist SR 141716, or receptor knock down with
small interfering RNA (siRNA), induces UCP-1 expression in murine white adipocytes in a
time- and concentration-dependent manner at both RNA and the protein level [209]. This
was also associated with an augmentation in the number of mitochondria present as
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indicated by mitochondria-specific fluorescent staining and electron microscopy. 
Furthermore, SR 141716 treatment enhanced cytochrome C oxidase activity and increased 
cellular oxygen consumption [209]. These important findings suggest that CBi blockade could 
promote transdifferentiation of white adipocytes into a BAT phenotype, and may thus 
contribute to weight loss and improved energy homeostasis. The discrepancy between these 
studies may be atrributed to the different CBi antagonists employed or due to possible 
differences in the WAT cell lines.
The studies described in this chapter suggest that the inhibition of pre-adipocyte 
proliferation, along with induction of adipocyte maturation, may in part explain the 
peripheral anti-obesity effects of CBi antagonist treatment by a reduction in total body fat 
mass. However, these data have been obtained from work performed using in vitro models of 
animal-derived cells, and therefore cannot be conclusively applied to human physiology 
without further study. The next chapter aims to address this by replicating these experiments 
in a human model with the use of primary pre-adipocytes.
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CHAPTER 4 : EFFECT OF CANNABINOID RECEPTOR MODULATION
ON PROLIFERATION AND DIFFERENTIATION IN 
HUMAN PRIMARY PRE-ADIPOCYTES.
4.1 INTRODUCTION
The previous chapter has described the effects of CB receptor modulation on pre-adipocyte 
proliferation and adipogenesis using in vitro models with the 3T3-L1 and PAZ6 cell lines 
representing WAT and BAT respectively. These studies demonstrated no influence of CB 
receptor agonism or antagonism on PAZ6 biology, but significant effects, albeit small, were 
noted in 3T3-L1. However, there are certain limitations associated with conclusions drawn 
from investigations performed with the use of cell lines. Firstly, 3T3-L1 is a murine cell line 
therefore any study conclusions have to be applied with caution to human physiology. One 
difference is that cell lines such as 3T3-L1 undergo one or two cycles of cell division prior to 
differentiation, whereas human pre-adipocytes can undergo adipogenesis without post­
confluence mitosis [161]. Cell lines are specifically developed outside their natural 
environment with an exaggerated potential for proliferation and lipid accumulation, and are 
thus not exposed to factors which may influence normal physiology in vivo. There is a 
commercially available immortalised human pre-adipocyte cell line with a preserved 
differentiating capacity, Chub-S7, derived from the subcutaneous adipose tissue by co­
expression of human telomerase reverse transcriptase and papillomavirus E7 oncoprotein 
genes [210]. The use of this cell line is however, limited by its expense. Furthermore, there is 
increasing evidence that white pre-adipocytes derived from different locations have distinct 
molecular and physiological properties. Subcutaneous and visceral adipocytes retain 
differences in gene expression, adiponectin secretion, and insulin action and signalling, and 
excess visceral adiposity is associated with an increased risk of DM and CVD [11, 12, 211]. 
Though 3T3-L1 represents a model of WAT it cannot account for these depot specific
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differences that have been observed in humans. In order to address these short-comings it 
was necessary to repeat some of the previous experiments with human primary cultures 
derived from both subcutaneous and adipose tissue depots.
4.1.1 Human Primary Cultures
While the use of human primary cultures may be preferred over non-human cell lines for the 
reasons discussed above, this is not without its own difficulties. Adipose tissue is an internal 
organ and therefore obtaining samples requires a surgical procedure. Such a project therefore 
requires approvals from local Research and Development departments as well as the local 
Research Ethics Committee. These processes are time-consuming and therefore prolong the 
duration of any proposed study. Care must also be taken to ensure the study is performed in 
accordance with the 'Declaration of Helsinki' [212]. Individuals participating in these studies 
must be approached appropriately and informed consent needs to be obtained, as well as co­
operation from surgical colleagues and theatre staff not directly involved in the project. Once 
isolated, primary pre-adipocytes are more susceptible to contamination due to the methods 
used for extraction and these cells also exhibit considerably slower rates of proliferation 
compared to cell lines thus similar experiments require longer periods of study. Unlike the 
immortalised cell lines, primary cells can enter a period of senescence and thus cells of low 
passage number (in these studies < 2) are required, further limiting the number of 
experiments possible with any given sample. Despite these drawbacks human primary 
cultures are still considered the 'gold standard' method for in vitro studies and results 
obtained from such work can be applied to human physiology with greater confidence than 
cell lines.
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4.1.2 Adipose Tissue Depot-Specific Differences
In vivo, WAT is present in a variety of locations, including subcutaneous, omental, pre-orbital, 
synovial, bone marrow and retroperitoneal depots. Pre-adipocytes isolated from different 
areas have different adipogenic potential, the basis for which is not fully understood. 
Individuals with increased visceral adiposity have a greater risk of insulin resistance, 
dyslipidaemia, and cardiovascular disease than those of equivalent weight but a higher 
degree of subcutaneous adiposity [3]. Surgical removal of visceral fat by omentectomy 
improves insulin sensitivity while elimination of subcutaneous fat by liposuction has limited 
effect on insulin resistance and metabolic abnormalities [213, 214].
Intra-abdominal and subcutaneous adipose tissue exhibit important metabolic differences 
that may underlie the association of visceral, but not subcutaneous, fat with obesity-related 
cardiovascular and metabolic problems [215], Expression of adiponectin and C/EBPa (which 
regulates adipogenesis and adiponectin gene expression), have been shown to be higher in 
subcutaneous adipocytes, whereas cellular inhibitor of apoptosis2 (CiAP2) mRNA expression 
is greater in omental adipocytes [211, 216]. CiAP2 may be involved in the regulation of TNFa 
signaling, therefore this raises the possibility that depot-specific differences may exist in the 
regulation of adipocyte apoptosis [216]. Previous studies have also demonstrated a two- to 
three-fold higher insulin-stimulated glucose uptake in visceral adipocytes as well as 
exaggerated lipolysis particularly in response to adrenergic stimulation, resulting in higher 
free fatty acid (FFA) concentrations [211, 217]. Circulating FFAs promote insulin resistance in 
the liver and muscle, and increase hepatic gluconeogenesis and lipoprotein production.
4.1.3 Adiponectin
Another hypothesis to explain the physiological mechanism linking excess body fat to adverse
metabolic, and thus health, consequences is thought to be via modification of the
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adipocytokine profile, the details of which have been discussed in Chapter 1. A reduction in 
adiponectin or an elevation in TNFot, IL-6, and leptin is associated with greater insulin 
resistance. Previous investigators have illustrated the inverse correlation of adiponectin 
levels w ith most components of the metabolic syndrome, defined by the IDF criteria (detailed 
in Chapter 1), as illustrated in Figure 4.1 [218]. Measurement of this key adipocytokine was 
therefore included in the present studies of CBi receptor modulation on adipogenesis.
Figure 4.1: Association Of Reduced Serum Adiponectin With Features Of The Metabolic 
Syndrome In Males & Females As Defined By The IDF Criteria
[adapted from Santaniemi et al [218])
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4.1.3.1 Enzyme-Linked Immunosorbent Assay (ELSIA)
As previously discussed in Chapter 1, adiponectin is found in low and high molecular weight 
forms w ith the latter being metabolically more important. Most of the commercially available 
assays, including Duoset® ELISA (R&D systems, Oxford, UK) used in this study measure total 
adiponectin using the following method illustrated in Figure 4.2 [219].
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Figure 4.2: Schematic Representation Of The ELISA Technique
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The ELISA technique is based on the principle of an 'antibody sandwich'. First, a capture 
antibody specific to the analyte of interest is bound to a microtitre plate to create the solid 
phase. The plate is then washed to remove any unbound antibody and then coated with a 
blocking reagent. Following a further wash, samples, standards, and controls are then 
incubated w ith the solid phase antibody in order to capture the analyte. The plate is then 
washed again to remove unbound analyte following which a conjugated detection antibody 
(e.g. biotin-labelled antibody] is added. This detection antibody binds to a different epitope of 
the molecule being measured, completing the sandwich. This process is again followed by a 
wash to remove unbound detection antibody, after which a detection reagent (e.g. 
Horseradish-peroxidase (HRP] conjugated streptavidin) is added. The plate is washed and a 
substrate solution (e.g. tetramethylbenzidine peroxide) is added. The substrate is converted 
by the HRP to a blue coloured product in proportion to the amount of bound analyte. Colour 
development is stopped upon the addition of an acidic solution turning the colour yellow, and
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the intensity of the yellow colour is measured by reading the optical density at A450 on a 
microtitre plate reader.
4.1.4 Chapter Aims
There have been numerous in vivo observational and interventional studies in animal and 
human populations evaluating the effect of CB receptor influence on adiposity and these have 
been reviewed in Chapter 1. Most of the published studies of CB receptor influence on pre­
adipocyte proliferation and differentiation have been performed with in vitro models using 
non-human cell lines as discussed in the preceding chapter, but there is a scarcity of data 
from human models. Other investigators have shown that both precursor and mature 
adipocytes derived from subcutaneous and omental depots express functional plasma 
membrane CBi and CB2 receptors, though their physiological role has not been directly 
examined in vitro [220].
In order to address some of the uncertainties regarding the extrapolation of cell line data to 
humans and the depot specific differences seen in WAT physiology, this chapter aims to 
assess the biological effect of CBi receptor agonism and antagonism on proliferation and 
adipogenesis using human primary cultures, both to confirm or refute the findings from the 
previous cell line studies, and to compare these effects in cells derived from subcutaneous 
and omental adipose tissue.
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4.2 MATERIALS AND METHODS
4.2.1 Study Approvals & Patients Studied
Approvals were obtained from the Cardiff and Vale NHS Trust Research and Development 
Office and the South Wales Research Ethics Committee to approach individuals undergoing 
elective, open abdominal surgery for non-metabolic causes at the University Hospital of 
Wales, Cardiff. Following admission to the surgical wards, potential study participants were 
provided w ith a patient information sheet (Appendix 1). The exclusion criteria applied were 
pregnancy or treatment with the oral contraceptive pill, oestrogens, androgens, 
glucocorticoids, growth hormone or thyroxine therapy due to the well-established effects of 
these hormones on adipocyte function. Patients with lipodystrophy, and subjects receiving 
highly active antiretroviral therapy (HAART) for HIV infection or other conditions/treatment 
with a known effect on adipose tissue were also excluded as were diabetics unless treated 
with dietary therapy alone. Informed consent was obtained (Appendix 2) and data were 
collected on the individual's age, past medical and drug history, as well as measurements of 
height, weight, waist and hip circumference, and body fat percentage (Tanita Body fat 
monitor/scale TBF-538, Tanita corporation, Tokyo, Japan). The surgeons (Mr. M Puntis, Mr. B 
Rees and Mr. N Kumar) kindly harvested paired subcutaneous and omental adipose tissue 
samples during surgery for subsequent extraction of pre-adipocytes.
4.2.2 Reagents And Culture Media
The CB receptor modulators, cell culture materials and methods were identical to those used 
in the cell line experiments with 3T3-L1 as described in the previous chapter. All culture 
medium constituents were obtained from BioWhittaker (Belgium) unless otherwise stated.
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4.2.3 Explants
Adipose tissue samples were cut into small fragments (0.5-1 mm diameter), placed into 6 well 
plates and covered with just enough CM to prevent sample dehydration. A few drops of fresh 
CM were added every 48 hours. Pre-adipocytes were noted to migrate out of the explants and 
attach on to the surface of the culture plate, however it would take several weeks to collect 
enough pre-adipocytes by this process for use in experiments, therefore the collagenase 
digest method was used instead.
4.2.4 Collagenase Digest
Primary pre-adipocytes were successfully isolated from paired subcutaneous and omental 
adipose tissue depots (n=8) by collagenase digest followed by centrifugation through phthalic 
acid dionyl ester. The adipose tissue samples retrieved from theatre were cut into 0.5-1 mm 
fragments and approximately 3 ml adipose tissue was placed into individual 20 ml universal 
containers. The tissue was combined with 7 mis Hank's balanced salt solution (HBSS), 2 mis 
7.5% w /v  bovine serum albumin (BSA, Sigma Aldrich) and 1 ml (30mg/ml) type II 
collagenase, and incubated for 1 hour in a 37°C water bath while shaking every 5 minutes. 
The contents were then transferred to a clean 15 ml falcon tube and 2 mis phthalic acid dionyl 
ester mixed isomer was added to each sample prior to centriguation at 1500 rpm for 5 
minutes at 4°C to allow separation into different cell and lipid layers as illustrated in Figure 
4.3.
The supernatant was removed and the resultant cell pellet was resuspended in 10 mis CM in a 
75 cm2 Nunclon™ delta surface flask (Nunc, Roskilde, Denmark). Initially red blood cell 
removal was attempted with ammonia sulphate but this was not very effective therefore after 
24 hours the cells were washed twice with 5 mis HBSS to remove any residual red cells, and 
this process was repeated after a further 24 hours if  still required.
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Figure 4.3: Isolation Of Primary Pre-Adipocytes Using Collagenase Digest Followed By 
Centrifugation Through Phthalic Acid Dionyl Ester.
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4.2.5 Routine Maintenance Of Human Primary Pre-Adipocytes
All cell culture experiments were performed in sterile conditions at 37°C in an atmosphere 
containing humidified 5% CO2 in air. Both subcutaneous and omental pre-adipocytes were 
grown in 75 cm2 flasks. Culture medium was refreshed every 48 hours and upon reaching 
confluence, the cells underwent passage by trypsinisation as described in Chapter 3. It was 
noted that the primary pre-adipocytes invariably became senescent after the third passage, 
therefore where possible proliferation experiments were performed after the first, and 
differentiation experiments after the second passage.
4.2.6 Proliferation Studies
4.2.6.1 Cell Culture Protocol
Subcutaneous and omental pre-adipocytes were grown to confluence and trypsinised as 
described previously. The approximate number of cells per ml solution was calculated with
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the aid of a haemocytometer (Camber counter, Weber Scientific International Ltd, Middlesex, 
UK). Cells were subsequently diluted and seeded at lx lO 3 per well in 24 well plates 
(Nunclon™ delta surface, Nunc, Roskilde, Denmark) and incubated at 37°C overnight to 
enable optimal attachment. Cells were then incubated in control CM alone, or supplemented 
with increasing concentrations of ACEA (1 nM to 10 pM) or AM251 (10 nM to 500 nM). Each 
experiment was completed in quadruplicate and performed twice.
4.2.6.2 Direct Cell Counting
Proliferation rates in primary cells were considerably slower than in the cell lines, therefore 
the pre-adipocytes were collected for direct cell counting after 72 and 168 hours of treatment 
Each well was washed with 0.5 mis of 1% w /v  trypsin and then incubated with a further 0.5 
mis trypsin until cells were free in suspension. The contents of individual wells were 
transferred to corresponding cell counting cuvettes containing 10 mis each of Coulter Isoton 
II Diluent (Beckman Coulter, Gmbh, Germany). Cell densities were measured using a Coulter 
particle counter (Z2, Beckman Coulter Gmbh, Germany) w ith particle size set between 3.8 nm 
and 9.0 nm. Each sample was counted twice and the average value used for statistical 
analysis.
4.2.7 Adipogenesis Studies
4.2.7.1 Cell Culture Protocol
Subcutaneous and omental pre-adipocytes were plated in 6 well plates and adipogenesis 
induced in confluent populations of pre-adipocytes by replacing CM with DM as described in 
Chapter 3. Cells were maintained in DM alone, or supplemented with lOOnM ACEA or lOOnM 
AM251, for 21 days with DM changes occurring every 72 hours. Morphological changes of 
differentiation were monitored by microscopic examination.
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4.2.7.2 Isolation Of Total RNA & Reverse Transcription To cDNA
Samples for RNA extraction were collected on days 0, 7, 14 and 21. Total RNA was isolated 
using Invitrogen's TRIzol reagent as described in the previous chapter. The RNA 
concentration and quality was assessed by spectrophotometry (GeneQuant, GE Healthcare) 
and analysis on a 1.2% agarose gel. Samples were stored at -80°C until further use. Also, as 
per the cell line study methods, the RNA was treated with DNase, reverse transcribed to 
cDNA, and conventional PCR performed with primers for the human housekeeping gene PGK- 
1 to confirm the absence of contaminating genomic DNA.
4.2.7.3 QPCR Measurement Of Markers Of Adipogenesis
Real-time QPCR was performed to measure the expression of LPL, a terminal marker of 
adipogenesis and the housekeeper gene APRT. QPCR was performed using Stratagene's 
Brilliant® SYBR® Green Master Mix. The reaction components and thermal cycling protocol 
were identical to those detailed in chapter 3. Standard curves obtained from serial dilutions 
of PCR amplicons sub-cloned into pGEM-T vectors at 106 to 102 copies were included for each 
gene.
4.2.7.4 ELISA Measurement Of Adiponectin
Adiponectin concentrations were measured in conditioned medium collected on days 0, 7,14
and 21 of the differentiation protocol using the Human Adiponectin Duoset® ELISA
development system (R&D Systems, Oxford, UK) according to the manufacturer's instructions.
Costar ELI 96 well plates (R&D Systems, Oxford, UK) were coated with 100 pi /  well capture
antibody (55 pi /  ml PBS) and stored overnight. Prior to use the next day, the plates were
washed twice with wash buffer (0.05% Tween 20 in PBS, pH 7.4) following which the wells
were blocked with diluent (1% w /v  BSA in PBS) for 2 hours. After repeating the wash
process, 100 pi of serially diluted adiponectin standards (25 to 4000 pg /  ml) or 100 pi neat
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conditioned medium was added to individual wells and incubated at room temperature for 2 
hours. Once again the plates were washed and each well coated with 100 pi horseradish 
peroxidase conjugated Streptavidin (50 pi /  ml), incubated at room temperature, washed 
again and coated with 100 pi substrate solution (tetramethylbenzidine peroxide). The 
reaction was terminated by the addition of 50 pi stop solution (10% sulphuric acid) and 
optical density was measured using an OpsysMR microplate reader (Dynex Technologies, 
Chantilly, USA) set to 450nm. The intra- and inter- assay coefficient of variation was less than 
4%.
4.2.8 Statistical Analysis
Data were analysed using the SPSS (version 14.0) statistical software package.
The data generated by the proliferation and adipogenesis studies were not normally 
distributed (determined by generating Q-Q and P-P plots of data obtained) and therefore 
analysed according to median and interquartile ranges (IQR) using non-parametric statistical 
tests. The Friedman's test was performed on each experiment and the Wilcoxon Signed Ranks 
test was performed on individual treatments relative to control conditions. The QPCR data 
were analysed as absolute values per input microgram of mRNA and corrected relative to the 
appropriate housekeeper gene expression.
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4.3 RESULTS
4.3.1 Study Participant Demographics
Table 4.1 lists the anthropometric measurements of the patients who participated in this 
study. Paired subcutaneous and omental adipose tissue samples were collected from all 8 
patients.
Table 4.1: Anthropometric Data Of Study Participants
1 55 M 1.78 69.9 22.1 1.02 10
2 76 M 1.75 62.2 20.3 0.94. 83
3 75 M 1.78 82 25.9 0.88 26
4 64 F 1.63 74 27.9 0.83 31
5 74 F 1.55 48 20.0 1.0 27
6 74 F 1.63 59.5 22.4 0.85: 30
7 30 F 1.55 60 25 - -
8 66 F 1.52 57 24.7 0.77 35
4.3.2 Primary Pre-Adipocyte Cell Culture
Examples of the microscopic appearance of the primary pre-adipocytes, including the 
presence of atypical cells in the omental adipose tissue, are given in Figure 4.4. The primary 
pre-adipocytes were noted to be larger than the cell lines and exhibited much slower 
proliferation rates in comparison, with a population doubling time of almost 5 days, therefore
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the number of cells available for use in experimentation was more limited than with the cell 
lines.
Figure 4.4A : Subcutaneous Pre-Adipocytes Figure 4.4B: Omental Pre-Adipocytes
(magnification 200x) (magnification 200x)
Atypical cells
Pre-adipocytes derived from all 8 individuals were used in the proliferation experiments but 
only the first 5 were used in the adipogenesis studies. This was due to difficulties encountered 
with the initial pre-adipocyte extraction method (explants) where sufficient numbers of cells 
could not be generated despite prolonged cell culture. Also it was noted in our early 
experiments that it was not possible to induce differentiation in primary pre-adipocytes 
beyond the third passage due to cell senescence. Lastly in one individual who underwent 
surgery for abdominal malignancy, a significant number of atypical cells were noted in the 
omental samples (Figure 4.4B) and thus could not be used for our studies.
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4.3.3 CBi Agonist ACEA Stimulates Subcutaneous Pre-Adipocyte Proliferation
Exposure to the selective CBi agonist ACEA for 72 hours was associated w ith a significant, 
concentration-dependent increase in proliferation of the subcutaneous pre-adipocytes as 
illustrated in Table 4.2 and Figure 4.5.
Table 4.2 Mean, Median & IQR For Subcutaneous Cells Treated With ACEA For 72 Hours
Control (0.1% ethanol) 3766 3876 3332-4162 n/a
In M 3861 3904 3468-4232 0.029
10 nM 4050 4123 3602-4524 <0.001
100 nM 4230 4317 3741-4711 <0.001
1 pM 4375 4528 3734-4965 <0.001
10 pM 4324 4411 3706-4902 <0.001
Figure 4.5: Effect Of ACEA On Subcutaneous Pre-Adipocyte Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman’s test for overall experiment
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Exposure to the CBi agonist ACEA for 168 hours was also associated with a significant, 
concentration-dependent increase in proliferation of the subcutaneous pre-adipocytes as 
illustrated in Table 4.3 and Figure 4.6.
Table 4.3 Mean, Median & IQR For Subcutaneous Cells Treated With ACEA
For 168 Hours
Control (0.1% ethanol) 9416 9691 8329-10405 n/a
In M 9653 9760 8671-10582 <0.001
10 nM 10126 10308 9005-11312 <0.001
100 nM 10576 10793 9353-11779 <0.001
1 pM 10938 11320 9337-12410 <0.001
10 pM 10810 11028 92655-12255 <0.001
Figure 4.6: Effect Of ACEA On Subcutaneous Pre-Adipocyte Proliferation At 168 Hours
Cells were counted 168 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.
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4.3.4 CBi Agonist ACEA Stimulates Omental Pre-Adipocyte Proliferation
Exposure to the selective CBi agonist ACEA for 72 hours was associated with a significant, 
concentration-dependent increase in proliferation of the omental pre-adipocytes as 
illustrated in Table 4.4 and Figure 4.7.
Table 4.4: Mean, Median & IQR For Omental Cells Treated With ACEA For 72 Hours
Control (0.1% ethanol) 4531 4564 4193-4937 n/a
In M 4882 4830 4500-5294 <0.001
10 nM 4780 4677 4306-5139 <0.001
100 nM 5157 4979 4571-5648 <0.001
1 pM 5344 5312 4913-5780 <0.001
10 pM 4527 4495 4168-4901 0.753
Figure 4.7: The Effect Of ACEA On Omental Pre-Adipocyte Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman’s test for overall experiment
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Exposure to the CBi agonist ACEA for 168 hours was associated with a significant,
concentration-dependent increase in proliferation of the omental pre-adipocytes as
illustrated in Table 4.5 and Figure 4.8.
Table 4.5: Mean, Median & IQR For Omental Cells Treated With ACEA For 168 Hours
Control (0.1% ethanol) 8239 8298 7624-8976 n/a
In M 8877 8782 8182-9627 <0.001
10 nM 9559 9355 8612-10277 <0.001
100 nM 9919 9575 8792-10862 <0.001
1 pM 9717 9658 8933-10508 <0.001
10 pM 9432 9354 8684-10210 <0.001
Figure 4.8: The Effect Of ACEA On Omental Pre-Adipocyte Proliferation At 168 Hours
Cells were counted 168 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for individual treatments relative to control & Freedman’s test for overall experiment.
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4.3.5 CBi Antagonist AM 251 Inhibits Subcutaneous Pre-Adipocyte Proliferation
Exposure to the CBi antagonist AM 251 for 72 hours was associated with a significant, 
concentration-dependent reduction in proliferation of the subcutaneous pre-adipocytes as 
illustrated in Table 4.6 and Figure 4.9.
Table 4.6 Mean, Median & IQR For Subcutaneous Cells Treated With AM 251
For 72 Hours
Control (0.1% ethanol) 4226 4251 3809-4603 n/a
10 nM 4156 4195 3840-4489 0.036
50 nM 3855 3810 3542-4161 <0.001
100 nM 3502 3451 3211-3776 <0.001
250 nM 3322 3216 2954-3608 <0.001
500 nM 3286 3137 2977-3515 <0.001
Figure 4.9: Effect Of AM251 On Subcutaneous Pre-Adipocyte Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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Exposure to the CBi antagonist AM 251 for 168 hours was associated with a significant,
concentration-dependent reduction in proliferation of the subcutaneous pre-adipocytes as
illustrated in Table 4.7 and Figure 4.10.
Table 4.7: Mean, Median & IQR For Subcutaneous Cells After AM 251 For 168 Hours
Control (0.1% ethanol) 9829 9885 8857-10705 n/a
10 nM 9447 9534 8728-10202 <0.001
50 nM 9179 9072 8433-9908 <0.001
100 nM 8755 8629 8027-9440 <0.001
250 nM 8518 8245 7577-9251 <0.001
500 nM 8216 7843 7444-8790 <0.001
Figure4.10 Effect Of AM251 On Subcutaneous Pre-Adipocyte Proliferation At 168 Hours
Cells were counted 168 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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4.3.6 CBi Antagonist AM 251 Inhibits Omental Pre-Adipocyte Proliferation
Exposure to the CBi antagonist AM 251 for 72 hours was associated with a significant, 
concentration-dependent reduction in proliferation of the omental pre-adipocytes as 
illustrated in Table 4.8 and Figure 4.11.
Table 4.8: Mean, Median & IQR For Omental Cells Treated With AM 251 For 72 Hours
Control (0.1% ethanol) 3889 3588 3178-4607 n/a
10 nM 3794 3509 3092-4445 0.001
50 nM 3459 3276 2811-4062 <0.001
100 nM 3055 2926 2601-3450 <0.001
250 nM 2773 2756 2334-3162 <0.001
500 nM 2721 2798 2235-3140 <0.001
Figure 4.11: The Effect Of AM 251 On Omental Pre-adipocyte Proliferation At 72 Hours
Cells were counted 72 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment.
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Exposure to the CBi antagonist AM 251 for 168 hours was associated with a significant,
concentration-dependent reduction in proliferation of the omental pre-adipocytes as
illustrated in Table 4.9 and Figure 4.12.
Table 4.9: Mean, Median & IQR For Omental Cells Treated With AM 251 For 168 Hours
Control [0.1% ethanol) 9046 8344 7392-10714 n/a
10 nM 8624 7976 7028-10101 <0.001
50 nM 8236 7801 6693-9672 <0.001
100 nM 7638 7315 6502-8626 <0.001
250 nM 7110 7067 5984-8108 <0.001
500 nM 6802 6996 5588-7850 <0.001
Figure 4.12: Effect Of AM 251 On Omental Pre-Adipocyte Proliferation At 168 Hours
Cells were counted 168 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for individual treatments relative to control & Friedman's test for overall experiment
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4.3.7 CBi Antagonist AM 251 May Exert A Preferential Effect On Omental Pre-
Adipocyte Proliferation
It was also noted that the inhibitory effect of CBi antagonism was greater in omental as 
compared to the subcutaneous cells obtained for individual patients at any given BMI in most 
but not all cases (Figure 4.13A). A trend was also observed for a greater reduction in omental 
preadipocyte number w ith increasing BMI but not in the subcutaneous populations. CBi 
agonist treatment was associated w ith an increased proliferation effect in the omental cells in 
subjects w ith a higher BMI (Figure 4.13B).
Figure 4.13A: Effect Of 500 nM AM 251 On Primary Pre-adipocyte Proliferation
Cells were counted 168 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for subcutaneous vs. omental for each individual patient
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Figure 4.13B: Effect Of 10 pM ACEA On Primary Preadipocyte Proliferation
Cells were counted 168 hours after treatment after plating 1 x 103 cells/well. Results represent the mean and SD 
from 2 independent experiments performed in quadruplicate (n=8). Statistical significance determined by 
Wilcoxon Signed Ranks test for subcutaneous vs. omental for each individual patient
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4.3.8 Summary Of The Effects Of Cannabinoid Receptor Modulation On Pre-
Adipocyte Cell Line Proliferation
In the primary cell populations exposure to CBi agonist treatment resulted in a 
concentration-dependent increase in both subcutaneous and omental preadipocyte 
proliferation while CBi antagonism was associated w ith a reduction in cell numbers. The 
degree of inhibition by CBi antagonism was greater in omental pre-adipocytes compared to 
subctaneous cells in all individuals.
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4.3.9 Adipogenesis In Primary Subcutaenous & Omental Cell Cultures
The effect of cannabinoid receptor modulation on adipogenesis was investigated by 
quantification of LPL expression by QPCR and measurement of adiponectin production. 
Morphological changes in the cells were observed microscopically and visible lipid droplet 
accumulation confirmed w ith oil red 0 staining. Differentiation in the primary cultures tended 
to occur in multiple foci as compared to the more generalised adipogenesis noted in the 3T3- 
L1 cell line. In the omental samples the foci were smaller and more multiple whereas the 
subcutaneous foci were larger in size and fewer in number (Figure 4.14).
Figure 4.14A Subcutaneous Adipocytes
(magnification 20Ox)
Figure 4.14B: Omental Adipocytes
(magnification 200x)
v y y
ipid-rich mature adipocytes 
Subcutaneous pre-adipocytes Omental pre-adipocytes
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4.3.10 The Effect Of CBi Agonist ACEA & CBi Antagonist AM 251 On LPL
Expression In Subcutaneous Adipogenesis
Treatment w ith the CBI agonist ACEA had no significant effect on subcutaneous pre­
adipocyte differentiation as measured by LPL expression whereas exposure to the CBI 
antagonist AM 251 resulted in an increase in LPL expression (Table 4.10 and Figure 4.15).
Table 4.10: Effect Of ACEA & AM251 On LPL Expression In Subcutaneous Adipogenesis
Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or 
AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression and also expressed as 
fold-change relative to Day 0. Statistical significance for gene expression determined by Wilcoxon Signed Ranks
test for individual treatments relative to control
Patient N 1 2  3 -1 5 Mean p-value
Day 0
LPL Copy Ns 223 255 331 255 270 267
n/a
Normalised to 
APRT Copy Nfl 999 1183 1248 1282 1312 1204
Day 21 
Control 
(0.1% 
ethanol)
LPL Copy Nfi 2738 2913 2266 3255 2201 2675
n/aNormalised to APRT Copy Nfi 19257 13313 10281 16997 10700 14110
FOLD change 19.3 11.3 8.2 13.3 a is 11.7
Day 21 
100 nM 
ACEA
LPL Copy Nfi 2356 3528 2877 3677 3387 3165
0.605Normalised to APRT Copy Nfi 10685 18150 9006 20218 15752 14762
FOLD change 10.7 15.3 7.2 15.7 12.0 12.3
Day 21 
100 nM 
AM 251
LPL Copy Nfi 5741 5818 5818 4947 4477 5360
<0.001Normalised to APRT Copy Nfi 37791 35380 30145 32070 26230 32323
FOLD change 37.8 29.9 24.2 25.0 20.0 26.8
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Figure 4.15: Effect Of ACEA & AM251 On Subcutaneous Adipogenesis
Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or 
AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance 
determined by Wilcoxon Signed Ranks test for individual treatments relative to control.
p <0.001
p = 0.605
Q.■o
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DayO Control 100 nM ACEA 100 nM AM 251
(0.1% ethanol) Day 21 Day 21
Day 21
4.3.11 The Effect Of CBi Agonist ACEA & CBi Antagonist AM 251 On UCP-1
Expression In Terminally Differentiated Subcutaenous Adipocytes
QPCR was performed on cDNA derived from RNA collected on day 0 and day 21 of the 
differentiation protocol and transcript expression for UCP-1 was normalised to housekeeper 
gene [APRT] expression. Transcript expression was at the lim it of QPCR detection (Ct values > 
35) and did not alter with adipogenesis in control conditions or when supplemented with 
ACEA or AM 251.
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4.3.12 The Effect Of CBi Agonist ACEA & CBi Antagonist AM 251 On LPL
Expression In Omental Adipogenesis
Treatment w ith the CBI agonist ACEA had no significant effect on omental pre-adipocyte 
differentiation as measured by LPL expression whereas exposure to the CBI antagonist AM 
251 resulted in an increase in LPL expression (Table 4.11 and Figure 4.16).
Table 4.11: Effect Of ACEA & AM251 On LPL Expression In Omental Adipogenesis
Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or 
AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression and also expressed as 
fold-change relative to Day 0. Statistical significance for gene expression determined by Wilcoxon Signed Ranks
test for individual treatments relative to control.
B
Day 0
LPL Copy Ns 2 58 2 6 6 282 225 235 253
n /a
Norm alised to 
APRT Copy N2
1368 95 7 1372 1412 1467 1315
Day 21 
Control 
(0.1%  
ethanol)
LPL Copy Ns 3671 28 48 26 64 438 237 20 24
n /aNorm alised to 
APRT Copy Ne
15209 15012 11943 20 08 1099 92 97
FOLD change 11.1 15.7 8.7 1.5 0.8 7.06
Day 21 
100 nM 
ACEA
LPL Copy Ns 2730 24 10 3521 361 355 1875
0 .906Norm alised to 
APRT Copy Ns
10380 94 6 7 13994 2469 1810 76 24
FOLD change 7.6 9.9 10.2 1.7 1.2 5.8
Day 21 
100 nM 
AM 251
LPL Copy Ns 6149 6062 46 78 363 347 35 19
<0.001Normalised to 
APRT Copy Ns
40 24 6 25 49 9 19171 2323 1617 17771
FOLD change 29.4 26.6 14.0 1.6 1.1 13.5
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Figure 4.16: Effect Of ACEA & AM251 On Omental Adipogenesis
Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or 
AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance 
determined by Wilcoxon Signed Ranks test for individual treatments relative to control
p <0.001
50000 -
p = 0.906
30000 -
DayO 100 nM ACEA 
Day 21
100 nM AM 251  
Day 21
4.3.13 The Effect Of CBi Agonist ACEA & CBi Antagonist AM 251 On UCP-1
Expression In Terminally Differentiated Omental Adipocytes
QPCR was performed on cDNA derived from RNA collected on day 0 and day 21 of the 
differentiation protocol and transcript expression for UCP-1 was normalised to housekeeper 
gene (APRT) expression. Transcript expression was at the lim it of QPCR detection (Ct values > 
35) and did not alter with adipogenesis in control conditions or when supplemented with 
ACEA or AM 251.
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4.3.14 The Effect Of CBi Agonist ACEA & CBi Antagonist AM 251 On Adiponectin
Production During Subcutaneous & Omental Adipogenesis
Treatment w ith CBi antagonist was also associated w ith an increase in adiponectin 
concentration in both primary cell populations w ith a significantly greater effect in omental 
(Table 4.12 and Figure 4.17) as compared to subcutaneous adiponectin production (Table
4.13 and Figure 4.18).
Table 4.12: Effect Of ACEA & AM251 On Omental Adiponectin Production
Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or 
AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance 
determined by Wilcoxon Signed Ranks test for individual treatments relative to control
Day 0
Adiponectin
pg/ml
54 59 49 54 33.0 n/a
Day 21 
Control
Adiponectin
pg/ml
149.5 960.0 233.5 447.6 187.5
n/a
(0.1%
ethanol) FOLD change 2.8 16.2 4.8 8.3 5.7
Day 21
Adiponectin
pg/ml
143.0 940.5 211.0 431.5 206.0
0.394100 nM 
ACEA FOLD change 2.6 15.9 4.3 7.9 6.2
Day 21
Adiponectin
pg/ml
1128.5 1417.5 825.5 1024.0 946.5
0.026100 nM 
AM 251 FOLD change 20.8 24.0 16.8 18.9 28.6
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Figure 4.17: Effect Of ACEA & AM251 On Omental Adiponectin Production
Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or 
AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance 
determined by Wilcoxon Signed Ranks test for individual treatments relative to control
p = 0.02b
r *> 1300 -
g p - 0.394
i
*  1000  -
i  800-
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DayO Control 100 nM ACEA 100 nM AM 251
(0.1% ethanol] Day 21 Day 21
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Figure 4.18: Effect Of ACEA & AM251 On Subcutaneous Adiponectin Production
Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or 
AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance 
determined by Wilcoxon Signed Ranks test for individual treatments relative to control
p = 0.009
c; 8*c-
p = 0.739
I i
Day O
 1------
Control
(0 .1 %  e th a n o l)
Day 21
100 nM ACEA
Day 21
100 nM AM 251
Day 21
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Table 4.13: Effect Of ACEA & AM251 On Subcutaneous Adiponectin Production
Data represent 2 independent experiments performed in triplicate following 21 days culture in DM, ACEA or 
AM251 (n=5). LPL expression has been normalised to housekeeper gene ARP expression. Statistical significance 
determined by Wilcoxon Signed Ranks test for individual treatments relative to control
Patient 1 2 3 4 5 p-value
Day 0
Adiponectin
pg/ml
51 48.5 62.5 146.5 52.5 n /a
Day 21 
Control 
(0.1%  
ethanol)
Adiponectin
pg/ml
486.0 176.5 337.5 2196.5 272.0
n/a
FOLD change 9.5 3.6 5.4 15.0 5.2
Day 21 
100 nM 
ACEA
Adiponectin
pg/ml
481.0 158.5 311.0 1987.0 303.5
0.739
FOLD change 9.4 3.3 4.9 13.6 5.8
Day 21 
100 nM 
AM 251
Adiponectin
pg/ml
935.0 578.0 745.0 4258.0 597.0
0.009
FOLD change 18.3 11.9 11.9 29.0 11.4
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4.4 DISCUSSION
Adipose tissue is now recognised as a dynamic endocrine organ producing biologically active 
adipocytokines involved in the regulation of energy metabolism and body weight 
homeostasis. These adipocytokines play a crucial role in development of obesity and the 
pathophysiology of obesity-related disease processes. Abdominal obesity is associated with 
an elevated risk of type II DM and CVD. The ECS has been implicated in obesity, promoting 
adverse metabolic processes resulting in weight gain, lipogenesis, insulin resistance and 
dyslipidaemia. Clinical studies have confirmed that intermediate-term CBi receptor blockade 
is associated with loss of body weight and waist circumference and an improvement in the 
metabolic profile including reductions in triglycerides, fasting insulin, HbAlc, blood pressure 
and an increase in HDL and adiponectin [77-80, 221].
The previous chapter demonstrated an increase in pre-adipocyte proliferation with CBi 
agonism in studies using the murine white pre-adipocyte cell line, 3T3-L1, whereas CBi 
antagonism had the opposite consequence. The anti-proliferative effect was associated with a 
block at the Gl/S phase of the cell cycle. These findings are in keeping with those published 
elsewhere in the literature [207]. In this chapter these experiments have been repeated using 
human primary pre-adipocytes derived from both subcutaneous and omental adipose tissue 
depots. The same effects on proliferation were noted in both the subcutaneous and omental 
cell populations with a significantly greater effect of CBi antagonist-induced inhibition in the 
omental pre-adipocytes in all paired samples. As such this represents a novel observation 
since no other in vitro studies directly examining the effect of CB modulation in human 
primary subcutaneous and visceral pre-adipocytes are evident. These results may in part 
explain some of the anti-obesity effects observed with CBi antagonist treatment, including a 
reduction in waist circumference.
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Sarzani et al have described an altered pattern of CBi receptor expression in adipose tissue in 
overweight individuals [222]. The investigators have demonstrated the highest mRNA 
expression of CBi to be in subcutaneous adipose tissue in normal weight subjects (BMI < 25 
kg/m2) whereas CBi expression was increased in omental adipose tissue in individuals with a 
BMI £ 25 kg/m 2 suggesting CBi-mediated overactivity of the ECS in visceral adipose tissue in 
obesity [222]. This role is further supported by evidence from Matias et al that patients with 
obesity or hyperglycaemia caused by type 2 DM exhibit higher concentrations of endogenous 
endocannabinoids in visceral fat or serum, respectively, than their corresponding controls 
[76]. The differences in receptor expression may explain the possible differential effect of CBI 
receptor antagonism observed in the current experiments in cells derived from the 
subcutaneous and omental adipose tissue depots.
The anti-proliferative and cell cycle blocking effects of CBi antagonism are not limited to 
adipose tissue. Recent in vitro studies using SR 141716 have illustrated inhibition of human 
breast cancer cell proliferation in highly invasive metastatic MDA-MB-231 cells [223]. This 
effect was not accompanied by cell apoptosis or necrosis, and was characterised by arrest in 
the Gl/S phase of the cell cycle [224]. Similarly CBi antagonism has been shown to inhibit 
proliferation of peripheral blood mononuclear cells, also associated with Gl/S transition 
blockade [224]. Cell line studies of murine white pre-adipocytes indicate inhibition of MAP 
kinase activity by CBi blockade which may be one of the mechanisms involved in inhibition of 
cell proliferation [207, 208].
In addition to the anti-proliferative effects, in the preceding chapter we have also described
an increase in mRNA expression of terminal markers of mature adipocytes following CBi
antagonist treatment. These findings are also seen in the human primary cultures, where an
increase in LPL expression was observed in both the subcutaneous and omental adipocytes.
CBi agonist treatment did not appear to have an effect on primary adipogenesis. We also
observed significantly greater levels of adiponectin produced by the cultured subcutaneous
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and omental adipocytes after exposure to CBi antagonist treatment. These results are also in 
keeping w ith the cell line data in Chapter 3 as well as those published from other in vitro cell 
line studies in the literature [207, 225]. Alterations in the adipocytokine profile, as well as the 
anti-proliferative effects described previously, provide evidence for direct modulation of 
adipocyte function as part of the mechanism of action of the ECS on energy metabolism.
The data presented in this thesis do not demonstrate any increase in UCP-1 expression in the 
WAT cell line 3T3-L1 or in human primary cultures and thus do not support CBi blockade- 
mediated transdifferentiation towards a brown fat phenotype as part of the mechanism to 
explain the weight loss and improvement in metabolic parameters observed with CBi 
antagonism. This is in contrast to a recent study by Perwitz et al who demonstrated that CBi 
blockade w ith the antagonist SR 141716, or receptor knock down with small interfering RNA 
(siRNA), induces UCP-1 expression in murine white adipocytes in a time- and concentration- 
dependent manner at both the RNA and the protein level [209]. Whether these discrepancies 
are due to the differing cell types and CBi antagonist used for study, or secondary to the 
limitation of our QPCR technique for low copy number detection, still requires further 
clarification.
The first pharmacological CBi antagonist to be developed, SR 141716 or rimonabant, was 
associated with a significant adverse event profile and its clinical use has therefore been 
discontinued. Nevertheless, CBi receptor blockade still represents a new alternative for 
managing obesity and its associated risks. Further work is still required to fully elucidate the 
mechanism behind its observed clinical effects and also to explore the possibilities for body 
fat redistribution and white to brown fat transdifferentiation for greater metabolic benefit. 
Development of future agents w ill however require further clarification of both long-term 
effectiveness and an acceptable safety profile. Furthermore, any pharmacological intervention 
for the treatment of obesity can only be justified when accompanied by individuals' dietary 
and lifestyle modification to ensure benefits are sustained long-term.
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CHAPTER 5: EFFECT OF METFORMIN ON VASCULAR FUNCTION,
BODY COMPOSITION & METABOLIC PROFILE IN PCOS
5.1 INTRODUCTION
PCOS is the commonest endocrinopathy in women of reproductive age, affecting 
approximately 7% of the pre-menopausal population [226]. In addition to its effects on 
reproductive health it is now well recognized that PCOS is a metabolic disorder characterized 
by increased insulin resistance [88] which leads to an excess lifetime risk of type II diabetes 
[84, 85]. Patients with this condition display a cluster of metabolic disturbances, including 
obesity [227], dyslipidaemia [89], impaired fibrinolysis [228] and hypertension [87], which 
are often apparent at a young age, and it is therefore unsurprising that a number of studies 
have highlighted an increased prevalence of the metabolic syndrome amongst women with 
PCOS ranging from 15 to 50%.
Figure 5.1: Age-Adjusted Prevalence Of Features Of The Metabolic Syndrome In Women 
W ith PCOS, Age-Matched Controls And Women From the NHANES Study.
(Adapted from Dokras etal, 2005 [127])
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For example, as illustrated in Figure 5.1, Dokras et al reported a 47.3% prevalence rate of the 
metabolic syndrome, according to the WHO criteria, in PCOS in contrast to 4.3% in an age- 
adjusted control population and 23.4% in comparison to the National Health and Nutrition 
Examination Survey (NHANES) study cohort [127].
Although epidemiological studies have thus far failed to demonstrate an increase in 
cardiovascular mortality in women with PCOS, these abnormalities are likely to contribute to 
an increased risk of cardiovascular disease, based on data from studies using surrogate 
markers such as carotid intima media thickness [134, 229]. Developing therapeutic strategies 
to minimise this vascular burden is therefore important.
Insulin resistance is intricately linked to large blood vessel compliance [230, 231] and 
endothelial function [232], and could contribute to the vascular dysfunction observed in 
patients w ith PCOS. For example, the inability of insulin to reduce aortic stiffness (as 
measured by augmentation index) in obese insulin-resistant subjects correlates closely with 
whole-body insulin resistance [233, 234], implying that defects in the metabolic action of 
insulin are accompanied by abnormal vascular function. Endothelial dysfunction, an early 
marker of vascular damage, has been demonstrated in women with PCOS [90, 91, 131, 135, 
235] and is accompanied by reduced insulin-mediated vasodilatation [135]. Arterial stiffness, 
as assessed by pulse wave velocity (PWV), a strong independent predictor of cardiovascular 
mortality in subjects with type II diabetes [236] and other disease states [237, 238], is also 
increased in women with PCOS [135, 235], and correlates with insulin resistance [235, 239].
It is clear from these studies that insulin resistance per se may be an important vascular
therapeutic target in women with PCOS and that medical therapies which improve insulin
sensitivity might also improve vascular function. The oral biguanide metformin has been
shown to improve insulin sensitivity in women with PCOS [139], and reduces circulating
concentrations of endothelin-1 [140], a marker of endothelial dysfunction. More recently,
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some studies have also shown that metformin can improve endothelial function in women 
with PCOS [240-243] while others reported either a neutral effect on vascular function [244, 
245] or variable improvement or worsening dependent on smoking status [246]. However, 
interpretation of these studies is difficult due to their observational [240, 242-244] or open 
label [241, 245, 246] study designs. In light of this uncertainty and to minimise the potential 
for bias, the following studies sought to determine whether short-term metformin therapy 
could improve arterial stiffness and endothelial function in patients with PCOS using a 
randomized, double-blind, placebo-controlled crossover design.
5.1.2 Arterial Stiffness
5.1.2.1 Mechanisms Of Arterial Stiffness
The arterial wall is comprised of three layers -  the outer adventitia consisting of connective 
tissue and the vessel's vascular supply, the smooth muscle and elastin-containing media 
which is the major determinant of elasticity, and the inner endothelium which regulates 
vascular tone, haemostasis and inflammatory processes. The Windkessel theory describes the 
circulation as a central elastic reservoir, comprised of compliant and expansile large arteries, 
into which the heart pumps, from which blood is transported to the tissues via relatively non­
elastic peripheral vessels [247]. The elasticity of the proximal large arteries is largely the 
result of the high elastin to collagen ratio w ithin the media layer of the vessel wall. Arterial 
stiffness can therefore arise as a consequence of structural changes within the vessel, for 
example secondary to age-related progressive elastin fibre degeneration, as well as disease 
states affecting vascular endothelial function such as hypertension and diabetes. A number of
genetic factors have also been implicated including polymorphic variations in the fibrillin-1
[248] and endothelin receptor genes [249].
198
5.1.2.2 Arterial Pressure Waveform
The arterial pressure waveform is a composite representation of the pressure waves 
generated during ventricular systole (1st waveform peak) which then travels through the 
circulation until resistance is encountered at the peripheries when it is reflected back upon 
itself during diastole. The 2nd waveform peak represents a summation of the reflected waves 
as illustrated in Figure 5.2. Augmentation index (AIx), a composite measure of wave reflection 
and systemic arterial stiffness, is defined as the difference between the first and second 
systolic peaks of the central pressure waveform, expressed as a percentage of the central 
pulse pressure (Figure 5.2).
Figure 5.2: Schematic Representation Of The Arteria l Pressure Waveform
(adapted from Oliver et a l, 2003 [247])
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With increasing arterial stiffness the speed with which the left ventricular ejection pressure 
wave travels through the arterial circulation increases, thus resulting in an earlier return of 
the reflected wave from the peripheries (Figure 5.3). If the reflected wave continues to return
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less in diastole and more in systole itself, this can augment the late systolic pressure on the 
left ventricle (afterload) and reduce the coronoary arterial perfusion pressure during 
diastole. This process leads to a greater risk of ischaemic heart disease (due to decreased 
coronary perfusion in diastole), cerebrovascular disease (due to increased central systolic 
pressure) and cardiac failure (due to increased left ventricular load).
Figure 5.3: Schematic Representation Of Healthy & Stiffened Arterial Waveforms
(adapted from Oliver et al, 2003 [247])
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5.1.2.3 Arterial Stiffness & Cardiovascular Risk
Arterial stiffness can be assessed by measuring a number of factors including central blood 
pressure, AIx, and PWV. A number of studies have demonstrated an association between 
these indices of arterial stiffness and other cardiovascular risk factors. For example, 
Wilkinson and colleagues showed increased AIx and aortic PWV (aPWV) in subjects with 
hypercholesterolaemia [250] and type I diabetes [251]. Chronic smoking is associated with 
higher AIx and central systolic blood pressure (cSBP) when compared to matched non­
smoking controls [252], while increased aPWV is also seen in individuals with essential
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hypertension meeting the criteria for the metabolic syndrome [253]. A positive correlation 
has also been demonstrated between the inflammatory marker high-sensitivity C-reactive 
protein (hsCRP), and both aortic and brachial PWV [254], while declining endothelial 
function is also associated w ith elevated large artery stiffness and central systolic blood 
pressure (cSBP) [255]. There is also evidence for an independent association between 
manifestations of increased arterial stiffness derived from non-invasive pulse wave analysis 
(PWA), and the presence of CAD in individuals undergoing coronary angiography [256]. 
Arterial stiffness is independently predictive of cardiovascular mortality in a number of 
disease states, including renal failure, hypertension, and glucose intolerance/type II diabetes 
[236-238], and interventions to reduce stiffness indices are associated with improvements in 
survival. For example, survival of patients w ith end-stage renal disease is significantly better 
for patients whose aortic PWV declines in response to BP lowering intervention [257].
These studies illustrate the importance of arterial stiffness in predicting cardiovascular risk, 
thus making this a significant parameter w ith potential clinical application when evaluating 
patient risk, disease progression and response to intervention. The development of quick, 
reproducible, and non-invasive tools to measure arterial stiffness may also facilitate 
incorporation into diagnostic and therapeutic clinical trials.
5.1.3 Non-invasive Assessment Of Arterial Stiffness
There are numerous invasive and non-invasive methodologies that have been employed to 
measure arterial elasticity in vivo. While invasive techniques are more accurate, their 
widespread use is limited in research and clinical practice. The non-invasive measures can 
broadly be divided into three categories - analysis of arterial waveforms, measurement of 
pulse wave velocity, and relating change in arterial diameter to distending pressure.
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5.1.3.1 Analysis Of Arterial Waveforms
A number of technologies, including the SphygmoCor™ apparatus (AtCor Medical Ltd, 
Sydney, Australia] used in this study, utilise analyses of specific components of the arterial 
pressure waveform (Figure 5.2] to measure arterial stiffness. Peripheral arterial pressure 
waveforms from, for example, the radial, femoral, or carotid artery, can be acquired using 
applanation tonometry [258]. This involves placing a highly sensitive pressure transducer on 
the skin over the site of the peripheral pulse whilst compressing the artery against a firm 
structure such as bone. The sensor is then able to detect dynamic pressure and volume 
changes in the underlying vessel to generate the peripheral arterial waveform (Figure 5.4]. 
This waveform is calibrated to conventionally measured peripheral blood pressure and the 
system software applies a validated mathematical transfer function to generate the central 
arterial waveform and measure the central blood pressure [259]. Pulse wave analysis (PWA] 
can then be performed to calculate AIx and T r as described in the previous section.
Figure 5.4: Schematic Representation Of Applanation Tonometry
Ti ansducer
Artery
Bone
The principle of applanation tonometry -  the artery is partially 
compressed against a firm structure (e.g. bone] and the pressure 
transducer detects force on the arterial wall.
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5.1.3.2 Measurement Of Pulse Wave Velocity
PWV refers to the speed with which the arterial wave travels across a specified distance, and 
can be measured by a number of methods. Doppler ultrasound [260] or applanation 
tonometry [258], can be used to record the arterial waveform from a proximal site, e.g. the 
carotid, and a more distal site, e.g. the femoral artery. In order to travel between these two 
locations the arterial wave needs to traverse most of the abdominal aorta, an artery 
particularly prone to atherosclerotic change. The time-delay for the arrival of the foot of the 
arterial wave at these two sites can be calculated by either simultaneous measurements at 
both sites, or by gating to the peak of the R-wave of the ECG [247]. The distance between the 
two sites is measured externally and PWV calculated as distance/time in metres per second.
The manual measurement of distance between these two sites is an approximation of the true 
distance and depends upon the subject's body habitus and vessel tortuosity. A more accurate 
measurement can be obtained using magnetic resonance imaging (MRI) though this is 
significantly more expensive and not always readily available.
5.1.3.3 Relating Change In Arterial Diameter To Distending Pressure
The change in diameter of an artery can be related to the distending pressure and measured 
using imaging modalities such as ultrasound or, less commonly, MRI. Diameter-pressure 
curves of the common carotid artery can be generated over the systolic-diastolic range by 
continuously recording both the pulsatile changes in internal diameter and, simultaneously 
on the contralateral artery, the pressure waveform using applanation tonometry [261]. This 
allows determination of the carotid pressures, though some investigators use brachial blood 
pressures instead. Distensibility can then be compared at the mean arterial pressure and at a 
fixed distending pressure e.g. 100 mm Hg, w ith decreasing distensibility indicating a higher 
degree of arterial stiffness.
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5.1.3.4 Comparison Of Non-invasive Measures Of Arterial Stiffness
Table 5.1 summarises the relative strength and weaknesses of the major methods used to 
measure arterial stiffness.
Table 5.1: Advantages & Disadvantages Of Non-invasive Measures Of Arterial Stiffness
(adapted from Oliver et al, 2003 [247])
Ease of use +++ + ++ +
Affordability +++ ++ +++ +
Quality of ++ ++ ++ +++validation
Freedom from  
operator bias ++ + ++ +++
Evidence of 
prognostic value ++ ++ +++ +
Endothelial 
function testing +++ + ++ + +
Of these techniques, measurement of AIx by PWA using applanation tonometry requires the 
least training, can be rapidly measured and thus easily incorporated into clinical trials. PWV 
and ultrasonography are more time-consuming and the latter in particular requires 
additional training and dedicated staff. MRI measures are also time-consuming and are 
further limited by affordability and availability. Both PWV and AIx can be measured with a 
high degree of reproducibility [258] and have been shown to carry significant prognostic 
value. For these reasons, as well as local availability, it was decided to measure PWX and AIx 
using PWA to assess arterial stiffness in the present clinical trial. Furthermore, this technique 
was also used for endothelial function testing and w ill be discussed in greater detail below.
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5.1.4 Vascular Endothelium & Endothelial Dysfunction
The vascular endothelium lining the luminal surface of all blood vessel walls plays an integral 
role in the regulation of vascular tone, haemostasis and permeability, mediated by a number 
of endothelium-derived factors (Figure 5.5). Of the vasoactive factors that the endothelium 
can release, prostacyclin (PGh), nitric oxide (NO), and endothelium-derived hyperpolarizing 
factor (EDHF) are the most significant [262]. NO is synthesized from L-arginine by NO 
synthases (NOS) present in the endothelium (eNOS), or inflammatory cells (iNOS). NO is a 
lipophilic agent and is thus able to traverse cell membranes causing vasodilatation via 
activation of soluble guanylyl cyclase generating cyclic guanosine monophosphate within 
vascular smooth muscle cells [263]. NO production by eNOS can be stimulated directly by 
shear stress, as well as by muscarinic or bradykinin receptor-mediated calcium channel 
activation [264]. NO also inhibits the vascoconstrictive actions of angiotensin-II (AT II) and 
endothelin-1 (ET-1). AT-II binds to the G-protein-coupled angiotensin receptor on vascular 
smooth muscle cells which stimulates phopholipase C (PLC) mediated inositol triphosphate 
(IP3) production leading to an increase in intra-cellular calcium and consequent 
vasoconstriction [265]. ET-1, generated within the endothelial cells, acts upon the endothelin 
A receptor on smooth muscle cells, which in turn is also linked to PLC as well as voltage 
operated calcium channels leading to vasoconstriction [266]. When testing endothelial 
function, nitrate-containing pharmacological agents such as glyceryl trinitrate (GTN) can be 
used as direct, or endothelium-independent vasodilators due to direct delivery of NO to the 
vascular smooth muscle cells. Endothelium-dependent function can be examined using shear 
stress or drugs that depend upon NO generation via eNOS, for example, salbutamol [267].
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Figure 5.5: Modulators Of Vascular Tone [262-266]
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PGI2 is synthesized from arachidonic acid by cyclooxygenase [COX] isozymes expressed in the 
vascular endothelium and is thought to contribute to the maintenance of vascular 
homeostasis. PGI2 elicits smooth muscle relaxation by activating specific cell-surface 
receptors that are G-protein-coupled to adenylyl cyclase thereby elevating cyclic adenosine 
monphosphate [cAMP] levels and inducing smooth muscle relaxation [268]. PGI2-mediated 
vasodilation can also be stimulated by ET-1 via stimulation of the endothelin B receptor 
[266].
The identity of EDHF remains unclear, although several candidates have been proposed 
including K+ ions, cAMP, cytochrome p450 2C products, H20 2, spread of electrotonic current 
and, most recently, C-type natriuretic peptide [CNP] [262, 269]. It is, however, accepted that
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vasorelaxation resulting from EDHF follows opening of endothelial calcium-activated 
potassium channels, and that hyperpolarization of vascular smooth muscle associated with 
EDHF activity involves activation of the Na+/K+-ATPase and inward-rectifying potassium 
channels ( K ir )  [262].
5.1.5 Non-invasive Assessment Of Endothelial Function
Established methods for assessing vasomotor endothelial function centre on measuring the 
response to an endothelium-dependent, NO-mediated stimulus such as acetylcholine or 
reactive hyperaemia, and a direct (endothelium-independent) nitrovasodilator like sodium 
nitroprusside (SNP) or glyceryl trin itrite  (GTN) [270]. However, these methods are not 
practical for inclusion in large-scale trials. PWA in combination with provocative 
administration of GTN (endothelium-independent) and salbutamol (endothelium-dependent), 
provides a simple, reproducible, and non-invasive means of in vivo assessment of endothelial 
function. Here, the magnitude of change in AIx in response to pharmacological stimulation 
represents the functional state of the endothelium.
Endothelial function can also be assessed by radiological measurements, usually by 
ultrasound, of vessel dilatation in response to pressure-controlled forearm blood flow 
(reactive hyperaemia test, or flow-mediated dilatation) [91]. This technique requires 
considerably more training than PWA, and comparative studies have demonstrated a 
significant correlation between both these methods [270].
5.1.6 Clinical Trial Design
The clinical tria l described in this chapter compares the effect of our investigational medicinal
product (IMP), metformin, to that of placebo using a randomised, double-blind, crossover
study design. The main advantage of the crossover study design is that each individual acts as
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his or her own 'control/ thus reducing the influence of confounding variables. Removing 
patient variation in this way makes crossover trials potentially more efficient than similar 
sized, parallel group trials in which each subject is exposed to only one treatment -  IMP or 
control [271]. In theory treatment effects can be estimated with greater precision given the 
same number of subjects. Another significant advantage is that a substantial within-subject 
correlation is expected, i.e. an individual's tendency to vasodilate in response to GTN should 
be consistent. The main drawback is the potential to carry-over a treatment effect from the 1st 
treatment phase to the 2nd. This can be overcome to a large extent by ensuring an adequate 
wash-out period and performing baseline measures prior to each treatment phase.
5.1.7 Chapter Aims
This chapter aims to describe the results obtained from a clinical trial analysing the effects of 
metformin on vascular function, body composition and metabolic profile in PCOS. The 
primary outcome measures for this study were defined as changes in markers of arterial 
stiffness (AIx, T r, bPWV, aPWV), endothelial function and blood pressure (peripheral and 
central). The secondary outcome measures were to evaluate the effects of metformin therapy 
on anthropometric measurements of body composition (weight, BMI, fat percentage, waist 
and hip circumference), changes in serum androgens (testosterone, sex hormone binding 
globulin (SHBG), free androgen index (FAI)), insulin resistance (fasting insulin, glucose, 
HOMA-IR), lipid profile (TC, HDL, LDL, TG) biochemical markers of vascular risk (hsCRP, PAI- 
1), and adiponectin.
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5.2 MATERIALS AND METHODS
5.2.1 Trial Approval & Funding
Prior to commencement of the clinical trial, the project was approved by the Research and 
Development Department at the University Hospital of Wales (Ref 05/CMC/3456E), the South 
Wales Reserch Ethics Committee (Ref 06/WSE04/33), and the United Kingdom Medicines 
and Healthcare Products Regulatory Authority (MHRA) (Ref 2005-005471-69). The study was 
sponsored by Cardiff University (Ref SPON CU 153) and placed on the International Standard 
Randomised Controlled Trial Number register and ascribed the registration ISRCTN 
61785174 (http://www.controlled-trials.com/isrctn/) .
The study was supported by the Lewis Thomas Gibbon Jenkins of Briton Ferry Fellowship 
Award from the Royal College of Physicians. The funding source had no input in the design, 
conduct, management, analysis or interpretation of the study.
5.2.2 Trial Participants -  Inclusion & Exclusion Criteria
Patients were recruited from the endocrine and dermatology clinics at the University Hospital 
of Wales (UHW). A diagnosis of PCOS was made according to the Rotterdam criteria [93]. 
Specifically, patients with androgen excess (clinical symptoms of hyperandrogenism and/or 
elevated testosterone) with ovulatory dysfunction (fewer than 6 menstrual cycles per year) 
were recruited, supported by ovarian ultrasound where available (polycystic ovaries present 
in 24/30 subjects on imaging). Congenital adrenal hyperplasia, Cushing's syndrome, 
androgen-secreting tumours, hyperprolactinemia and thyroid disease were excluded by 
biochemical testing.
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Patients were aged between 18 and 35 years and were excluded from participation if  they 
were pregnant or planning to become pregnant, breastfeeding, had a history of current or 
recent (within 6 months) use of oral contraceptives, antidiabetics or antiandrogens, or had 
any contraindications to metformin therapy including renal or hepatic impairment. Patients 
with a history of known hypertension, hyperlipidemia or diabetes were also excluded. As 
metformin is known to improve ovulation rates in women with PCOS, study participants were 
advised to use barrier methods of contraception if  they were sexually active; pregnancy tests 
were performed at each visit with a plan for study withdrawal if  pregnancy was confirmed.
5.2.3 Consent
Initial contact was made by providing each subject with a patient invitation letter and 
information sheet explaining the nature of the study, its purpose, the procedures involved, the 
expected duration, the potential risks and benefits involved and any discomfort it may entail 
(Appendix 3). This was followed by a telephone call a week later to determine interest in 
study participation and confirm eligibility. A personal visit at the Clincal Research Facility in 
UHW was then arranged where written informed consent was obtained (Appendix 4) prior to 
study commencement. Each subject was informed that participation in the study is voluntary 
and she may withdraw from the study at any time and that withdrawal of consent w ill not 
affect her subsequent medical treatment or relationship with the treating physician.
5.2.4 Treatments & Interventions
Thirty participants were randomized to receive consecutive 12 week treatment periods of
either metformin followed by placebo tablets of identical appearance or placebo followed by
metformin administration. To minimise gastrointestinal side-effects metformin was given in a
dose of 500mg once daily for 1 week, 500mg twice daily for 1 week then 500mg three times
daily for the remaining 10 weeks (matched with equal tablet numbers in the placebo phase).
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A washout interval of 8 weeks separated the two treatment phases. Metformin and placebo 
capsules were both supplied by Merck-Sante (Lyon, France) and packaged in a licensed 
pharmaceutical laboratory (St Mary's Pharmaceutical Unit, Cardiff, UK). The clinical trial 
study design is illustrated in Figure 5.6.
Figure 5.6: Summary Of Clinical Trial Design
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5.2.5 Measurements
Participants were assessed in the Clinical Research Facility at the UHW at four points: 
baseline tests at visit 1 and at the end of the wash-out phase (visit 3) and after each treatment 
(metformin or placebo) phase (visits 2 and 4). On each occasion blood samples were collected 
after an overnight fast, followed by assessment of body composition, arterial stiffness and 
endothelial function. A full clinical history was obtained at the first visit and any changes 
recorded upon each subsequent visit. An example of the study visit case report form can be 
found in Appendix 5.
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5.2.5.1 Measurement Of Arterial Stiffness & Endothelial Function
All measurements, were performed in a quiet, temperature-controlled room, and taken 
exclusively by the author of this thesis to avoid any inter-observer variability. Smokers were 
asked to refrain from smoking on the morning of their visit. Blood pressure was measured at 
the brachial artery of the dominant arm using a validated semi-automated oscillometric 
device (Omron 705IT, Omron Corporation, Tokyo, Japan) after 10 minutes rest in the seated 
position. Each blood pressure measurement used in this study was the mean of two 
recordings. Peripheral pressure waveforms were captured from the radial artery of the 
dominant hand at the wrist using a micromanometer (SPC-301; Millar Instruments, TX, USA) 
connected to the SphygmoCor™ apparatus (Model MM3, AtCor Medical Ltd, Sydney, 
Australia; software version 8.0). After 20 sequential waveforms had been acquired, with 
operator quality index of over 75%, the central (ascending aortic) pressure waveform was 
derived from an averaged peripheral waveform using a validated, generalized transfer 
function [259]. The AIx, and central aortic pressure were derived from analysis of the central 
waveform. The estimated aPWV was calculated as the time between the foot of the pressure 
wave and the first inflection point ( T r) .  An example of a PWA measurement using this 
technique is given in Figure 5.7.
Pulse wave velocity (PWV) was measured by the Sphygmocor system by sequentially 
recording ECG-gated carotid and femoral waveforms (for aortic PWV; aPWV) and carotid and 
radial waveforms (for brachial PWV; bPWV) as described previously.
Endothelial function was assessed using a validated, non-invasive method whereby the 
change in AIx in response to the administration of nitroglycerin, (GTN, an endothelium- 
independent nitrovasodilator), and salbutamol (an endothelium-dependent p2-adrenoceptor 
agonist) is determined by pulse wave analysis. Briefly, a 500 pg tablet of GTN (Alpharma,
Barnstable, UK) was placed under the tongue for 3 minutes and then removed;
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haemodynamic recordings (pulse, blood pressure and AIx) were then made at 3, 5,10,15, 20 
and 30 minutes after administration. At 30 minutes after GTN administration, 400 pg 
salbutamol (IVAX pharmaceuticals, London, UK) was given by inhalation through a spacer 
device and haemodynamic recordings were taken at 5, 10, 15 and 20 minutes after 
salbutamol administration. The response to GTN or salbutamol was defined as the maximum 
change in AIx after drug administration. Each of the above measurements was performed 
twice and averaged prior to data entry.
Figure 5.7: Example Of SphygmoCor™ Generated PWA
Clinical Detailed
PATIENT DATA I
Patient ID
Patient Code_______
STUDY DATA
Medication 
Notes 
Operator
Age, Sex 
Address
Height, Weight (BMI) 188cm. 83kg (23.48 kg/m1!
QUALITY CONTROL
AORTICRADIAL
Peripheral T1.T2. AIx 96ms. 192ms. 6 1 *
CENTRAL HAEMODYNAMIC PARAMETERS
Heart Rate. Penod 83 bpm. 727 ms P1 Height (P1 - Dp) 23 mmHg Buckberg SEVR (Ad/As) 1 4 8 *  (335172264)
Ejection Duration 273 ms. 3 8 *  Augmentation 3 mmHg MP. (Systole. Diastole) 100, 90 mmHg
Aortic T1,T2.Tr 1 0 5 ,1 9 9 .1 4 2  ms AIx (AG/PP. P2/P1) 1 0 * . 1 1 1 * End Systolic Pressure 101 mmHg
Aortic AIx (AG/PP)@HR?5 1 4 *
213
5.2.5.2 Anthropometric Measurements
Body height was measured to the nearest 0.5 cm using a stadiometer and body weight (in 
light clothing without shoes) to the nearest 0.5 kg on a balance beam scale. Waist 
circumference was measured at minimal respiration and reported to the nearest 0.5 cm by 
positioning a flexible anthropometric tape parallel to the floor and immediately above the 
iliac crest. Hip circumference was measured at the maximum circumference over the buttocks 
and recorded to the nearest 0.5 cm. Body mass index (BMI) was calculated as weight (kg) 
divided by height (m) squared. Percentage fat was measured by bioimpedance (Tanita Body 
Fat analyser TBF-305, Tanita Corporation, Japan).
5.2.5.3 Metabolic Biochemistiy Measurements
Blood samples were collected on the morning of each visit following an overnight fast. Serum
was prepared by centrifugation of blood at 4000 rpm for 8 minutes and stored at -20°C prior
to analysis in a single laboratory at the UHW. The intra- and interassay coefficients of
variation (all less than 9%), lower limits of assay detection and reference ranges used for
biochemical testing, are listed in Table 5.2. Serum sex hormone binding globulin (SHBG) was
measured using an Elecsys E170 automated immunoassay analyser (Roche SHBG assays,
Roche Diagnostics, Lewes, UK), and testosterone, oestradiol, and progesterone using the
Siemens Centaur automated immunoassay analyser (ADVIA Centaur Testosterone/Estradiol-
6/Progesterone assays, Bayer, Newbury, UK). The free androgen index (FAI) was calculated
using the equation: FAI = (testosterone/SHBG) x 100. Serum total cholesterol (TC), high-
density lipoprotein cholesterol (HDL), and triglycerides were assayed using an aeroset
automated analyser (Abbott Diagnsotics, Berkshire, UK); LDL cholesterol (LDL) was
calculated using Friedewald's formula [272]. Insulin was measured using an immunometric
assay specific for human insulin (Invitron, Monmouth, UK). Glucose was measured using the
Aeroset chemistry system (Abbott Diagnsotics, Berkshire, UK). High sensitivity C-reactive
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protein (hsCRP) was assayed via nephelometry (BN™ II system, Dade Behring, Milton Keynes, 
UK) and PAI-1 was measured using a tissue plasminogen activator coated ELISA plate that 
assays only active PAI-1 (Zymutest, Hyphen Biomed, Nodia, Amsterdam). Insulin resistance 
was estimated using the homeostasis model assessment method (HOMA-IR) calculated by the 
formula: fasting serum insulin (pU/ml) x fasting serum glucose (mmol/l)/22.5 [273]. Serum 
adiponectin was measured in duplicate by ELISA (R&D Systems, Oxford, UK) as described in 
Chapter 4.
Table 5.2: Biochemical Assay Information
Insulin 4.1-4.9% Im U /l N/A
Glucose 1.5-2.2% 0.1 mmol/1 N/A
Triglycerides 0.8-l.l% 0.07 mmol/1 0.6-2.0 mmol/1
HDL 5.5-1.4% 0.13 mmol/I 0.7-1.7 mmol/1
Total cholesterol 0.8-1.6% 0.16 mmol/1 N/A
SHBG 1.1-4.0% 0.35 nmol/1 19.8-122 nmol/Ll (pre-menopausal)
Testosterone 2.7-7.6% 0.35 nmol/1 <2.5 nmol/1 (females)
Oestradiol 7.9-8.3% 0.37 nmol/1
69.4-905.5 (follicular) 
130.3-2094.8 (mid-cycle) 
82.9-939.5 (luteal)
Progesterone 4.1-6.7% 0.67 nmol/1
0.48-4.45nmol/l (follicular) 
10.62-81.28 nmol/1 (luteal) 
14.12-89.14 nmol/1 (mid-luteal)
hsCRP 2.5-4% 0.1 mg/1 0-3.0 mg/1
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5.2.6 Randomisation & Blinding
The treatment assigned to each participant was determined according to a computer 
generated randomization list produced by an independent external pharmacist (St Mary's 
Pharmaceutical Unit, Cardiff, UK). The participant study drug boxes were labelled with unique 
patient identification numbers. When a participant was found eligible for the study, she was 
allocated a unique patient identification number in sequential, chronological order. The 
participant was then treated with the medication labelled with the same number. If a 
participant was withdrawn from the study, her medication was not reallocated. All 
participants and investigators remained blind to treatment allocation for the duration of the 
study.
5.2.7 Outcome Measures
The primary outcome measures were defined as changes in arterial stiffness (AIx, T r, bPWV 
and aPWV), endothelial function, and blood pressure (peripheral and central). Secondary 
outcome measures were defined as changes in serum androgens (testosterone, SHBG and 
FAI), body composition (weight, BMI, percentage fat, waist and hip circumference) and 
metabolic biochemistry (TC, HDL, LDL, Triglycerides, PAI-1, adiponectin, hsCRP, HOMA-IR).
5.2.8 Sample Size & Power Calculation
Sample size advice was obtained from Professor R. Newcombe, Department of Primary Care 
and Public Health, School of Medicine, Cardiff University. Subsequently the aim was to recruit 
32 subjects into the study in order to provide over 80% power to detect a shift of 0.5 times 
the standard deviation of within-group changes at the 5% alpha level using a paired t-test. 
Because the main rationale for using a crossover study was that a substantial within-subject
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correlation was anticipated, it was therefore expected that the power should be well in excess 
of this figure.
5.2.9 Statistical Methods
All statistical analyses were performed using SPSS version 14 for Windows (SPSS, Chicago, 
IL). All analyses were performed as per pre-established protocol and in line with previous 
guidance on analysis of crossover trials [274]. This assessment of treatment efficacy
compares the within-subjects period I minus period II differences between the treatment
sequence groups AP (active-placebo) and PA (placebo-active) by unpaired t-test. In the event 
of serious departure from Gaussian distributional form, scale transformation was used. Point 
and interval estimates of the treatment difference (estimated as above) are given as well as p- 
values. 5% and 1% levels of significance were set for the primary and secondary outcome 
measures, respectively.
5.2.10 Procedures & Instructions
5.2.10.1 Adverse Event Reporting
An adverse event was any undesirable sign, symptom or medical condition occurring after the 
patient has given informed consent. A serious adverse event (SAE) was defined as an 
undesirable sign, symptom or medical condition which:
1. was fatal or life-threatening
2. required or prolongs hospitalisation
3. was significantly or permanently disabling or incapacitating
4. constituted a congenital anomaly or a birth defect
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5. was medically significant, jeopardised the subject or required medical or surgical 
intervention to prevent one of the outcomes listed above.
Information about all non-serious and SAEs, irrespective of causality, whether volunteered by 
the subject, discovered by investigator questioning, or detected through physical 
examination, laboratory test or other means, was collected and recorded. Adverse events 
were followed as appropriate. Where possible, each adverse event was described by:
1. Its duration
2. The severity grade (mild, moderate, severe)
3. Its relationship to study drug (suspected, not suspected)
4. The action(s) taken
Pregnancy was managed as a SAE and followed up to determine details of birth, outcome, 
including spontaneous or voluntary abortion, the presence or absence of any birth defects or 
congenital abnormalities, or any maternal/newborn hazards. Periodic safety reports were 
provided to all regulatory authorities. All SAEs were reported immediately to the trial 
sponsor (Cardiff University), regardless of the causal relationship and expectedness, as well 
as the MHRA as per European Union requirements and in accordance with Good Clinical 
Practice.
5.2.10.2 Emergency Procedure For Unblinding
The randomisation codes for each patient were held at the Pharmacy Department at UHW in 
individual sealed envelopes for emergency use only. Emergency unblinding was considered in 
the event of a SAE provided that knowledge of the subject's treatment allocation would be of 
benefit in her management.
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5.2.10.3 End Of Study Unblinding
After completion of the final subject's final visit, a complete electronic database was created 
which contained all the data collected on vascular, anthropometric and metabolic parameters. 
A copy of this database was supplied on a CD-ROM to a research governance officer from 
Cardiff University who undertook a final study closure inspection and confirmed source 
verification of the data. The Pharmacy department was then given permission to release the 
randomisation codes so data analysis could be performed.
5.2.11 Project Management & Administrative Procedures
The author of this thesis was responsible for the day-to-day conduct of the study, and 
therefore co-ordinated recruitment, obtained consent, performed the blood sampling and 
measured PWV and AIx in all study participants. In the event of an emergency, the author was 
contactable 24 hours a day. Contact information was provided to all study participants and 
was printed on all study medication containers.
Formal meetings were undertaken on a weekly basis with Dr Aled Rees, the Principal 
Investigator, to discuss all aspects of the study and to plan the work for the forthcoming week. 
Informal discussions regarding any difficulties that arose with the project took place as 
required.
All data was entered into a secure electronic database kept locked within the department. 
Study data w ill be stored for 15 years after completion of the clinical trial. Dr Rees w ill act as 
custodian of this data and only the study investigators w ill have access to the data. In addition 
the tria l master files and case report forms have been stored in hard copy form at the Cardiff 
University off-site archiving facility.
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5.2.11.1 Auditing Procedure
As part of Good Clinical Practice the study protocol and all documentation were closely 
monitored. The study was conducted as outlined in the study protocol and in accordance with 
all applicable government regulation. All study documentation was made available for 
inspection at any time by appropriate regulatory authorities including internal audits by the 
Cardiff and Vale NHS Trust and Cardiff University Research and Development audit officers.
5.2.11.2 Handling Of Study Medication
All study medication was dispensed by the Pharmacy Directorate at UHW. Drug supplies were 
stored in an appropriate, secure area and all drug supplies were used only for this protocol 
and not for any other purpose.
5.2.12 Intra-Observer Variability
Formal training was undertaken for all aspects of pulse wave analysis at an ‘Arterial Stiffness 
Theory & Practice' course at the Vascular Research Unit in Addenbrooke's Hospital, 
Cambridge, UK. Prior to commencement of the clinical trial, intra-observer variability was 
established by performing PWA on 20 healthy volunteers at two time points 30 minutes 
apart, to measure AIx. The mean overall intra-operator variability was less than 2% [Table 
5.3).
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Table 5.3: Intra-Operator Variability
1 M 42 180 102 132/74 23 22.5 0.50
2 M 38 175 71 128/64 15 13.5 1.50
3 M 37 166 70 127/84 24 24 0.00
4 M 35 175 71 120/81 14.5 14 0.50
5 M 35 173 78 134/83 14.5 13.5 1.00
6 M 33 173 80 120/80 7 5 2.00
7 F 56 163 57 138/88 29 28 1.00
8 F 40 161 58 98/70 17 16 1.00
9 F 40 156 59 127/81 29 29 0.00
10 F 38 158 80 144/104 41 38 3.00
11 F 37 164 123 131/68 17.5 15 2.50
12 F 37 160 53 121/94 31 27 4.00
13 F 36 158 75 118/75 30 27 3.00
14 F 34 146 74 116/75 24 22 2.00
15 F 31 160 78 132/78 31 27.5 3.50
16 F 29 160 69 119/88 18 16 2.00
17 F 28 165 83 141/93 -4.5 -5 0.50
18 F 26 167 72 110/71 11 11 0.00
19 F 22 180 69 122/67 -6 -8 2.00
20 F 20 167 78 132/73 19 16 3.00
Mean intra-operator variability (SD) 1.65(1.2)
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5.5 RESULTS
5.3.1 Subject Recruitment And Trial Completion
Figure 5.8 summarises the flow of participants through each phase of the study. 200 patients 
from the Endocrine and Dermatology clinics at the University Hospital of Wales, Cardiff, were 
screened for tria l eligibility of which 80 fulfilled all the inclusion criteria. Of these a final 30 
women consented to tria l participation and were randomised accordingly.
Figure 5.8: Flow Of Participants Through Each Phase Of The Clinical Trial
Screened for e ligibility n=200 
Inclusion criteria 
Aged 18 to 35 years 
Definition of PCOS met
i Excluded (n=120)
Met inclusion criteria (n=80)
Randomized (n=30)
 I  .
Refused/couldn't be 
contacted (n=50)
Metformin
(n=15)
1 r
V .
Discontinued (n=3) 
due to non-attendance
««
***
Placebo
(n-15)
1 r
Discontinued (n=2)
1 due to pregnancy 
1 due to non-attendance
-  -----------------------
Metformin
_____________^  _________________
Placebo
(n=13) (n=12)
End of study analysis (n=25)
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25 subjects completed the full protocol. This gave a slightly reduced power of 70% to detect a 
shift of 0.5 times the SD of within-group changes. Five subjects were withdrawn during the 
course of the study: 1 participant because of pregnancy and 4 individuals because of protocol 
violation (non-attendance for study visits). The data analysed are therefore for the 25 
subjects who completed the study. No significant carryover effect was noted in any of the 
measurements.
5.3.2 Baseline Demographic & Anthropometric Data
Table 5.4 summarises the baseline demographic and anthropometric characteristics of the 
study population. The mean age for the group was 30 years and 20% reported current 
smoking. The average BMI was 34.9 kg/m2, consistent w ith obesity, and associated with an 
increased mean waist circumference of 107.6 cm.
Table 5.4: Baseline Demographic & Anthropometric Characteristics
Values are based upon all 30 study participants & are expressed as mean (SD) or median (range).
Age (yr) 30 (18 - 35)
Smokers (n) 6 (20%)
Ferriman-Gallwey score 11 (2 - 23)
Weight (kg) 96.5 (23.4)
BMI (kg/m2) 34.9 (6.8)
Waist circumference (cm) 107.6 (21)
Hip circumference (cm) 119.5 (19.2)
Fat percentage 48 (21 - 57)
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5.3.3 Baseline Vascular Parameters
Table 5.5 summarises the baseline vascular markers for the study population. Reference 
values for AIx using the SphygmoCor apparatus have been provided by the manufacturer 
(Atcor medical) derived from unpublished data by Cockroft et al (Cardiff, UK) available at 
http://www.atcormedical.com. Based upon their data the mean AIx for a similar mean aged 
population is quoted to be 3.03% (95% Cl -15.57 to 24.5) compared with a value of 18.5% in 
our PCOS study population, which may suggest increased baseline arterial stiffness. However, 
the demographic and anthropometric characteristics of this reference population are not 
stated in the manufacturer's literature. The baseline vascular parameters for PWV and blood 
pressure are comparable to those reported in similar studies in PCOS cohorts [245].
Table 5.5: Baseline Vascular Parameters Of Study Participants
Values are based upon all 30 study participants & are expressed as mean (SD).
Tr (msec) 145.7 (11.4)
AIx (%) 18.5 (10.5)
bPWV (m/sec) 7.7 (1.1)
aPWV (m/sec) 7.0 (1.2)
Peripheral SBP (mm Hg) 127 (11)
Peripheral DBP (mm Hg) 85 (9)
Central SBP (mm Hg) 117(11)
Central DBP (mm Hg) 85 (9)
Fall in AIx after GTN (%) -16.8 (5)
Fall in AIx after salbutamol (%) -14.6 (6.4)
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5.3.4 Baseline Metabolic Biochemical Parameters
Table 5.6 summarises the baseline metabolic parameters for the study population.
Table 5.6: Baseline Metabolic Biochemical Parameters Of Study Participants
Values are based upon all 30 study participants &  are expressed as mean (SD) or median (range).
Adiponectin (pg/ml) 474.3 (95.3 -1915.3)
hsCRP (mg/liter) 3.4 (0.16 -14.4)
Insulin (pmol/liter) 20.7 (5.1-42.2)
Glucose (mmol/liter) 5.1 (0.5)
HOMA-IR 2.5 (0.7 - 4.8)
TC (mmol/1) 4.8 (0.7)
HDL (mmol/1) 1.2 (0.3)
LDL (mmol/1) 3.0 (0.5)
Triglycerides (mmol/liter) 0.9 (0.4 - 5.2)
PAI-1 (ng/ml) 1.75 (0.5 - 23.9)
Testosterone (nmol/liter) 2.6 (0.8)
SHBG (nmol/liter) 33.2 (18.5 -174.3)
FAI 7.6 (0.8 -17.4)
Oestradiol (pmol/1) 156 (70-707)
Progesterone (nmol/1) 3.5 (2-31.5)
5.3.5 Prevalence Of Features Of The Metabolic Syndrome In Study Population
There was an increased prevalence of features of the metabolic syndrome based on the 2006
IDF definition amongst the study population (Table 5.7). The commonest abnormality was an
increased waist circumference, a marker of visceral adiposity, in 93% of the subjects. 60%
had evidence of hypertension, 53% low HDL, 20% hypertriglyceridaemia, and 13% impaired
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fasting glucose. 47% fulfilled the criteria for the metabolic syndrome with > 3 features 
present. These findings are in keeping with reports in the literature by Dokras et al [127] who 
reported a prevalence of 34% of the metabolic syndrome in PCOS, and 43% by Apridonidze 
and colleagues [129] as discussed previously.
Table 5.7: Prevalence Of Features Of The Metabolic Syndrome In PCOS 
Based On the 2006 IDF Criteria
Waist circumference (> 80 cm) 28 (93 %)
Triglycerides (> 1.7 mmol/1) 6 (20 %)
HDL cholesterol (< 1.29 mmol/1) 16 (53 %)
BP (Systolic £ 135 or diastolic £ 85 mmHg) 18 (60 %)
Dysglycaemia (Fasting glucose > 5.6 mmol/1) 4 (13 %)
Central obesity + 2 other criteria 14 (47 %)
5.3.6 Treatment Compliance & Adverse Events
All adverse events were recorded in the tria l case report forms and reported to the Cardiff 
and Vale NHS Trust Research and Development Department as well as Cardiff University 
(study sponsor). Annual safety reports were submitted to the South Wales Resarch and Ethics 
Committee as well as the Medicines and Healthcare Regulatory Authority.
Overall the study medication (active and placebo) was well tolerated. Five adverse events 
were reported during the course of the study, three of which were expected (gastrointestinal 
discomfort during the active treatment phase) but mild and self-limiting. One subject 
described a headache (while on metformin) and this was also mild in intensity and self- 
limiting. Another participant became pregnant (while on placebo) and was immediately
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withdrawn from the study. The pregnancy was followed to term w ith no maternal or foetal 
complications.
5.3.7 Effect Of Metformin On Vascular Function
Metformin therapy significantly improved all markers of arterial stiffness in our study 
population (bPWV, aPWV, AIx; all p<0.001] w ith the exception of T r which did not change 
(Figures 5.9 and 5.10].
Figure 5.9: Effect Of Metformin Therapy On Augmentation Index In PCOS
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Figure 5.10: Effect Of Metformin Therapy On Brachial & Aortic PWV In PCOS
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These improvements in measures of arterial stiffness following metformin therapy were 
accompanied by a lowering of peripheral and central aortic systolic (Figures 5.11 and 5.12) 
and diastolic blood pressure (all p<0.001).
Figure 5.11: Effect Of Metformin Therapy On Peripheral Blood Pressure In PCOS
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Figure 5.12: Effect Of Metformin Therapy On Central Systolic Blood Pressure In PCOS
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Metformin also improved endothelium-dependent and endothelium-independent vascular 
responses as evidenced by an increased reduction in AIx post-salbutamol (p=0.003) and post- 
GTN (p<0.001) respectively. A summary of the primary vascular outcome measures for the 
study is given in Table 5.8.
Table 5.8: Effect Of Metformin vs. Placebo On Vascular Outcome In PCOS
H h
AIx (%) -6.1 -8.46 to -3.74 <0.001
bPWV(m/s) -0.73 -1.09 to -0.38 <0.001
aPWV (m/s) -0.76 -1.12 to -0.4 <0.001
Peripheral SBP (mmHg) -7.65 -10.47 to -4.84 <0.001
Peripheral DBP (mmHg) -5.83 -8.4 to -3.22 <0.001
Central SBP (mmHg) -9.02 -12.05 to -6 <0.001
Central DBP (mmHg) -5.96 -8.74 to -3.17 <0.001
AIx post-GTN (%) -4.68 -6.93 to -2.43 <0.001
AIx post-salbutamol (%) -5.38 -8.68 to -2.07 0.003
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5.3.8 Effect Of Metformin On Anthropometric Measurements
Table 5.9 summarises the results of the anthropometric measures. Metformin significantly 
reduced body weight (p<0.001), BMI (p<0.001), waist circumference (p<0.001), fat 
percentage (p<0.001), with only a minimal change of doubtful significance noted in hip 
circumference. These results suggest the weight loss may have been related to a reduction in 
central, or visceral, adiposity.
Table 5.9 : Effect Of Metformin vs. Placebo On Anthropometric Measurements In PCOS
Weight (kg) -2.05 -2.9 to -1.2 <0.001
BMI (kg/m 2) -0.75 -1.06 to -0.43 <0.001
Fat percentage (%) -2.46 -3.26 to -1.65 <0.001
Waist circumference (cm) -4.88 -6.96 to -2.81 <0.001
Hip circumference (cm) -0.82 -1.62 to -0.02 0.045
5.3.9 Effect Of Metformin On Metabolic Biochemical Parameters
Metformin significantly increased adiponectin concentrations (p=0.001) as illustrated in 
Figure 5.13 and was also associated with a fall in plasma triglycerides. There were no changes 
observed with metformin therapy in hsCRP, insulin, glucose, HOMA-IR, total cholesterol, HDL, 
LDL, PAI-1, testosterone, SHBG, FAI, oestradiol or progesterone. Table 5.10 summarizes the 
results of the metabolic biochemistry.
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Figure 5.13: Effect Of Metformin Therapy On Adiponectin In PCOS
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Table 5.10: Effect Of Metformin vs. Placebo On Metabolic Markers In PCOS
Adiponectin (pg/m l) +81.5 +18.7 to +144.3 0.001
hsCRP (mg/1) -0.13 -0.34 to +0.86 0.216
Insulin (pmol/1) -0.08 -4.75 to +4.58 0.971
Glucose (mmol/1) -0.13 -0.46 to +0.21 0.43
HOMA-IR -0.46 -2.21 to +1.3 0.583
TC (mmol/1) -0.75 -2.42 to +0.92 0.35
HDL (mmol/1) -0.69 -2.36 to +0.99 0.39
LDL (mmol/1) -0.67 -2.35 to +1.02 0.41
Triglycerides (mmol/1) -0.16 -0.26 to -0.56 0.004
PAI-1 (ng/m l) +0.08 -1.69 to +1.84 0.3
Testosterone (nmol/1) -0.81 -2.48 to +0.86 0.31
SHBG nmol/1 -3.31 -17.25 to +10.63 0.62
FAI -1.26 -3.34 to +0.82 0.22
Oestradiol (pmol/1) +15.34 -25.24 to +55.93 0.44
Progesterone (nmol/1) +2.66 -2.85 to +8.18 0.33
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5.4 DISCUSSION
A number of studies have recently examined the effects of metformin on vascular function 
[240-246], especially endothelial function, in young women with PCOS, although to the 
author's knowledge, this is the first study to prospectively test this in a randomized, double­
blind, placebo-controlled design. It was deemed justifiable to include a short-term placebo 
arm because the study patients were not seeking fertility treatment, treatment for oligo- 
/amenorrhea, or systemic therapy for management of their hirsutism. A crossover design was 
chosen because a substantial within-subject correlation was anticipated, such that smaller 
sample sizes would be required to detect significant differences, and used a washout period of 
8 wk to minimize the potential for a carryover effect. Although endothelial function has been 
found to vary according to phase of the menstrual cycle [275], we were unable to apply these 
temporal limitations to the vascular measurements because of the need for equal treatment 
duration in each phase of the crossover design. Nevertheless, it is not considered likely that 
any potential confounding influences of metformin on improved menstrual cyclicity [245] 
might account for the changes observed in vascular function because estradiol and 
progesterone levels did not differ after the metformin and placebo phases.
The data demonstrated that metformin significantly improved endothelial function in the
PCOS cohort, an observation consistent w ith some [240-243], but not all [244-246], previous
studies in young women with PCOS. The latter studies employed flow-mediated dilatation of
the brachial artery as their method to assess endothelial function. An alternative technique
based on a similar principle was used in the present study, whereby changes in AIx in
response to endothelium-dependent (salbutamol) and endothelium-independent (GTN]
pharmacological challenges are measured by pulse wave analysis [270]. Although this
technique may offer reduced precision compared with flow-mediated dilatation in measuring
endothelial function [276], it  provides a more global assessment of endothelial function,
including conduit and resistance vessel endothelial function, and correlates strongly with gold
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standard measures [270]; hence, it was anticipated that the current findings would be 
comparable to other methodologies.
Endothelial dysfunction is an important process in the progression of atherosclerosis and
independently predicts cardiovascular morbidity [277, 278]. An improvement in large artery
stiffness was observed w ith metformin therapy as evidenced by a reduction in AIx and slowed
brachial and aortic PWV. A slowing of aortic PWV in response to metformin is especially
noteworthy given that this measure of arterial stiffness is independently predictive of
cardiovascular mortality in a number of disease states, including renal failure, hypertension,
and glucose intolerance/type II diabetes [236-238]. A 1 m/sec increase in aortic PWV was
associated w ith a 39 and 8% increase in mortality in patients with renal failure [237] and
type II diabetes [236] respectively; hence, the observed reduction of almost 0.8 m/sec is likely
to be clinically important. In contrast, Meyer and colleagues [245] failed to detect a change in
PWV with 6 months of metformin treatment in their population of women with PCOS but did
note an increase in PWV with a high-dose oral contraceptive (35g ethinyl estradiol/2 mg
cyproterone acetate), related principally to increased insulin resistance. These divergent
effects on arterial stiffness of the two most commonly prescribed treatments for young
women with PCOS thus has important practical implications when considering choice of
therapy in the clinic. The study population in Meyer et al. had a similar mean age [31 years),
BMI [36.3 kg/m 2), systolic blood pressure [121mmHg), and aortic PWV [7.47 m/sec) to that
described here; hence these discrepancies cannot be accounted for on the basis of differences
in patient characteristics at baseline. Furthermore, although their sample size calculations
were performed primarily for changes in insulin sensitivity, their study was also adequately
powered to detect a 3-4% difference in PWV [245]. However, in contrast to the present
findings, the participants in Meyer and colleagues' study did not lose weight, nor did their
blood pressure change, which suggests that the vascular improvements observed in this
thesis with metformin might be dependent at least in part on changes in these variables. In
support of this, weight loss alone [8% over 1 yr) has been shown to reduce aPWV by 0.5
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m/sec in subjects w ith type II diabetes [279], and a blood pressure reduction of 24/9 mm Hg 
with valsartan and hydrochlorothiazide is associated with a reduction in aortic PWV by 1.8 
m/sec [280].
A fall in peripheral blood pressure with metformin therapy has been reported previously in 
women with PCOS [281, 282], although the reduction observed here in central aortic blood 
pressure is likely to have even greater clinical relevance because this has been shown to be a 
more powerful predictor of mortality than brachial blood pressure in patients with CVD 
[283]. The 2-kg reduction in weight and 0.75 kg/m2 fall in BMI is consistent with the findings 
of a recent systematic review of insulin-sensitizing drugs on weight loss in women with PCOS 
in which a weighted mean difference of 0.68 in BMI was found compared with placebo [284]. 
The reduction in waist circumference suggests a predominant action on the visceral fat 
compartment, which others have confirmed using computerized tomography [285]. In 
keeping with this, in the present tria l an increase in adiponectin was noted, which has 
previously been reported w ith metformin in overweight women with PCOS [286]. This rise 
may in itself have contributed to the improvements in vascular function because adiponectin 
enhances nitric oxide production by endothelial cells with attendant benefits on endothelial 
function [287].
It was a surprise that insulin resistance as measured by HOMA-IR did not improve with 
metformin, in contrast to a number of other studies that demonstrate improved insulin action 
with metformin in women with PCOS [139, 245]. These studies typically employed more 
sensitive measures of insulin resistance than HOMA-IR, and it is possible that an 
improvement in insulin resistance with metformin treatment might have been observed had a 
more robust measure been employed. Nevertheless, it is worth noting that the baseline values 
of HOMA-IR in this study were relatively low, suggesting only a modest degree of insulin 
resistance in the tria l subjects despite their elevated BMI. Hence, the possibility that
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metformin might be exerting its beneficial actions on the vasculature by a mechanism 
independent of improved insulin sensitivity cannot be entirely discounted.
Metformin was also noted to lower triglyceride levels but did not alter HDL, LDL, or TC. A 
proatherogenic dyslipidemia, characterized by raised triglyceride levels and reduced HDL 
concentrations accompanied by increased small, dense LDL particles, is common in women 
with PCOS [115]. This tria l did not undertake any qualitative lipoprotein analysis; hence, an 
effect of metformin on LDL subclass cannot be excluded, but these findings of reduced 
triglycerides, although modest, are in agreement w ith some reports that have shown a 
reduction w ith metformin treatment, albeit w ith large variation among individuals [236, 
288]. No changes in testosterone, FAI, or SHBG were observed with metformin therapy, 
suggesting that the beneficial effects of metformin on vascular function are independent of 
changes in androgen status. The impact of androgens on vascular function in women with 
PCOS is controversial, w ith some studies demonstrating an association of endothelial 
dysfunction w ith androgen level [90, 140] and others suggesting a favourable effect of 
androgens on vascular function [239, 289].
The improvements noted in vascular function raise the question as to how metformin might
be exerting its benefits. The crossover design of the present study precluded the use of
regression analysis to explore the major contributors to the improved vascular action.
However, the magnitude of change [mean difference/SD of the active-placebo differences) for
each variable significantly affected by metformin therapy was very similar, suggesting that
these were all being influenced by the intervention to a similar degree and hence possibly by
the same pathway. It may be speculated that this pathway might involve the key energy
sensor AMP kinase (AMPK) [290]. In addition to metformin's ability to activate AMPK in the
liver and in muscle, with consequent benefits on enhanced glucose uptake and reduced
hepatic glucose output, metformin has also been shown to activate AMPK in the endothelium
and in vascular smooth muscle, where it mediates vascular relaxation through the a l subunit
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in an endothelium-independent manner [291, 292]. These findings may thus explain our 
observations whereby metformin enhanced endothelium-independent (NTG) as well as 
endothelium-dependent (salbutamol) vascular responses.
In conclusion, the data presented in this chapter support an important action of metformin in 
improving vascular function in young overweight women with PCOS, but further studies are 
needed to confirm these findings and to delineate the potential mechanisms in operation. In 
particular, this study was limited by the lack of a weight-loss control group; hence, further 
trials that include this as a control arm are required to fully assess whether metformin 
therapy has additional benefits on vascular function beyond weight loss alone. Furthermore, 
overweight, anovulatory women with PCOS may be particularly at risk of insulin resistance 
and vascular dysfunction. Therefore, trials in normal weight and eumenorrheic 
subpopulations are also required before these findings can be generalized to all women with 
PCOS. Additional studies should also explore the potential for additive or synergistic 
interactions with other agents known to improve vascular function, such as statins, or 
exercise regimens, which also have the potential to activate AMPK.
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CHAPTER 6 : GENERAL DISCUSSION
6.1 Background
Global cardiometabolic risk represents the overall likelihood of developing type II diabetes, 
cardiovascular disease, or both, due to a cluster of modifiable adverse factors [21]. These 
include classic risk factors such as smoking, high LDL cholesterol levels, hypertension and 
elevated blood glucose, in addition to others closely associated with abdominal obesity, such 
as insulin resistance, low HDL cholesterol, high triglycerides and elevated inflammatory 
markers [21]. The rationale for the concept of the metabolic syndrome arises from the 
observation that a clustering of these adverse metabolic and vascular risk factors represents a 
high-risk group requiring careful attention and treatment following an integrated approach.
Treatment approaches to date have largely been directed at individual traits such as 
hypertension and dyslipidaemia. However, the pathogenesis of the components of the 
metabolic syndrome is largely linked to underlying obesity, especially an accumulation of 
central or visceral adiposity, and insulin resistance. Therefore therapies targeting these 
factors should help minimise the increasing health burden arising from CVD and type II 
diabetes attributable to obesity.
6.2 Thesis Aims
The aims of this thesis were to examine the effects of existing (metformin) and novel (CBi 
antagonist) pharmacological agents that target components of the metabolic syndrome using 
appropriate models of the syndrome in vivo (PCOS) and in vitro (adipogenesis) by:
1. Evaluating the actions of cannabinoid receptors on proliferation, differentiation and 
adipokine production in models of in vitro adipogenesis.
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2. Determining the in vivo effects of metformin therapy on arterial stiffness, endothelial 
function, adipokine profile and insulin sensitivity in young women with PCOS.
It was hypothesised that these agents may exert their benefits not only by improving insulin 
sensitivity and obesity, but also through indirect mechanisms involving a switch in the 
adipokine profile.
6.3 Current Pharmacological Therapies For The Management Of Obesity
Obesity trends amongst adults in the UK continue to increase. The National Heart Forum 
report published in February 2010 predicts that by 2020 the proportion of adults who w ill be 
overweight aged 20-65 is 40% for men and 32% for women [293]. The team also predict a 
23% rise in the prevalence of obesity-related stroke, a 34% rise in obesity-related 
hypertension, a 44% rise in obesity-related coronary heart disease and a 98% rise in obesity- 
related diabetes [293].
Effective weight management requires lifestyle modification to encourage healthy eating 
habits and increased levels of physical activity to ensure that energy expenditure is at least 
equal to, i f  not greater than energy intake. A number of studies including the Diabetes 
Prevention Programme [DPP) and the Finnish Diabetes Prevention Trial (FDPT) have 
provided convincing evidence for the benefits of lifestyle interventions facilitating weight loss 
in the prevention of diabetes [294, 295]. However, such approaches are not always sufficient 
to achieve and maintain weight loss outside of clinical tria l settings. Given the health risks 
associated with increased adiposity, there is a demand for safe and effective anti-obesity 
agents to act as an adjunct to lifestyle modification in both promoting and maintaining weight 
loss, to help improve co-morbidity.
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The early drugs used for weight loss were centrally-acting appetite suppressants including 
amphetamines but these are no longer an option due to their high addiction potential. 5- 
hydroxytryptamine (5-HT) uptake inhibitors such as fenfluramine have been used in the past 
as well but have been removed from the market due to an association with pulmonary 
hypertension and valvular heart disease [296].
Until recently there have only been two drugs available as pharmacological adjuncts for 
weight loss w ith license for use in the developed world. Orlistat can cause modest weight loss 
and acts by inhibiting the absorption of ingested fat w ithin the gastrointestinal tract, though 
its use can be limited by the side effects of faecal incontinence and interference with the 
absorption of fat soluble vitamins [297]. Sibutramine, a centrally acting drug that stimulates 
the sensation of satiety and increases energy expenditure, was the alternative agent. 
However, in January 2010, the MHRA announced the suspension of the marketing 
authorisation for sibutramine following a review by the European Medicines Agency (EMA). It 
was determined that sibutramine's cardiovascular risks outweigh its benefits, with emerging 
evidence to suggest an increased risk of non-fatal heart attacks and strokes with this 
medicine [298].
A third agent, the first-in-class CBi receptor blocker drug, rimonabant was available from 
2006 to 2008, and represented a novel approach targeting both central and peripheral sites in 
the regulation of weight and energy homeostasis. However, due to safety concerns (detailed 
below) the drug is no longer available but the endocannabinoid system still remains a 
promising therapeutic target for further research and development, and w ill be discussed in 
greater detail in the following section.
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6.4 The ECS As A Therpeutic Target In The Management Of Obesity & The
Metabolic Syndrome
6.4.1 The Role Of CBi Receptors In The Regulation Of Metabolism
In one of the earliest animal studies examining the effect of CBi receptor blockade on appetite 
suppression by Colombo and colleagues, chronic administration of rimonabant resulted in a 
transient reduction in food intake as well as a longer lasting reduction in body weight, 
suggesting a beneficial metabolic effect of this treatment independent of energy intake [299]. 
This has been supported by further observations in CBi receptor-deficient mice who exhibit 
hypophagia and leanness compared to their wild-type littermates, and also maintained a lean 
phenotype in comparison to the wild-type mice despite identical paired feeding, indicating 
possible altered energy expenditure and metabolism [59]. Diet induced obesity in mice is 
accompanied by dyslipidaemia, insulin resistance and fatty liver, and can thus be considered a 
murine model of the metabolic syndrome [21]. Once daily treatment with rimonabant at 10 
mg/kg for forty days, has been shown to result in a 50% reduction in adipose tissue mass in 
mice with diet-induced obesity [300]. Furthermore, CBI receptor knockout mice are resistant 
to diet induced obesity and maintain a more favourable metabolic profile when compared to 
the wild-type mice who do become obese on an identical high calorie diet [58].
The human clinical trials of rimonabant in obesity (RIO) have been divided into four main
groups: RIO-North America [79], RIO-Europe [221], RIO-Lipids [78] and RIO-Diabetes [80]. In
these studies up to two years treatment w ith rimonabant resulted in significant weight loss
that was also associated w ith improvements in the metabolic profile including lower plasma
TG, increase in HDL, reductions in the elevations of plasma insulin and leptin, and an increase
in adiponectin concentration [78-80, 221]. An interesting observation is that the majority of
the weight loss occurred during the first year of treatment whereas improvements in lipid
and glycaemic profiles continued even in the second year, and thus may not be attributable to
240
weight loss alone [221, 301]. These findings support an additional role of the ECS in 
peripheral sites, including adipose tissue, to produce beneficial metabolic effects beyond 
weight loss in obese patients.
6.4.2 In Vitro Studies Supporting A Role Of Peripheral CBi Receptors
The relevance of the ECS to adipocyte physiology is supported by studies, including the 
experiments described in this thesis, demonstrating CBi receptor expression in pre­
adipocytes which changes dynamically through adipogenesis, becoming more prominent in 
mature adipocytes and is closely associated with PPARy receptor profiles during adipocyte 
differentiation [76, 207]. In keeping with these findings, Bouboula et al demonstrated PPARy 
transcriptional activation in the presence of endogenous endocannabinoids in murine 3T3-L1 
though this remains to be confirmed in human in vitro models [302]. Perhaps more 
interesting is the observation that CBi receptors are differentially expressed in WAT derived 
from different depots [222]. The current studies confirmed a more significant effect of CBi 
receptor antagonism in cells originating in omental adipose tissue, thus modifying an 
important adverse cardiovascular risk marker. Similarly, higher levels of the 
endocannabinoid 2-AG have been detected in the intra-abdominal visceral, but not 
subcutaneous fat of obese subjects [303], and an increase in circulating 2-AG has been shown 
to positively correlate w ith important cardiometabolic risk factors, such as BMI, waist 
circumference, fasting plasma triglyceride and insulin levels, low HDL cholesterol, and 
adiponectin levels [304].
CBi activation in adipose tissue is not limited to promoting cell proliferation but also acts to
increase energy storage. Endocannabinoids stimulate lipogenesis by inducing triglyceride
accumulation through the inhibition of adenylate cyclase and the consequent reduction of
lipolysis, and via activation of lipoprotein lipase to provide exogenous fatty acids for the
adipocytes [59, 300]. In addition, endocannabinoids increase the expression and activity of
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enzymes involved in fatty acid and triglyceride biosynthesis thus promoting de novo 
lipogenesis [59]. CBi activation in adipocytes also modulates insulin signalling and glucose 
uptake in order to increase energy storage and modify insulin sensitivity [303]. Therefore it 
would be interesting to expand the in vitro studies detailed in the previous chapters to 
examine the effects of CBi receptor blockade upon energy storage within adipose tissue and 
to determine if  a differential effect exists between WAT derived from different fat depots.
Adipose tissue is now recognised as an endocrine organ capable of secreting a number of 
adipokines which influence adipocyte physiology. The present studies have illustrated an 
increase in adiponectin production arising from CBi antagonism treatment in in vitro models 
of adipogenesis using human primary cultures, which may in part explain the changes in 
insulin sensitivity observed with rimonabant therapy. Further studies looking at the effects 
upon other adipokines including visfatin, leptin and IL-6, for example, may improve our 
understanding of the mechanisms by which CBi antagonists exert their metabolic effects.
Recent studies have found that the administration of CBi antagonists in diet-induced obese 
Wistar rats induces an increase in energy expenditure, thus identifying another possible 
peripheral mechanism contributing to a reduction in adipose mass [305]. This is thought to 
be mediated by CBi antgonist-mediated generation of futile, or substrate, cycles, where two 
metabolic pathways (in this instance glycogen synthesis and glycolysis) run simultaneously in 
opposite directions resulting in the dissipation of energy in the form of heat [300]. Although 
in the studies presented in this thesis CBi modulation did not alter UCP-1 expression, a 
marker of BAT, Perwitz et al have highlighted a rimonabant-induced transdifferentiation in 
white adipocytes towards a mitochondria-rich brown fat phenotype [209]. CBi receptor 
antagonist treatment may therefore also lead to an eventual increase in energy expenditure 
via mitochondrial thermogenesis by increasing brown-type adipocytes. Though the presence 
of BAT has recently been described in adult humans [181,182], the functional significance is 
not yet well established and still demands further study.
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CBi receptor blockade has also been shown to increase mitochondrial biogenesis in cultured 
white adipocytes by inducing the expression of eNOS [306] and is accompanied by the 
prevention of high-fat diet-induced fat accumulation, without concomitant changes in food 
intake [306]. A possible mediator of these functions may be the AMPK system. 
Endocannabinoids decrease AMPK activity in adipose tissue, contributing to a rise in 
adiposity and lipogenesis and resulting in decrease in energy expenditure, and induction of 
AMPK activity has been found to increase mitochondrial content in adipocytes. [306]. Thus, 
the anti-obesity effects associated with CBi blockade may also result from enhanced (3- 
oxidation of free fatty acids elicited by AMPK activation and by eNOS-dependent 
mitochondrial biogenesis.
The aforementioned studies and the experiments described in this thesis support a significant 
role for the ECS in the periphery in targeting obesity and thus the metabolic syndrome. This is 
of importance when considering the future of CBi antagonist therapy given the adverse 
events associated with the first generation drug in this class, rimonabant which have largely 
been attributable to central CBi blockade.
6.4.3 Adverse Events Associated W ith Rimonabant
The reduction in weight and changes in metabolic parameters observed with rimonabant 
therapy have unfortunately been accompanied by a significant side effect profile. Pooled data 
obtained from analyses of the RIO studies following 1 year of treatment with rimonabant 
highlights adverse effects which can be broadly categorised into three main groups: 
psychiatric symptoms (1.9% vs. 0.8% in treatment group vs. placebo), gastrointestinal 
disturbances predominantly in the form of nausea (1.4% vs. 0.1%), and neurological 
alterations including headaches and vertigo [301]. Altogether, 13.8% of patients receiving 20 
mg rimonabant daily discontinued treatment in comparison to 7% of those receiving placebo 
[301].
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In October 2008, the EMA recommended suspending its marketing authorisation for Sanofi- 
Aventis's first-in-class CBi receptor blocker rimonabant, due to an increased risk of 
psychiatric side-effects including severe depression, anxiety and stress disorders which 
outweighed the potential benefits [307]. This led to the decision by Sanofi-Aventis in 
November 2008 to withdraw rimonabant from the market world-wide and discontinue 
clinical trials of rimonabant for all clinical indications [308]. This move was followed closely 
by termination of development programmes and clinical trials of other CBi receptor blocking 
compounds by competing pharmaceutical companies including Pfizer (otenabant) and Merk 
[taranabant] [309].
Previous studies have shown that up to 48% of obese individuals exhibit features of 
depression and that obese women in particular are 20% more likely to have experienced 
suicidal ideation and 23% more likely to have actually attempted suicide in comparison to 
their non-obese counterparts [310]. Whilst in clinical tria l settings subjects are rigorously 
screened for such conditions, it  is not clear how robustly this is undertaken in general clinical 
practice, and may have also contributed to the increase in mood-related adverse effects. 
Since overweight individuals represent one of the target populations for this class of drugs, 
any future drug development w ill need to address the potential for psychiatric disturbance.
However, abandoning the ECS as a potential therapeutic target in weight management may be 
a little premature, and recently some efforts have been made to circumvent the psychiatric 
side-effects currently limiting the use of this class of drugs. This has largely focused on 
targeting the ECS in peripheral tissues which may still preserve some of the metabolic 
benefits described in the previous section.
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6.4.4 Future Drug Development Targeting The ECS
The initial approach towards modulating the ECS to affect weight has predominantly focused 
on targeting central CBi receptors with the aim of appetite suppression [299, 311], though 
later studies, including the experiments described in this thesis, have supported the 
additional role of peripheral mechanisms contributing to the reduction in adiposity [207, 
225]. Initially drug development included optimising the compound for high brain 
penetration and antagonism of central CBi receptors, thus also contributing to the CNS- 
mediated psychiatric side-effects. New strategies now include developing agents that 
preferentially target peripheral CBi receptors located within, for example, adipose tissue, 
liver, muscle and the gastrointestinal tract, with the aim of maintaining the peripherally- 
mediated beneficial effects whilst minimising the central adverse consequences.
Pavon et al have developed a novel CBi receptor antagonist, LH-21, a triazol derivative with 
poor penetration into the central nervous system [312]. When given acutely it decreases food 
intake and enhances the anorectic actions of oleoylethanolamide, a feeding suppressant lipid 
that acts on peripheral sensory terminals, in a similar way to rimonabant [312]. However, 
unlike rimonabant, chronic administration of LH-21 (3 mg/kg) reduces feeding but does not 
improve hypertriglyceridaemia or hypercholesterolaemia; nor does it reduce liver fat 
deposits in Zucker rats suggesting that antagonism of central CBi receptors may be necessary 
for the metabolic benefits of CBi blockade, but not for the appetite reduction [312].
Another scientific group working at Jenrin Discovery have developed two CBi receptor
antagonists, JD 2114 and JD 5006 whose structures are yet to be disclosed, that have been
chemically modified to possess little potential to cross the blood-brain barrier [313]. Both
these substances have been shown to have high affinity for CBi receptors (< 30 nM) with
greater selectivity versus CB2 receptors [313]. Animal studies have been conducted with
these compounds using once daily oral administration at doses of 10 mg/kg in diabetic and
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dyslipidaemic obese mice, and compared to control populations treated with rimonabant. 
Significant weight loss was observed with all these substances as well as a reduction in fasting 
blood glucose, insulin and triglycerides within seven days of treatment thus demonstrating 
beneficial effects of CBi receptor antagonism by targeting peripheral receptors, though 
further work is still required to establish efficacy and safety in humans [313].
An alternative avenue that is being pursued by some research groups focuses on targeting a 
binding site on the CBi receptor by developing ligands that act as allosteric inhibitors of 
agonist signalling efficacy. One of the first in vivo reports using this class of agents describes 
the use of PSNCBAM-1, a novel allosteric antagonist at the CBi receptor, which in an acute rat 
feeding model decreased food intake and body weight [314]. Another technique in 
development is to bypass the CB receptors and modulate the endocannabinoid system by 
different means. One such approach involves targeting the enzyme fatty acid amide hydrolase, 
thus affecting the breakdown of endogenous endocannabinoids [315]. Whether these 
approaches w ill result in weight reduction and improvements in metabolic profiles in 
humans, whilst maintaining a satisfactory risk-benefit ratio, remains to be determined.
6.5 Metformin In PCOS -  An In Vivo Model Of The Metabolic Syndrome
PCOS is the commonest endocrinopathy affecting women of reproductive age and a 
significant proportion of the affected women fulfil the criteria for the metabolic syndrome, a 
finding confirmed in the clinical trial reported in this thesis [316]. PCOS therefore represents 
a useful model to evaluate treatment effects upon cardiometabolic risk. In the presented 
clinical trial, metformin reduced arterial stiffness and improved endothelial function in young 
women with PCOS [317]. The improvements noted in vascular function do however raise the 
question as to how metformin might be exerting its beneficial effects.
246
Metformin is an oral biguanide and the most commonly prescribed insulin sensitiser used for 
the treatment of type II diabetes. Its principal metabolic action is thought to be mediated via 
suppression of hepatic gluconeogenesis and lipogenesis while improving peripheral glucose 
uptake and glycolysis [138]. Increasing recognition of its pleiotropic actions on a variety of 
tissues including the liver, adipose tissue, skeletal muscle and endothelium, have led to recent 
interest in expanding the therapeutic potential of this old drug originally used only for the 
management of established diabetes [138].
6.5.1 Action Of Metformin In Adipose Tissue
Although adipose tissue is not thought to be the principal site of action of metformin, there is 
evidence for modest effects on this tissue. There is conflicting evidence regarding the effect of 
metformin therapy on insulin-mediated glucose transport in adipose tissue [318, 319], but 
there are data supporting its effects on adipose tissue lipolysis. In primary rat adipocytes 
stimulated with TNFa and/or high glucose concentrations, metformin treatment inhibits 
agonist-induced lipolysis [320]. The resulting reduction in available systemic FFAs could also 
contribute to the insulin sensitising effects of metformin.
In experiments using murine 3T3-L1 cells, metformin has been associated with counteracting 
adipose tissue expansion via a direct inhibition of adipogenesis through AMPK-dependent 
stimulation of FA oxidation and inhibition of lipogenesis [321]. This observation may in part 
explain the weight loss noted in the clinical tria l presented in this thesis via a mechanism 
independent of metformin's actions upon insulin sensitivity.
Metformin may also affect adipose tissue endocrine function by modulating adipokine
synthesis and secretion [138]. Leptin deficiency is associated with hyperphagia, a reduction in
energy deficiency and morbid obesity [322], and a positive correlation between insulin
resistance and hyperleptinaemia has been noted in women with PCOS [323]. In a brown
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adipocyte model, metformin treatment resulted in a dose-dependent inhibition of leptin 
secretion through the stimulation of MAPK [324]. Adiponectin is an insulin-sensitising 
adipokine secreted exclusively from adipocytes, whilst resistin has been implicated in the 
pathogenesis of obesity and type II diabetes [325]. Lewandowski and colleagues have 
demonstrated a reciprocal correlation between adiponectin and resistin independent of 
insulin resistance in PCOS, though the role of the resistin in PCOS and cardiometabolic risk in 
this group is not yet fully understood [326, 327].
6.5.2 Action Of Metformin In The Vascular Endothelium
The endothelium is a major target of insulin and endothelial function is considered a marker 
of insulin sensitivity in the vasculature, thus insulin plays an important role in linking 
metabolic and cardiovascular pathophysiology [138]. Treatment with insulin sensitising 
agents such as metformin have been associated w ith improvements in endothelial function 
[240]. However, metformin may also exert direct and beneficial effects on the endothelium 
independent of glucose lowering and insulin sensitisation as suggested by the improvements 
in vascular function noted in this thesis without a significant change in insulin sensitivity. In 
addition to metformin's ability to activate AMPK in the liver and in muscle, w ith consequent 
benefits on enhanced glucose uptake and reduced hepatic glucose output, metformin has also 
been shown to activate AMPK in the endothelium and in vascular smooth muscle, where it 
mediates vascular relaxation through the a l  subunit in an endothelium-independent manner 
[291, 292]. Additionally, AMPK may stimulate FA oxidation thereby reducing FFAs, and 
inhibit glyceride synthesis and thus alleviate endothelial lipotoxicity, a known factor 
contributing to increased superoxide production and impaired NO activity [328]. Further 
work is however still required to ascertain these underlying mechanisms.
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6.5.3 Direct Effect Of Adiponectin On Endothelial Function
Levels of adiponectin inversely correlates with weight, and a reduction in serum adiponectin 
is closely related to peripheral arterial endothelial dysfunction [329], and is considered to be 
an independent predictor of cardiovascular disease [330]. Hypoadiponectinaemia observed 
with weight gain is thus hypothesised to be a potential underlying regulator for the impaired 
vascular function associated with obesity. A recent study by Deng et al provided evidence 
that the diminished ability of endothelium-dependent vasodilation in high-fat diet induced 
obese rats-derived aortic segments can be partially restored by incubation with adiponectin 
[331]. This process not only improved endothelium-dependent relaxation but also increased 
total NO production as well as enhanced eNOS activity thus supporting a role for a direct 
endothelial effect of adiponectin [331].
A significant rise in serum adiponectin concentration associated with metformin therapy was 
observed in the tria l presented in the previous chapter, and appeared independent of the 
insulin sensitising effects of metformin. This change in the adipokine profile in the PCOS 
subjects could therefore underlie some of the effects noted with metformin therapy. Similarly, 
adiponectin has also been shown to activate AMPK and thereby stimulate FA oxidation and 
glucose uptake thus improving endothelial function as decribed above [332].
6.5.4 Future Studies
This discussion has concentrated on the potential effects of pharmacotherapy with metformin 
to improve cardiometabolic risk. What is not clear however is whether metformin produces 
these additional effects beyond weight loss alone. Future studies are required to compare the 
effects of metformin therapy w ith and without lifestyle modification with a control arm of 
subjects managed with lifestyle change alone using a randomised, double-blind, placebo-
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controlled parallel group design trial. This would help clarify the effects of weight loss alone 
and direct effects of metformin in improving cardiometabolic risk.
6.6 Conclusion
Owing to the long-term health risks associated with increased adiposity and the limited 
efficacy of existing anti-obesity agents, there is an urgent need for further development of 
alternative therapeutic options to serve as an adjunct to diet and exercise to promote weight 
loss, and thus reduce the risk of developing obesity-related illnesses. This thesis has 
described benefits w ith both novel (CBi antagonism) and existing (metformin) treatment 
approaches targeting models of the metabolic syndrome, though further work is still required 
to elucidate the mechanism underlying the observed effects. Although the first CBi receptor 
antagonist rimonabant carried an unacceptable psychiatric risk profile, this should not deter 
future research in this field since the benefits observed with this drug and preliminary data 
emerging from the newer generation of agents in this class indicate that there is still potential 
to more selectively target the ECS in the management of obesity, and thus the metabolic 
syndrome. Both the in vitro and in vivo studies have demonstrated an increase in adiponectin, 
either by direct effect on adipose tissue (CBi antagonist studies) or associated with 
accompanying weight loss (metformin effect in PCOS). Treatments targeting a switch in the 
adipokine profile as the therapeutic goal may therefore represent a new approach to 
addressing global cardiometabolic risk associated w ith the metabolic syndrome. 
Furthermore, the AMPK pathway is also emerging as a key player in regulating energy 
balance, and both CBi antagonists and metformin, as well as adipokines such as adiponectin 
exert metabolic effects at least in part through this system, providing yet another potential 
future target for treatment of the metabolic syndrome.
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Appendix 1
PATIENT INFORMATION SHEET
Version 2 May 2006
1. Title of study
Physiological and pharmacological modulation of adipose/connective tissue remodelling.
2. Introduction
You are being invited to take part in a research study. Before you decide whether you wish to 
become involved it is important that you understand why the research is being done and 
what it w ill involve. Please take time to read the following information carefully and discuss it 
with others if  you wish.
Ask us if  there is anything that is not clear or if  you would like more information. Take time to 
decide whether or not you wish to take part.
3. What is the purpose of this study?
A number of hormones can change the amount of fat that is stored in the body. Our research 
group is interested in studying the effects of some of these hormones, including thyroid 
hormones, growth hormone and a hormone called DHEA which is made in the adrenal gland, 
on the function of fat cells in the laboratory. Not all fat reacts in the same way. In some parts 
of the body hormones may cause fat to build up while in others it may break down.
In order for us to fully understand how these hormones affect fat cells, we are asking people 
to donate a small sample of their fat to us for our research studies. This sample w ill be 
obtained during your planned operation. We w ill measure how the cells grow and work in 
response to treatment w ith hormones.
We are also interested in studying whether changes in genes controlling growth hormone 
levels and function can have an effect on fat cells. In order for us to test this we w ill also ask 
you to donate a blood sample for us to analyse your growth hormone genes.
4. Why have I been chosen?
You have been chosen for this study as your surgeon has identified you as someone who w ill 
be undergoing an operation soon. A total of 100 patients w ill be studied.
5. Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you w ill be given this 
information sheet to keep and be asked to sign a consent form. You are still free to withdraw 
at any time and without giving a reason. A decision to withdraw at any time, or a decision not 
to take part, w ill not affect the standard of care you receive. If you withdraw your permission 
after we have obtained your samples, any stored blood or tissue samples that can still be 
identified as yours w ill be destroyed i f  you wish.
6. What w ill happen to me if  I take part?
A sample, about the size of one sugar cube, w ill be taken from the fat under your skin during 
your planned surgery. I f  you are having abdominal surgery we would also plan to remove a 
further sample of fat of the same size from the fat tissue that sits around your bowel (called
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omental or visceral fat). This procedure w ill not affect your operation scar. The fat samples 
would be used in laboratory experiments for further study. During these we would break up 
the fat and separate it into different cell types. We w ill measure how the cells grow and work 
in response to treatment w ith hormones.
The tests to examine your growth hormone genes [called GH1 and GHR) would involve us 
taking an extra sample of blood (equivalent to roughly two tablespoons). We would plan to 
take this sample while you are under anaesthetic during your operation so that you do not 
feel any discomfort.
7. What do I have to do?
There are no lifestyle or dietary restrictions and you can continue your daily activities 
normally. There w ill be no changes to the way in which you need to prepare for your 
operation and your surgical team w ill fully instruct you on this as normal. With your 
permission we w ill check w ith you and in your records on your previous medical health in 
case you have a medical condition or are taking any medication which may affect our ability 
to analyse your fat cells.
8. What are the possible disdvantages of taking part?
Occasionally patients may experience discomfort (temporary pain, swelling, bruising and 
rarely infection) caused by the collection of blood. Removing a small sample of fat from under 
the skin or from around the bowel is unlikely to cause any additional complications to those 
which could be expected from your type of operation.
The genetic blood sampling w ill test for variation in your growth hormone genes. These 
changes occur extremely commonly in the general population and can be seen as a variation 
of normal. The samples w ill be fully anonymised and the results of these genetic tests w ill 
have no implications for you in terms of inherited risk, reproductive decisions or insurance 
status.
9. What are the possible benefits of taking part?
The study may provide us with important information in identifying how hormones affect fat 
cell function. While there are unlikely to be any direct benefits to you, we hope that the 
results of these studies may help in the future treatment of patients with weight-related 
conditions such as obesity and diabetes.
10. What if  there is a problem?
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who w ill do their best to answer your questions (Dr Aled Rees 02920 745002). If 
you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital.
You are unlikely to be harmed as a result of taking part in this research project, but if  you are 
you should be aware that there are no special compensation arrangements. If you are harmed 
due to someone’s negligence, then you may have grounds for a legal action but you may have 
to pay your legal costs. Regardless of this, if  you wish to complain, or have any concerns about 
any aspect of the way you have been approached or treated during the course of this study, 
the normal National Health Service complaints mechanisms should be available to you.
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11. W ill my taking part in this study be kept confidential?
All information which is collected about you during the course of the research w ill be kept 
strictly confidential. Any information about you which leaves the hospital w ill have your 
name and address removed so that you cannot be recognised from it.
With your permission your GP w ill be informed of your participation in this study.
If you join the study, some parts of your medical records and the data collected for the study 
may be looked at by the research team, by representatives of regulatory authorities and by 
authorised people from the Cardiff and Vale NHS Trust to check that the study is being carried 
out correctly. All w ill have a duty of confidentiality to you as a research participant and 
nothing that could reveal your identity w ill be disclosed outside the research site. Our 
procedures for handling, processing, storage and destruction of data are compliant with the 
Data Protection Act 1998.
12. What w ill happen to any samples I give?
After the sample of fat has been obtained at surgery the research doctors w ill immediately 
freeze this sample and store it for later analysis, or break it up and grow the fat cells in the 
laboratory. The blood samples w ill be used to test your growth hormone genes. Both the fat 
and blood samples w ill be stored securely in the Section of Endocrinology at the University 
Hospital of Wales (Room 168, 2nd Floor). The research investigators, Dr Aled Rees and Dr 
Marian Ludgate, w ill act as the day-to-day custodians for these samples. Only Dr Rees and Dr 
Ludgate, and immediate members of their research team w ill have access to the use of these 
samples. In addition, all the samples w ill be coded and anonymised such that your personal 
details w ill not be identifiable. We propose to store the fat and genetic samples for up to 15 
years. After this time the samples w ill be destroyed by incineration.
It is possible that we may wish to use your fat sample for future studies looking at how other 
hormone systems could affect fat cell function. If this is the case then a further application will 
be made to the Research Ethics Committee for consideration. Similarly, we may wish to 
conduct genetic studies on genes other than the growth hormone system in the future. If this 
is the case then this w ill also be submitted to an Ethics Committee for consideration. The 
results of these tests done for research purposes are unlikely to have any direct clinical 
implications for you. It is possible that these studies may be carried out by researchers other 
than Dr Rees or Dr Ludgate, including researchers working for commercial companies.
There is little prospect that the current studies w ill have any commercial significance but if  
future information from our research using your tissue samples shows any likelihood of 
commercial benefit, such as the development of a new treatment or medical test, then you 
would not benefit financially.
13. What w ill happen to the results of the research study?
The results of the research study w ill be prepared for publication in appropriate medical 
journals together with presentation at medical conferences. Patients participating in the 
study w ill be able to obtain a copy of the results after they have been published in the 
relevant journal(s). Patients w ill not be identified in any report/publication.
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14. Who is organising and funding the research?
The study is being organised by Dr Aled Rees and Dr Marian Ludgate in the Section of 
Endocrinology. Funding for the study is provided from the Section of Endocrinology and the 
doctors conducting the research are not being paid for including and looking after patients in 
the study, nor w ill they be able to sell for profit any samples that are collected.
15. Who has reviewed the study?
The study has been reviewed by the Cardiff and Vale NHS Trust Research and Development 
Office and by the South East Wales Local Research Ethics Committee.
16. Contact for further information
Should you have any further questions or queries regarding this research study, then please 
do not hesitate to contact me on 029 20745002. I can also be contacted via email 
(reesda@cf.ac.uk).
Thank you for considering taking part and taking time to read this sheet.
Aled Rees
Principal Investigator/Senior Lecturer in Endocrinology
You w ill be given a copy of this Patient Information Sheet and a signed consent form to keep
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Ap p en d ix  2
CONSENT FORM
Version 2, May 2006.
Thank you for reading the information about our research project. If  you would like to 
take part, please read and sign this form.
Patient Identification Number for this study:
Title of project: Physiological and pharmacological modulation of adipose/connective tissue 
remodelling
Name of researchers: Dr Aled Rees and Dr Marian Ludgate
Contact details for research team: Centre for Endocrine and Diabetes Sciences, University 
Hospital of Wales, Heath Park, Cardiff CF14 4XN. Telephone: 02920 742182.
Please initial boxes
1.1 have read the attached information sheet on this project, dated May---------------------- -------
2006 (version 2), and have been given a copy to keep. I have been able to ask
questions about the project and I understand why the research is being done 
and any risks involved.
2 .1 agree to give a sample of fat for research in this project. I understand -------
how the sample w ill be collected, that giving a sample for this research is
voluntary and that I am free to withdraw my approval for use of the sample -------
at any time without giving a reason and without my medical treatment or 
legal rights being affected.
3.1 give permission for someone from the research team to look at my -------
medical records to get information on my previous medical health. I
understand that the information w ill be kept confidential.
4 .1 understand that I w ill not benefit financially i f  this research leads to the 
development of a new treatment or medical test.
5 .1 know how to contact the research team if  I need to, and how to get 
information about the results of the research.
6 .1 consent to my GP being informed of my participation in the study.
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7. Consent for storage and use in possible future research projects
I agree that the sample I have given and the information gathered about 
me can be stored by Dr Aled Rees/Dr Marian Ludgate at the Centre for 
Endocrine and Diabetes Sciences, School of Medicine, Cardiff University for 
possible use in future projects, as described in the attached information sheet. 
I understand that some of these projects may be carried out by researchers 
other than Dr Aled Rees/Dr Marian Ludgate who ran the first project, 
including researchers working for commercial companies.
8. Consent for genetic research
A. I give permission for growth hormone 1 (GH1) and growth hormone 
receptor (GHR) genotyping to be carried out on the samples I give, as part of 
this project
B. I understand that the project/future research using the samples I give 
may include genetic research aimed at understanding the genetic influences 
on fat cell regulation but that the results of these investigations are unlikely 
to have any implications for me personally.
Name of patient Date Signature
(BLOCK CAPITALS)
Name of person taking consent Date Signature
(if different from researcher)
Name of Researcher Date Signature
Would you like to be sent information about the progress of the project? Yes No
Thank you for agreeing to participate in this research
1 copy for patient; 1 for researcher; 1 to be kept w ith hospital notes
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Ap p e n d ix  3
EFFECTS OF METFORMIN ON VASCULAR FUNCTION IN POLYCYSTIC OVARY SYNDROME
PATIENT INFORMATION SHEET 
(Version 3 May 2006)
1. Title o f study
A randomised, double-blind, placebo-controlled crossover trial of the effects of metformin 
therapy on vascular and metabolic risk in young women with polycystic ovary syndrome.
2. Introduction
You are being invited to take part in a clinical research study. Before you decide whether you 
wish to become involved it is important that you understand why the research is being done 
and what it w ill involve. Please take time to read the following information carefully and 
discuss it with others i f  you wish. Please do not hesitate to ask us if  there is anything that is 
not clear or if  you would like more information. Take time to consider whether or not you 
would wish to take part.
Thank you for reading this.
3. What is the purpose o f this study?
Polycystic ovary syndrome (PCOS) is the commonest hormone condition in women of 
reproductive age, affecting up to 10% of the premenopausal population. In addition to its 
well-recognised effects on weight gain, excessive hair growth and infertility, it is becoming 
increasingly apparent that PCOS is associated with long-term health risks including diabetes 
and arterial (blood vessel) disease, both of which are related to impaired action of insulin 
throughout the body, also known as insulin resistance. Metformin, a drug which acts by 
improving the action of insulin in the body, is helpful in regularising the menstrual cycle in 
such patients and restoring fertility.
There have not been many studies on the effects of metformin on the function of blood 
vessels in PCOS, but this may be an important area to study as research in the middle-aged 
and elderly without PCOS, has shown that insulin resistance is associated with an increased 
risk of blood vessel dysfunction, and thus heart disease. Other studies have shown that 
treating insulin resistance with metformin improves the function of their blood vessels, and 
therefore reduces this risk.
It is unclear at present whether metformin is able to reduce the risk of diabetes and blood 
vessel disease in PCOS. We aim to address this question by studying the effects of short-term 
metformin therapy on blood vessel function and insulin sensitivity in a group of women with 
PCOS.
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This study w ill involve four visits to the Endocrinology department at the Heath hospital and 
w ill last for a total of 32 weeks.
4. Why have I  been chosen?
You have been chosen for this study as your endocrinologist has identified you as having 
PCOS, and you have not been on any treatment for this in the recent past. A total of 36 
patients w ill be studied.
5. Do I  have to take part?
It is up to you to decide whether or not to take part. If you decide to take part you w ill be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, w ill not affect the standard of care you 
receive.
6. What w ill happen to me i f  I  take part?
The study w ill last for a total of 32 weeks and you w ill be asked to attend the Clinical 
Investigation Unit at the Henry Wellcome Biomedical Sciences building on 4 separate 
occasions. Each of these visits w ill last approximately 3 hours.
In order to know whether metformin changes blood vessel function we need to make 
comparisons. Metformin w ill be compared in this study with a placebo tablet. A placebo is a 
dummy treatment such as a pill which looks like the real thing but is not. It contains no active 
ingredient.
People w ill be put into two groups and then compared. The groups are selected by a 
computer which has no information about the individual i.e. by chance (or randomised). Half 
the patients w ill be put into group A and w ill receive metformin treatment for 12 weeks. The 
other half w ill be put into group B and w ill receive placebo treatment. These groups w ill be 
compared.
Neither you nor your doctor w ill know in which treatment group you are (although your 
doctor is able to find out if  he/she needs to do so). This is to make sure that the results cannot 
be influenced in any way.
At the end of 12 weeks of treatment you w ill have a break of 8 weeks before taking the other 
treatment for a further 12 weeks (placebo treatment if  you received metformin for the first 
part of the study and metformin if  you received placebo initially). The break of 8 weeks 
between treatments w ill ensure that the first drug is cleared from your body before you start 
the new treatment.
A summary of what w ill happen and when the study visits w ill take place is shown in the 
following flow chart.
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First treatment phase Wash-out Second treatment
Group A
Metformin (500 mg once daily 1 week] \
(500 mg twice daily for lweek) \  
(500mg three times a day for 10 weeks
Metformin (500 mg once daily 1 week]
(500 mg twice daily for lweek) 
(500mg three times a day for 10 w<
PlaceboGroup B Placebo
12 weeks 8 weeks 12 weeks
Visit 2 (Day 84) 
Post-treatment
Visit 3 (Day 140) 
Pre- treatment
Visit 4 (Day 224) 
Post-treatment
Visit 1 (Day 1) 
Pre-treatment 
Randomisation
On each visit the measurements performed are designed to measure the stiffness of your 
blood vessels. The techniques that we use are completely painless and 'non-invasive'. The 
main equipment we use is called a 'Sphygmocor' machine. This consists of a small pencil-like 
probe placed over the wrist, which measures the waveform of the pulse. During the 
measurements you w ill also be asked to take a puff of a salbutamol inhaler (like that used in 
asthma) and a GTN tablet under your tongue (like that used in angina). Both these drugs act 
to change the shape of the pulse waveform that we measure. Both drugs are safe and are 
unlikely to produce any side effects although you may experience a headache and flushing 
after the GTN.
During each visit we w ill also take blood samples (approximately three tablespoons) to check 
your hormones, cholesterol, insulin, clotting factors and CRP (a non-specific marker of 
inflammation in the body). As well as this we take measurements such as your height, weight, 
and blood pressure.
We w ill also require you to have a pregnancy test at each study visit before carrying out the 
above measurements.
If you wish then we w ill be able to reimburse any travelling expenses /  car parking fees 
incurred while attending for a study visit.
7. What do I have to do?
It is important that you take your regular medication in the normal way without altering the 
dose or timing of these during the course of the study. You should inform us of any dose 
adjustments. You w ill be asked to take the study medication regularly for the duration of the
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study. The tablets w ill be taken once a day for the first week, twice a day for the second week 
and then three times a day for the next ten weeks during each cycle of treatment.
There are no lifestyle or dietary restrictions and you can continue your daily activities 
normally. We request that you report any illnesses to us as they may influence the timing of 
the test visits.
You should inform us immediately if  you become pregnant.
For each of the study visits, we ask that you attend the Clinical Investigation Unit at 8 o'clock 
in the morning having fasted from midnight the previous night. You can drink water freely.
8. What is the drug that is being tested?
Metformin is a drug that is usually used to treat diabetes, but many patients with PCOS are 
now taking this treatment on a regular basis. It acts by improving the action of insulin in the 
body and in PCOS, is helpful in restoring menstruation and fertility. The drug comes in tablet 
form and we w ill provide you with a card to carry explaining the details of this trial. You 
should carry this w ith you at all times.
9. What are the side effects o f Metformin?
Metformin is a widely used drug and most patients tolerate it well, though some w ill 
experience gastrointestinal side effects such as nausea, vomiting, diarrhoea and abdominal 
pain. This is usually transient and we aim to minimise this by building up the dose gradually 
over the first three weeks of treatment. The side effects can also be reduced by taking the 
medication with, or immediately after food. You w ill be told if  any new side effect is found as 
a result of this study or any other studies using metformin.
If you become in any way concerned you should contact Dr Neera Agarwal on telephone 
number 02920 748251.
10. What are the possible disadvantages and risks o f taking part?
Metformin can rarely cause a low level of acidity in the blood, but this tends only to be in 
people whose liver, kidneys, or heart do not work properly. Other than possible discomfort 
(temporary pain, swelling, bruising and rarely infection] caused by the collection of blood, no 
other side effects are anticipated from the study procedures.
The risks to an unborn human foetus or a breastfed child from metformin are not fully known. 
Women who are pregnant or breastfeeding a child may therefore not participate in this trial, 
neither should women who plan to become pregnant during the study. All women w ill be 
asked to have a pregnancy test at each study visit. Women who could become pregnant must 
use an effective contraceptive during the course of this study. We would request that barrier 
methods are used, as the oral contraceptive pill and implantable contraceptives may influence 
some of the measurements we are taking. Any woman who finds that she has become 
pregnant while taking part in the study should immediately tell her research doctor.
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11. What are the potential benefits o f taking part?
Some patients experience restored menstruation and fertility, and we hope to demonstrate 
improved blood vessel function. However, this cannot be guaranteed. The information we get 
from this study may help us to treat future patients w ith PCOS better.
12. What i f  new information becomes available?
Sometimes during the course of a research project, new information becomes available about 
the drug that is being studied. If this happens, your research doctor w ill tell you about it  and 
discuss with you whether you want to continue in the study. If you decide to withdraw, your 
research doctor w ill make arrangements for your care to continue. If you decide to continue 
in the study you w ill be asked to sign an updated consent form.
Also, on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you from the study. He/she w ill explain the reasons and arrange for 
your care to continue.
13. What happens when the research study stops?
If you feel you would wish to continue metformin therapy at the end of the study you w ill be 
able to discuss this w ith your Endocrinologist.
14. What i f  something goes wrong?
This study is being indemnified by Cardiff University. If you are harmed by taking part in this 
research project, there are no special compensation arrangements. If you are harmed due to 
someone's negligence, then you may have grounds for a legal action but you may have to pay 
for i t  Regardless of this, if  you wish to complain, or have any concerns about any aspect of the 
way you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you.
15. Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research w ill be kept 
strictly confidential. Any information about you which leaves the hospital w ill have your 
name and address removed so that you cannot be recognised from it. With your permission 
your GP w ill be informed of your participation in this study. With your permission we may 
also look at sections of your medical notes which are relevant to the research study.
16. What will happen to the results o f the research study?
The results of the research study w ill be prepared for publication in appropriate medical 
journals together with presentation at medical conferences. Patients participating in the 
study w ill be able to obtain a copy of the results after they have been published in the 
relevant journal(s). Patients w ill not be identified in any report/publication. Patients w ill be 
able to discover which arm of the study they were in if  they so wish, but only after the study 
has been completed in its entirety.
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17. Who is organising and funding the research?
The study is being organised by Dr Aled Rees in the Section of Endocrinology (the Principal 
Investigator) and Dr Neera Agarwal (Research Registrar). Funding for the study is provided 
from the Royal College of Physicians UK, and the Section of Endocrinology in the Heath 
hospital. The doctors conducting the research are not being paid for including and looking 
after patients in the study.
18. Who has reviewed the study?
The study has been reviewed by the Cardiff and Vale NHS Trust Research and Development 
Office and by the South Wales Research Ethics Committee.
19. Contact fo r further information
Should you have any further queries regarding this research study, then please do not 
hesitate to contact me on 02920 748251 or 07816 888636, or Dr Aled Rees on 02920 742309. 
You can also contact me via e-mail on neeraagarwal@yahoo.co.uk
Thank you for considering taking part in this study.
Dr Neera Agarwal
Clinical Research Fellow in Endocrinology
You w ill be given a copy of this Patient Information Sheet and a signed consent form to keep.
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Ap p en d ix  4
EFFECTS OF METFORMIN ON VASCULAR FUNCTION IN POLYCYSTIC OVARIAN 
SYNDROME - CONSENT FORM (Version 3 May 2006)
Patient Identification Number for this trial:
Title of Study: A randomised, double-blind, placebo-controlled crossover trial of the
effects of metformin therapy on vascular and metabolic risk in young women with polycystic 
ovary syndrome.
Name of Researchers: Dr Aled Rees, Dr Neera Agarwal 
Please initial box
1. I confirm that I have read and understood the information sheet dated May 2006 (version 
3) for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected.
3. I understand that sections of my medical notes may be looked at by responsible
individuals from regulatory authorities where it is relevant to my taking part in research.
I give permission for these individuals to have access to my records.
4. I consent to my GP being informed of my participation in the Study.
5. I consent to a pregnancy test at each study visit.
6. I agree to take part in the above study.
Name of patient Date Signature
Researcher Date Signature
Name of person taking consent Date Signature
(if different from researcher)
1 copy for patient; 1 for researcher; 1 to be kept with hospital notes
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Ap p en d ix  5
EFFECTS OF METFORMIN ON VASCULAR FUNCTION IN POLYCYSTIC 
OVARY SYNDROME-CASE REPORT FORM
PATIENT DETAILS
Initials ..................................................................................................
Date o f B irth  ..................................................................................................
Trial Enrolment Number ...................................................................................................
Date of V is it............................. ...................................................................................................
INCLUSION CRITERIA
□  Diagnosis o f PCOS (require 2 out o f 3)
•  Androgen excess (clin ical or 
biochemical}
•  Ovulatory dysfunction
• Cysts on ovarian ultrasound
□  Age 18-30
EXCLUSION CRITERIA
□  Pregnancy
□  Breastfeeding
□  Current/previous use (w ith in  last 6 
months) of:
• Oral contraceptive p ill
•  Anti-diabetic drugs
•  Anti- hypertensive drugs
□  Renal im pairm ent
□  Hepatic im pairm ent
□  Diabetes
□  Hypertension
□  Discuss inform ation sheet & complete consent form.
□  Discuss contraception.
PREGNANCY TEST □  Negative □  Positive
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MEDICAL HISTORY
SMOKING STATUS
Current smoker □  No □  Yes D e ta ils ................................
Ex-smoker □  No □  Yes D e ta ils .................................
FAMILY HISTORY
DRUG THERAPY Previous OCP use
Drug .........................................................
Dose .........................................................
Duration .........................................................
Allergies ............................................
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MENSTRUAL HISTORY
Age at menarche ............................................................................
□  Eumenorrhoeic Cycle length......................................  Day No.
□  O ligomenorrhoeic LMP....................................................................
□  Am enorrhoeic LMP.....................................................................
CLINICAL EXAMINATION
BMI Height (cm )  W eight(kg)  B M I..
Body Composition Fat m ass(kg)  Fat % ...............
W aist:Hip W a is t(cm )  H ip(cm )  Ratio
Acanthosis Nigricans □  Yes □  No S ite ................
Ferrim an-G allw ey score ..........................................................................
ADDITIONAL INFORMATION
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AUGMENTATION INDEX & PULSE WAVE VELOCITY
Distance: Blood Pressure:
SSN to carotid pulse mm A. ...............................mmHg
SSN to radial pulse...............................mm B. ................................mmHg
SSN to femoral pulse........................... mm Average...............................mmHg
AUGMENTATION INDEX
A B Average
Augemtation index 
f% l
Central aortic 
pressure (mmHg)
Tr (ms)
PULSE WAVE VELOCITY
A B Average
Carotid-radial (m /s)
Carotid-femoral
(m /s)
ASSESSMENT OF ENDOTHELIAL FUNCTION -  BASELINE MEASUREMENTS
Time A B Average
5 mins
BP
HR
7 mins AIx
15 mins
BP
HR
17 mins AIx
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ENDOTHELIAL FUNCTION -  GTN
Time A B Average
0 m in Sublingual GTN
1 m in
BP
HR
3 m in
Remove GTN
AIx
5 mins AIx
7 mins
BP
HR
10 mins AIx
12 mins
BP
HR
15 mins AIx
17 mins
BP
HR
20 mins AIx
25 mins
BP
HR
28 mins AIx
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ENDOTHELIAL FUNCTION - SALBUTAMOI.
Time A B Average
0 m in 2 puffs salbutam ol via spacer (x2)
2 mins
BP
HR
5 mins AIx
7 mins
BP
HR
10 mins AIx
12 mins
BP
HR
15 mins AIx
17 mins
BP
HR
20 mins AIx
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LABORATORY RESULTS
Investigation Result
Testosterone
SHBG
HsCRP
PAI-1
Total cholesterol
LDL
HDL
TG
Glucose
Insulin
Adiponectin
---------------------------------------------------------------------------------------
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